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Summary
Histidine is an important amino acid involved in enzyme catalysis and metal 
binding in many proteins. Bacteria, fungi and plants synthesise histidine via the 10 
step histidine pathway, whereas histidine is an essential amino acid required in the 
diet of animals. The synthesis of histidine is energetically expensive with about 41 
ATP needed to produce one histidine. As a result the histidine biosynthetic pathway is 
tightly regulated and some microorganisms can consume excess histidine as a 
nitrogen and carbon source via a histidine utilisation (hut) pathway. The absence of a 
histidine biosynthetic pathway in mammals makes it a good target for the 
development of antimicrobial and antifungal drugs as well as herbicides.
In addition to an overall regulation of the histidine synthesis by charged 
histidyl-tRNA and histidyl-tRNA synthetase, the histidine pathway is regulated in 
various ways by the first enzyme of the pathway ATP-phosphoribosyltransferase 
(HisG). The enzyme catalyses the condensation of ATP and 
phosphoribosylpyrophosphate (PRPP) to form phosphoribosyl-ATP (PR-ATP) and is 
feedback regulated by histidine, the end product of the pathway. Furthermore, HisG is 
inhibited by its product PR-ATP and also by AMP and ppGpp, reflecting the overall 
energy status of the cell. Inhibition of HisG coincides with a change in aggregation 
state, in which the active dimers form inactive hexamers. Some bacterial genomes 
contain a hisG gene, which lacks about 80 residues at the C-terminus, but have an 
additional gene, hisZ. This short form of HisG itself is inactive and forms an active 
complex with HisZ.
This thesis describes the solution of the 3-dimensional structures of the 
hexameric forms of bacterial HisGs by X-ray crystallography. The structure of the 
Escherichia coli HisG was determined in the presence of the inhibitors AMP and PR- 
ATP. Additionally, a histidine-bound structure of HisG from the thermophilic 
bacterium Methanobacterium thermoautotrophicum has been obtained. The monomer 
of HisG comprises of three ot/p domains. The first two domains show a periplasmic 
protein-like fold with the active site located in a cleft between the two domains. The 
C-terminal domain, similar to Pn signal transduction proteins, binds histidine and is
mainly involved in the formation of the hexamers. Additionally the structure of HisG 
represents a new type of phosphoribosyltransferase. The structure of the binary 
complex with AMP has allowed the identification of the PRPP binding site and 
explains the competitive inhibition by AMP with respect to both substrates. 
Furthermore the AMP binary structure and the PR-ATP-complexed structure 
identified the binding site of the ATP purine ring. The histidine-bound structure 
explains the histidine inhibition by disruption of the PRPP binding site on the dimer 
interface by elongation of the dimer and hence the hexamer. A mode of inhibition 
common to all the inhibitors investigated is the formation of hexamers upon inhibitor 
binding which buries the active sites in the inside of the hexamer and makes the sites 
less accessible to the substrates.
Mutational and kinetic analysis showed that the extra C-terminal domain in the 
long form of HisG is not essential for activity. Subsequently, it was demonstrated that 
the naturally short form of HisG can be activated by thermal energy. This suggests a 
tense conformation for the short form of the enzyme which can be relaxed and 
activated by forming an oligomeric complex with HisZ.
The structure of an unidentified protein in the histidine utilisation (hut) 
pathway from Pseudomonas aeruginosa, PA5104, was determined to better than 1 A 
resolution. Solution of the structure was accomplished by a unique approach 
combining SIRAS phasing with direct methods (Sayre equation). PA5104 is an all-|3 
protein with a bicupin fold. One of the [3-barrels is open and accommodates a small 
molecule binding site. A different conformation of PA5104 was obtained from a 
second structure solved using a different crystal form. Comparison of the structures 
and interactions in the active site identifies glutamate or derivatives (intermediates in 
the hut pathway) as possible substrates, which can induce a conformational change 
and may give PA5104 a regulatory function.
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Chapter 1: Introduction
1.1 Histidine Biosynthesis -  General Introduction
In microorganisms and plants histidine is synthesised via a 10 step pathway 
(Figure 1-1). The histidine pathway has been studied well for the bacteria Escherichia 
coli and Salmonella typhimurium [Winkler, 1987]. In both organisms there are 8 
enzymes catalysing the 10 steps and these are encoded by 8 genes 
(hisG{IEjAHFBCD)1 arranged as a single operon (his operon) [Carlomagno et al
1988]. Three of the enzymes are bifunctional (HisIE, HisD, HisB) and two form a 
multienzyme complex catalysing one reaction (HisH:HisF) [Alifano et al., 1996]. 
Recent publications describe the histidine pathway enzymes from the gram-positive 
bacteria Lactococcus lactis [Delorme et a l, 1992], and from yeast [Bruni et a l, 1986] 
and plants [Fujimori and Ohta, 1998]. The nomenclature for the genes of the histidine 
pathway is different for bacteria and fungi. Table 1-1 shows the names of enzymes 
and the corresponding gene names for fungi and bacteria.
The histidine biosynthetic pathway is only present in bacteria, fungi, and 
plants, but absent in mammals. This makes it a good target for the development of 
antimicrobial and antifungal drugs as well as herbicides [Mousdale and Coggins,
1991]. A variety of selective inhibitors of the histidine pathway are known and used 
commercially as herbicides [Mori et a l, 1995]. These herbicidal compounds, e.g. 
amitrole, all inhibit imidazoleglycerol-phosphate dehydratase (the product of the hisB 
gene) in yeast and Salmonella, but there is evidence that there is an additional site of 
action in plants [Shaner, 1989]. A patent on the plant gene hisG emphasises the 
importance of the first enzyme and its role as an herbicidal target [Novartis AG, 
1999]. More recently potential inhibitors of HisG were identified by computational 
methods [Gohda et a l, 2001]. Knowledge of the structures of enzymes of the histidine 
pathway will help with the understanding of its function and provide a basis for the 
development of antimicrobials and herbicides. At the beginning of this project no 
3-dimensional structure of an enzyme of the histidine pathway had been determined.
1 gene names will be displayed in ‘italics'; gene products will be displayed in ‘Normal’ with the first 
letter in capital
1
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Although crystals had been obtained for HIS3 from Saccharomyces cerevisiae 
[Wilkinson et at., 1995] and HisA and HisF from Thermotoga maritima [Thoma et 
a l , 1999]. Whilst conducting this study the structures of HisG, HisA, HisF and HisH 
have been solved by other groups [Lang et a l, 2000; Banfield et at., 2001; Chaudhuri 
et a l, 2001]. This includes the structure of HisG from the pathogen Mycobacterium 
tuberculosis [Clio et a l, 2003], one of the targets organisms studied in this thesis.
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1.2 The Histidine Biosynthetic Pathway
The histidine pathway leads from the initial substrates 5-phosphoribosyl 
1-pyrophosphate (PRPP) and ATP to histidine. Figure 1-1 shows the reaction pathway 
and names the enzymes and the genes encoding for them. Synthesis of histidine is an 
expensive process in energy terms, with 41 molecules of ATP needed to synthesis one 
molecule of histidine [Brenner and Ames, 1971].
Intermediates of the histidine pathway seem to be conserved amongst different 
species, however the structure and arrangement of genes and corresponding enzymes 
varies [Smith and Ames, 1964; Fani et a l , 1995; Alifano et al., 1996]. In bacteria the 
genes are mostly arranged as an operon. Some bacteria such as E. coli have an operon 
containing all genes for histidine biosynthesis [Carlomagno et a l, 1988], some have 
an operon containing the majority of genes, e.g. T. maritima [Thoma et a l, 1998] and 
some have the genes scattered over the genome, e.g. Synechocystis [Kaneko et al,
1996]. In fungi the genes are spread over 6 chromosomes [Fani et a l, 1995]. The 
arrangement of the domains of the proteins involved in histidine biosynthesis varies 
considerably between species. For example in E. coli there are 3 bifunctional enzymes 
HisIE, HisB and HisD whereas in S. cerevisiae two genes are linked to form HIS4 
containing the HisIE and HisD activities and FlisB is split into two monofunctional 
enzymes encoded by HIS2 and HIS3 [Fani et al., 1995].
The initial substrates of the histidine pathway PRPP and ATP play a key role 
in intermediary and energy metabolism. Furthermore they link the histidine pathway 
to the biosynthesis of folates, purines, pyrimidines, pyridine nucleotides, and 
tryptophan. A by-product of the histidine pathway aminoimidazole carboxamide 
ribonucleotide (AICAR), formed by HisH;HisF, is a purine precursor (see Figure 1-1 
and Figure 1-2). For some bacteria and fungi it was found that the product of the HisI 
enzyme can be used in a shunt biosynthetic pathway which yields an intermediate of 
the purine biosynthesis [White, 1997]. The gene product of the Snz gene was 
identified as the possible enzyme for this reaction [Galperin and Koonin, 1997]. 
Additionally the pathway is linked to nitrogen metabolism via glutamine, a substrate 
for the HisH:HisF reaction (see Figure 1-2). Therefore the histidine pathway and its 
regulation are integrated with and influence overall cellular metabolism.
It is suggested that the histidine biosynthetic pathway was already established 
in the metabolism of the common ancestor of all cellular organisms [Lazcano et al,
4
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1992]. In addition, histidine might be a molecular remnant of a catalytic 
ribonucleotide present in the early stage of biochemical evolution in which RNA 
played a role in catalysis [White, 1976]. Gene duplication from a common ancestor 
gave rise to his A and hisF as indicated by evolutionary studies [Fani et a l, 1994; Fani 
et a l, 1997] and this proposal is supported by kinetic and structural findings [Lang et 
a l, 2000]. Several evolutionary events, such as elongation, gene fusion and 
duplication, have occurred in the histidine pathway during its evolution from the 
ancestral pathway to the pathway in modem organisms [Fani et a l, 1995].
5
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Figure 1-1 Histidine biosynthetic pathway. Shown is the reaction scheme with 
enzymes and genes encoding them.
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PRPP + ATP
Figure 1-2 Substrates and intermediates o f the histidine pathway. A simplified 
diagram showing the substrate and intermediates and their interaction with purine 
and pyrimidine biosynthesis as well as nitrogen metabolism.
7
Chapter 1 Introduction
1.3 Individual Enzymes of the Histidine Pathway
As research in this thesis focused on the first three enzymes of the histidine 
pathway catalysed by HisG and HisIE or HisI and HisE respectively, these will be 
described in further detail.
1.3.1 ATP-phosphoribosyltransferase (HisG or ATP-PRT)
The first enzyme of the pathway, ATP-phosphoribosyltransferase (ATP-PRT 
or HisG) encoded by the hisG gene, catalyses the condensation of ATP and PRPP to 
form A^-5’-phosphoribosyl-ATP (PR-ATP). The reaction scheme is shown in Figure 
1-3. The pyrophosphate group on C-l of PRPP is displaced by the N-l nitrogen atom 
of the purine ring to form PR-ATP with the inversion of the chiral centre of C-l 
[Chelsky and Parsons, 1975]. The enzyme is involved in several aspects of the 
regulation of histidine biosynthesis [Ames et al., 1961]. ATP-PRT binds to 
histidyl-tRNA and it is feedback inhibited by the end product of the pathway,
PR-A TP
Figure 1-3 Reaction scheme of HisG.
histidine [Voll et al., 1967]. Due to these properties and the connection of the 
histidine pathway with other biosynthetic and metabolic pathways, ATP-PRT plays an 
important role in the regulation of growth.
ATP-PRT was investigated in some detail in the 1970s and 1980s focusing on 
the enzymes from the bacteria E. coli [Dall-Larsen, 1988] and S. typhimurium [Ames 
et al., 1961]. The enzyme from these bacteria are closely related and share a high
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sequence homology of 94.7% [Carlomagno et al., 1988] but have slightly different 
properties [Dall-Larsen, 1988].
The sources for studies of ATP-PRT from E. coli and S. typhimurium were 
usually depressed mutants from which the enzyme was purified [Voll et a l, 1967; 
Klungsoyr and Atkinson, 1970; Tebar et a l, 1973]. More recently over-expression of 
ATP-PRT in conjunction with the his IE product was demonstrated [Davisson et a l, 
1994]. However in this case there was no interest in purifying and studying the 
enzyme in more detail; the goal was to obtain histidine biosynthetic intermediates. An 
over-expression construct with only the hisG gene from E. coli was made and a faster 
purification procedure designed [unpublished results A. Elwell and J.R. Coggins; 
[Lohkamp et a l, 2000]].
From the primary structure of ATP-PRT from E. coli the molecular weight for 
the 299 amino acid polypeptide is calculated to be 33,367 Da. Experimentally 
determined molecular weights describe various oligomers of ATP-PRT. 
Ultracentrifugation and gel permeation have shown that the enzyme is in equilibrium 
between its active dimeric form, inactive hexameric form and higher aggregates 
[Klungsoyr and Kryvi, 1971; Tebar et a l, 1973]. The hexameric form is stabilised by 
histidine, AMP, PRATP, high concentrations of ATP and high enzyme concentration 
[Klungsoyr and Kryvi, 1971; Kryvi and Klungsoyr, 1971]. The second substrate 
PRPP seems to dissociate higher aggregates resulting in an increase in the 
concentration of dimers [Tebar et a l, 1973].
The secondary structure of ATP-PRT was investigated by CD spectroscopy 
[Kryvi, 1973]. At that time it was proposed to consist of about 33% a-helix and 20- 
30% P-sheet with no change observed when the inhibitors AMP and/or histidine were 
bound. Furthermore it was proposed that the first 120 residues of ATP-PRT contain a 
nucleotide-binding fold arranged in a papappapap  pattern [Argos et a l, 1983]. 
Despite the fact that a number of structures of other phosphoribosyltransferases have 
been determined, no comparison of ATP-PRT with these has been reported (e.g. 
[Focia et al, 1998]).
A simple spectrophotometric assay for ATP-PRT is described in the literature 
which is based on the high extinction coefficient of PR-ATP at 290 nm [Smith and 
Ames, 1964; Martin et a l, 1971]. However due to the inhibition by the product PR- 
ATP modified assays have also been developed where the reaction is coupled with
9
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HisIE [Kleeman and Parsons, 1975; Kronenberg et al., 1975; Tebar and Ballesteros, 
1976].
The reaction catalysed by ATP-PRT follows an ordered mechanism with ATP 
binding first and pyrophosphate being released first as shown in Figure 1-4 [Morton 
and Parsons, 1976]. ATP-PRT binds 3 histidine per hexamer with high affinity i.e. 
one histidine per dimer [Klungsoyr and Atkinson, 1970]. PR-ATP and AMP enhance 
the binding of histidine to ATP-PRT, the latter with strong cooperativity [Dall-Larsen 
and Klungsoyr, 1976]. AMP itself binds with a stoichiometry of about 3 molecules 
per hexamer and competes with the binding of both substrates, ATP and PRPP 
[Kleeman and Parsons, 1976; Morton and Parsons, 1976]. Negative cooperativity of 
ATP binding was found for the Salmonella enzyme [Bell and Koshland, 1971]. The 
product PR-ATP binds preferentially at 1-2 sites per hexamer depending on several 
factors including Mg2+ and PR-ATP concentration [Dall-Larsen and Klungsoyr, 
1976].
E-ATP-PPi
Figure 1-4 Scheme of ordered mechanism of HisG.
Mutants bearing deletions in the hisG gene seem to be regulated normally 
[Scott et al., 1975], even so there is evidence for ATP-PRT being involved in 
regulation of the his operon. It has been shown that ATP-PRT from S. typhimurium 
binds to histidyl-tRNA [Kovach et a l, 1970] and is involved in the repression control 
of histidyl-tRNA synthetase [Coleman and Williams, 1974]. Furthermore it is 
proposed that it can bind to the leader mRNA [Ames et a l, 1983]. Earlier research 
suggested that it binds to the DNA of the his operon [Meyers et a l, 1975], but this 
was shown to be an error arising from incorrect DNA sequences [pers. comm. 
Yanofsky]. However, these experimental results suggest that ATP-PRT plays a role in 
regulating the histidine concentration in the cell.
10
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The ATP-PRTs from some bacteria are by about 80 residues shorter at the 
C-terminus compared to the enzyme from e.g. E. coli2. The genome of bacteria with 
this short form of the enzyme contains an additional gene, hisZ, which encodes for a 
histidyl-tRNA synthetase paralog [Renault et a l, 1995; Sissler et al., 1999]. It has 
been shown that HisZ is necessary for the catalytic activity of the short ATP-PRT. 
The histidyl tRNA synthetase paralog contains the catalytic core of a class II tRNA 
synthetase but lacks the aminoacylation function. Both HisG and HisZ appear to play 
a key role in regulation of histidine biosynthesis [Sissler et a l, 1999], Initial research 
suggested that the HisG-HisZ complex is octameric and is compromised of 6 HisG 
units and 2 HisZs [Champagne et a l, 2001]. Further investigation confirmed the 
octameric nature of the complex but demonstrated that it contains two of each HisG 
and HisZ dimers arranged as a dimer of hetero-tetramers [Bovee et a l, 2002].
HisG belongs to the class of phosphoribosyltransferases (PRT) some of which 
are linked to disease in humans [Musick, 1981]. At the beginning of the project two 
different types of PRT structures were known and another one predicted. Several 
reported structures, e.g. uracil PRT, show the type I fold of a five-stranded P-sheet 
surrounded by three or four a-helices (and a variable hood domain) (e.g. [Tomchick 
et a l, 1998]). Quinolinic acid PRT comprises a type II fold with two domains: a 
mixed a/p N-terminal domain and an p?a6 barrel C-terminal domain, similar to 
known (Pa)g barrels [Eads et a l, 1997]. Anthranilate PRT is predicted to give a 
typical (Pa)g barrel fold [Wilmanns and Eisenberg, 1993]. However the crystal 
structure was solved recently and showed a fold distinct from the previous known 
ones [Mayans et a l, 2002]. This type III fold has a central 7-stranded sheet on both 
sides flanked by several a-helices.
The structure of HisG was solved as part of this project. The fold shows a new 
type of PRT (IV) comprising three domains. This was confirmed by the structure of 
HisG from M. tuberculosis [Cho et a l, 2003],
2 Therefore if  necessary ATP-PRT or HisG is in the following referred to as long or long form and 
short or short form respectively.
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1.3.2 Phosphoribosyl-ATP pyrophosphatase, phosphoribosyl-AMP
cyclohydrolase (HisIE)
The second and third synthesis steps are performed by the enzymes 
phosphoribosyl-ATP pyrophosphatase (HisE) and phosphoribosyl-AMP 
cyclohydrolase (HisI). Firstly HisE hydrolyses the two phosphates from the ATP part 
of the PR-ATP and then HisI opens the purine ring [Smith and Ames, 1965]. The 
product N’-[(5’-phosphoribosyl)-formimino]-5-aminoimidazole-4-carboxamide- 
ribonucleotide (BBMII or Pro-FAR) and intermediates of this reaction are shown in 
Figure 1-5.
ProFAR
Figure 1-5 Reaction scheme of HisIE.
In bacteria the enzyme is either bifunctional (HisIE) encoded by the hisIE 
gene, e.g. E. coli, or there are two independent genes and corresponding 
monofunctional enzymes, e.g. in Methanococcus vannielli [Beckler and Reeve, 1986] 
and Azospirillium brasilense [Fani et al., 1993]. In Rhodobacter sphaeroides the HisI 
is also monofunctional with no link to the hisE gene [Oriol et a l, 1996; Oriol et al.,
1997]. In the bacterial bifunctional HisIE the N-terminal domain performs the third
12
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step (cyclohydrolase activity) and the C-terminal domain the second step 
(pyrophosphate hydrolase activity) [Donahue et a l, 1982].
In fungi the HisI and HisE activities are encoded by the multifunctional HIS4 
gene which also includes the activity for HisD [Donahue et a l , 1982].
Monofunctional HisI from M. vannielli was overexpressed and characterised 
[D'Ordine et a l, 1999]. The enzyme is present as a dimer with one equivalent of zinc 
ion per subunit. Both divalent cations Zn2+ and Mg2+ are required for cyclohydrolase 
activity of HisI [D'Ordine et a l, 1999].
HisIE from the plant Arabidopsis thaliana was cloned and identified as a 
bifunctional enzyme [Fujimori and Ohta, 1998].
Neither the individual enzymes HisI and HisE nor the bifunctional HisIE have 
been studied structurally to date.
1.4 Histidine degradation
1.4.1 Introduction
The synthesis of amino acids is energetically expensive and therefore tightly 
controlled in microorganisms. Excess amino acids, unlike glucose or fatty acids, 
cannot be stored but can be used as a carbon, nitrogen and energy source. 
Furthermore, amino acids can be scavenged from hosts or the environment and used 
per se or serve as nutrition. The amino acids can be degraded and used as an 
important metabolic intermediate and a source of energy for the microorganism.
C5 amino acids such as histidine, arginine, glutamine and proline are converted 
to glutamate and subsequently to a-ketoglutarate, which then feeds into the citric acid 
cycle [Stryer, 1988]. The amino acids are degraded by a series of enzymatic reactions 
into glutamic acid. In bacteria 4 or 5 individual enzymatic steps are exploited in the 
histidine utilisation depending on species. Both pathways yield as products ammonia, 
as a nitrogen source, and glutamate. The third product is a Ci compound, either 
formamide or formate. These two pathways of histidine utilisation are outlined in the 
following section.
13
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1.4.2 Histidine utilisation pathways
The histidine utilisation pathway 1 is common in most bacteria that have been 
studied, e.g. S. typhimurium, Klebsiella aerogenes, and B, subtilis. The degradation is 
accomplished by 4 enzymes, each catalysing a single reaction (Figure 1-6). Pathway 
2, which is present for example in Pseudomonas ssp., shares the initial three 
enzymatic steps with histidine utilisation pathway 1 but replaces the final enzyme 
with two distinct enzymes (Figure 1-7). This results in an additional intermediate and 
subsequently a different by-product of the final step, formate.
The first enzyme in the pathways, encoded by the hutH gene, is histidine 
ammonia-lyase (HutH). This 55.6 kDa protein catalyses the elimination of ammonia 
to yield the a-P~unsaturated /ram-urocanate, Urocanase (HutU) catalyses the second 
step of both histidine utilisation pathways, the conversion of urocanate to 4- 
imidazolone-5-propionate. HutU appears to be partially stabilised by the presence of 
pyridoxal phosphate. Imidazolone-5-propionate hydrolase (HutI) catalyses the ring- 
opening reaction, converting 4-imidazolone-5-propionate into iV-formimino-L- 
glutamate.
NH,
H u tG j
foim im inogliitanm tc
hydrolase
O
HcA^O
A .+  H 2N  'H  
form am ide
L-glutam atc
Figure 1-6 Histidine utilisation pathway 1.
The final step in histidine utilisation pathway 1 is catalysed by 
formiminoglutamate hydrolase (HutG) which hydrolyses vV-formimino-L-glutamate to 
yield L-glutamate and formamide.
14
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Histidine utilisation pathway 2 is different to pathway 1 in the conversion of 
ACformimino-L-glutamate to L-glutamate. The single step, performed in pathway 1 by 
HutG, is achieved by 2 enzymatic reactions. N-formiminoglutamate is initially 
converted to A-formyl-L-glutamate by formiminoglutamate deiminase (HutF) and the 
product of this reaction, TV-formyl-L-glutamate, is subsequently hydrolysed to yield L- 
glutamate and formate by formylglutamate deformylase (HutG3).
In evolutionary terms the mutation of HutGi to HutF with the production of a 
new intermediate, iV-formyl-L-glutamate, could have induced the recruitment of an 
enzyme capable of breaking it down [Hu et al., 1987]. This was possibly N- 
acetylglutamate synthase, an enzyme believed to be involved in arginine biosynthesis 
[Fruh and Leisinger, 1981].
r
< n h 2
L -histid ine
IN
<
h is tid ine  am m onia-lyase N 
H
OH
NH,
HutU
urocanase
N -form im ino-L -glu lom ale
H u tG ,
4-im idazolone-5-propiorm te
O
HO^^O
form ylg lu tam ate
deform ylase
L-glutam ate
N -foi m yl-L-glutanm te
+  NH, form ate
OH
Figure 1-7 Histidine utilisation pathway 2.
1.4.3 Organisation of operons and control of expression
A number of mechanisms that respond to changes in growth conditions control 
the gene expression of the histidine utilization (Hut) system. One effect is positive
3 It is somewhat confusing that both pathways name one gene hutG even though they are clearly two 
different genes encoding two different enzymes. If necessary in the following discussion these genes 
will be differentiated by subscripts 1 and 2 which refer to the two pathways respectively.
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regulation responding to cyclic AMP or the nitrogen source and repression provoked 
by succinate carbon metabolites. In addition to these global regulatory mechanisms, 
there is specific regulation of the enzymes involved in the pathway.
Genetic studies have revealed that the organisation of the hut genes shows 
considerable diversity in bacteria. In B. suhtilis the genes are arranged in a single 
operon, which can be induced by histidine and is controlled by a positive regulator 
[Kimlii and Magasanik, 1970]. Multiple transcription units are found in Klebsiella, 
Salmonella and Pseudomonas ssp. which are under negative control by a single 
repressor protein, the hutC gene product [Smith and Magasanik, 1971]. Additionally 
the expression of the hut genes can be induced by urocanate, the product of the first 
step in the pathway [Smith and Magasanik, 1971; Goldberg and Magasanik, 1975]. 
Urocanate can originate extracellularly either per se or as the product of 
imidazolylpropionate degradation [Coote and Hassall, 1973]. In Pseudomonas ssp. 
HutF and HutG2 are additionally induced by their respective substrates, 
formiminoglutamate and formylglutamate [Coote and Hassall, 1973]. In P. putida 
three operator sites for the hut genes were identified, the hutUHIG2 operator for this 
operon, a hutF operator and a separate one for hutG2 expression only [Hu et al.,
1989]. The inducer urocanate causes the dissociation of operator-repressor complexes 
for all three operators. Formylglutamate was found to inhibit the binding of the 
repressor to the separate hutG2 operator only and has no effect on the action of 
urocanate on the other operators. It was proposed therefore, that formylglutamate 
binds to a separate site from urocanate on the repressor [Hu etal., 1989].
hufG, hutC fw«
4—mmmm lniil 4mw*,dbvup0'ter hutH hutu ? jmmmmm
PP5030 PFWJl PP5W2
ppwze
-------- ,--------  1--------1-----   1----- “ i--------1------- 1--------1--------1------ 1---- -
5,730,000 5,735,000 5,740,000
Figure 1-8 Hut operon of P seu dom on as putida. Arrows indicate ORFs and their 
direction of expression. The gene names are shown on top of the arrows and their 
genome identifier at the bottom. The scale shows the position of the operon within in 
the genome.
Most genes of the hut operon of P. putida have been identified, but PP5034 
remains unidentified in this cluster (Figure 1-8). The gene preceding hutC, PP5034, is 
included in the same transcriptional unit as the repressor but was found to have no
16
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effect on the binding at the hutUHIG2 operator site [Allison and Phillips, 1990]. 
However it is possible that there is a separate regulatory factor involved in enhancing 
or modifying the effect of the hut repressor. This could be related to the possible 
bifunctional nature of the hut repressor [Hu et a l , 1989]. The corresponding gene of 
PP5053 in P. aeruginosa is PA5104 which was studied in this thesis.
1.5 Aims of the project
The aims of this study are centred around histidine metabolism in 
microorganisms. The primary aims were to characterise structurally and 
biochemically the first two (three) enzymes of the histidine pathway, HisG and HisIE. 
The secondary aims were more diverse and included structural investigations on a 
protein involved in regulation of histidine utilisation. Most of the aims were achieved, 
however because of time restrictions and diversification during the project, based on 
the results obtained, not all could be accomplished. The aims, listed in more detail, 
were as follows:
Determination of the 3-dimensional structure of E. coli HisG, the first enzyme 
of histidine biosynthesis, in complex with AMP by X-ray crystallography. 
This would represent the first structure of an ATP-phosphoribosyltransferase. 
The structure would give insight into the mode of inhibition by AMP and 
presumably help to understand the reaction mechanism.
Cloning and over-expression of HisGs, HisIEs and HisZ from various 
microorganisms. The availability of enzymes from different species increases 
the chance of obtaining diffraction quality crystals for structural 
investigations. Furthermore a diversity of enzymes with different properties 
can be studied, e.g. long and short forms of HisG and bifunctional HisIE in 
comparison to monofunctional HisI and HisE.
Crystallisation and structure determination of HisGs, HisIEs and the HisG- 
HisZ complex. Enzymes obtained from over-expression should be crystallised 
and, assuming that diffraction quality crystals were obtained (ideally in the 
presence of inhibitors or substrates), the 3-dimensional structure is to be 
determined by X-ray crystallography. The structures would provide insight 
into the reaction mechanism and mode of inhibition of the enzymes.
17
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Furthermore they would allow comparison of enzyme structures from different 
species and between different forms, aggregation states and conformations of 
the enzymes.
Investigation of differences between the short form and long form of HisG. 
The native long HisG and the short HisG, in isolation and in complex with 
HisZ, should be investigated structurally and kinetically. This would help to 
explain the lack of activity of the short form and the basis for the formation of 
the HisG-HisZ complex. Mutational analysis helps the investigation by 
separating functional and structural parts and domains of the enzyme.
Characterisation of oligomeric states of HisG. The oligmeric assemblies of 
HisG would be investigated by gel filtration experiments, DLS, X-ray 
crystallography and EM. This will help to understand the mode of inhibition 
by formation of hexameric or higher aggregates.
Determination of the 3-dimensional structure of PA5104 from P. aeruginosa 
by X-ray crystallography. The structure of PA5104 can give an indication of 
the function of the protein which is found in the operon which encodes 
enzymes of the histidine utilisation pathway 2.
18
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Chapter 2: Materials and Methods
2.1 Materials and Methods
2.1.1 Chemicals
Chemicals and biochemicals were generally analytical grade or else the 
highest grade available. Unless otherwise stated all chemicals were purchased from 
the Sigma Aldrich Company Ltd, Poole, UK or Fisher Scientific, Loughborough, UK. 
Bacto-tryptone, bacto-yeast extract and bacto-agar were obtained from Difco 
Laboratories, Detroit, USA. Agarose was obtained from GIBCO BRL Life 
Technologies, Paisley, UK. Complete™ EDTA free Protease inhibitor cocktail tablets 
were obtained from Boehringer Mannheim, Lewes, UK.
2.1.2 Proteins and enzymes
Restriction enzymes and their buffers were obtained either from New England 
Biolabs Inc. {Kpnl, Nde\ , XhoV), Hitchin, UK; Promega Corporation (Nsil, Sacl), 
Southhampton, UK; Stratagene (DpnY), Amsterdam, The Netherlands; or Boehringer 
Mannheim (BcoKV).
VentR® DNA polymerase was obtained from New England Biolabs. Taq DNA 
polymerase was purchased from Promega Corporation and PfuTurbo® DNA 
polymerase from Stratagene. Bacteriophage T4 DNA ligase and Calf Intestinal 
Alkaline Phosphatase (CIAP), were obtained from Boehringer Mannheim.
2.1.3 Oligonucleotides
Oligonucleotides for use both in the polymerase chain reaction were purchased 
from MWG-BIOTECH (UK) Ltd, Milton Keynes, UK. The primers were HPLC 
purified and 5’ phosphorylated when necessary.
2.1.4 Chromatography media
Q-Sepharose and Sephacel S-200 were obtained from Pharmacia Biotech, St 
Albans, UK. Reactive Green 19 agarose resin was purchased from Sigma Aldrich 
Company Ltd. Ni-NTA agarose resin was obtained from Qiagen Ltd, Crawley, UK.
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2,2 Media and supplements
2.2.1 Media for bacterial growth
E. coli strains PIR1, PIR2, DH5a, JM109, various C41(DE3) and BL21(DE3) 
were routinely cultured in Luria-Bertani medium (LB). Solid medium was obtained 
by adding 1.5% (w/v) bacto-agar to the liquid LB. Table 2-1 gives the composition of 
the growth media used.
Table 2-1 Growth media
Media Composition per litre Comments
LB (Luria-Bertani 
broth)
10 g bacto-tryptone 
5 g yeast extract 
5 g NaCl
Sterilised by autoclaving at 15 psi 
for 30 minutes.
LB agar LB plus 15 g bacto-agar Sterilised by autoclaving at 15 psi 
for 30 minutes.
SOC (for 100ml) 2 g bacto-tryptone 
0.5 g yeast extract 
1 ml 1 M NaCl 
0.25ml 1 M KC1
1 ml Mg2+/glucose stock 
(1 M MgCl2, 1 M MgS04,
2 M glucose) filter 
sterilised
Dissolve all (except Mg/glucose 
stock) in 97 ml dsH2Os autoclave, 
cool to RT, add Mg2+/glucose 
stock, filter sterilise medium 
through 0.22 pm filter.
M9 minimal media 100 ml lOx salt solution 
(see Table 2-3)
2 ml 1 M MgS04 
0.1ml 1 M CaCl2 
2 mg thiamine 
5 g glucose
Additional requirements: 
0.5 g all nucleotides 
40 mg all amino acids
2.2.2 Media to produce seleno-methionine substituted protein
To produce seleno-methonine substituted protein, expression was earned out 
in the methionine auxotroph strain B834(DE3)pLysS grown at 37°C in minimal
20
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media M9 (see Table 2-1) with glucose (5 g/1) as carbon source. Minimal media M9 
was autoclaved and then supplemented with thiamine (2 mg/1), all nucleotides 
(0,5 g/1) and all amino acids (40 mg/1) and filter sterilised. Media were prepared 
devoid of methionine, with 50 mg/1 methionine and 50 mg/1 seleno-methionine. 
Antibiotics were added as required at the concentrations listed in Table 2-2.
2.2.3 Antibiotics
Four different antibiotics were used, ampicillin, tetracycline, chloramphenicol 
and kanamycin. Stock solutions of the antibiotics were dissolved in the given solution 
and, if indicated, sterilised by filtration through a 0.22 pm filter (Table 2-2). The stock 
solutions were stored at -20°C. The growth medium was allowed to cool to 50-55°C 
before the addition of antibiotic to a final concentration as given in Table 2-2. All 
media and plates containing antibiotics were stored at 4°C and used within 4 weeks.
Table 2-2 Antibiotic stock solutions and concentrations
Antibiotic Concentration of 
stock solution
Concentration
used
Solute Filter
sterilisation
Ampicillin 100 mg/ml 50-100 pg/ml dsH20
Tetracycline 12.5 mg/ml 12.5 pg/ml 80% ethanol X
Chloramphenicol 34.5 mg/ml 34,5 pg/ml 100% ethanol X
Kanamycin 10 mg/ml 50 pg/ml dsH20
2.2.4 Buffers and solutions for molecular biology experiments
A variety of different buffers and solutions were used for various molecular 
biology experiments. Table 2-3 gives a list of buffers with the composition.
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2.2.5 IsopropyI-f3-D-thiogalactopyranoside (IPTG)
A I M  stock solution was made by dissolving 2 g of IPTG in a final volume of 
10 ml. The solution was filter sterilised through a 0.22 jam filter and stored at -20°C.
2.2.6 X-gal LB agar plates
LB agar medium was allowed to cool to 50-55°C before X-gal and IPTG stock 
solutions were added. The final concentrations were 40 pg/ml X-gal and 0.1 mM 
IPTG. The stock solution of X-gal was 40 mg/ml in DMF and was stored in the dark 
at -20°C. The appropriate antibiotic was added at the same time.
2.3 General methods
2.3.1 General laboratory methods
General molecular biological techniques were carried out as described in 
Sambrook et al. (1989). General laboratory methods for handling proteins and 
enzymes were as described in Deutscher (1990).
2.3.2 French pressure cell
Cells were broken by three passages through an automatic French pressure cell 
at 950 psi. The pressure cell was pre-cooled on ice before use.
2.3.3 pH measurement
pH measurements were made with a Orion 420A+ Benchtop pH Meter 
(Thermo Electron Corporation , USA). The pH meter was calibrated prior to use with 
3 different buffers at room temperature (20°C). It should be noted that given pH 
values are valid for room temperature and can differ when used at other temperatures 
due to the effect of temperature on the pKas of certain buffer components.
2.3.4 Determination of protein concentration
Protein concentrations were estimated by measuring the absoiption at 280nm. 
The molar extinction coefficient was calculated with the Schepartz Lab Biopolymer 
Calculator (http://paris.chem.vale. edu/extinct.htmD. Table 2-4 shows the calculated 
molecular weights and concentrations of standard solutions of the proteins 
investigated in this work.
Chapter 2 Materials and Methods
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Table 2-4 Calculated molecular weights and absorbance at 280nm of 
investigated proteins
Protein M W / D a MWtag1 / Da
A-280nm 
/ mg/ml
A280nmtag ’ 
/ mg/ml
Mth HisG 31,361.4 4.57
Mth HisGrel 37,625.0 1.32
Hin HisG 33,821.3 34,644.1 1.41 1.45
Hin HisG 33,821.3 34,644.1 1.41 1.45
Hin HisIE 25,096.7 25,919.5 0.68 0.71
BS HisG 23,621.3 24,444.1 1.54 1.60
BS HisZ 48,132.0 48,954.8 1.18 1.20
BS 6xG+2xZ 228,611.4 235,194.2 1.42 1.46
BS HisIE 23,901.1 24,723.9 0.81 0.84
Mtb HisG 30,481.0 31,303.8 1.38 1.42
Mtb HisI 12,465.0 14,171.9 0.86 0.97
Mtb HisE 10,274.7 11,981.6 0.71 0.82
Hin HisG short 25,347.3 26,170.1 1.51 1.56
Hin HisG 294 33,172.5 33,995.4 1.39 1.42
Hin HisG C-term 8,335.9 9,158.8 1.16 1.27
'tag means that this calculation includes the his-tag and his-tag with cleavage site when appropriate 
2this column indicates the protein concentration if  the absorbance at 280nm is 1 in a 1cm cell.
2.4 Bacterial strains and cloning vectors
2.4.1 Storage of Bacterial Strains
Bacterial strains were stored as glycerol stocks. These were made by the 
addition of sterile 50% (v/v) glycerol/water to overnight bacterial cultures to give a 
final glycerol concentration of 25% (v/v). Duplicate collections of stock cultures were 
stored at -20°C and -80°C. Some cultures were temporarily stored by streaking onto 
agar plates and maintained at 4°C for up to 4 weeks.
2.4.2 Bacterial strains
The bacterial strains and plasmids used in this project are listed in Table 2-5 
and Table 2-6.
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2.4.3 Growth of plasmid-containing E. coli
Growth of plasmid-containing E. coli cells was achieved in LB or on LB agar 
plates containing the appropriate antibiotic. Isopropyl p-D-thiogalactoside (IPTG) was 
added to the medium at a final concentration of 0.8 mM to induce expression of the 
desired gene.
2.4.4 Growth of cells and isolation of plasmids
This was carried out using standard techniques of inoculating a 1.5 ml 
overnight culture of LB (containing appropriate antibiotics), with a single colony of 
the correct strain. In the case of low copy number plasmids the overnight culture 
volume was 5 ml. These were then grown overnight in a shaking incubator at 37°C. 
Plasmid isolation was performed using a QIAprep Spin Minirep Kit (Qiagen Ltd. See 
Appendix II) as described in the manufacturer’s instructions, and the resulting 
plasmid DNA resuspended in 30 or 50 pi of sterile water.
2.4.5 Production of competent cells
2.4.5.1 Protocol ofHanahan [Hanahan, 1985]
A single colony of an E. coli strain (or 1 pi from a glycerol stock) was grown 
overnight at 37°C in 10 ml of LB. 6 ml of this overnight culture was then used to 
inoculate 74 ml LB in a 250 ml flask. The cells were grown at 37°C on a 
microbiological shaker at 200 rpm until they reached mid log phase 
(A6oonm=0.35-0.5). The cells were chilled on ice for 15 mins and kept at or below 4°C 
throughout the rest of the procedure. The culture was transferred to chilled centrifuge 
tubes and centrifuged at 3000 rpm in a Beckman J2-21 centrifuge for 15mins to pellet 
cells. The pellet was resuspended in 13 ml of ice cold RF1 (see Table 2-3). The cells 
were then incubated on ice for 60 mins and re-pelleted. The pellet was resuspended in 
3 ml of RF2 (see Table 2-3). Cells were aliquoted into 200 pi aliquots and used for 
transformations or flash frozen in a dry-ice/ethanol bath and stored at -80°C.
Competent cells can be stored at -80°C for an indefinite period without 
showing any significant reduction in transformation efficiency.
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2.4.5.2 Protocol using CaCh
For transformation of purified plasmid RIL and RP in BL21(DE3) and 
C41(DE3) Mg/Ca competent cells were used. The protocol is adapted from Sambrook 
et a l (1989).
A single colony of an E. coli strain (or 1 pi from a glycerol stock) was grown 
overnight at 37°C in 1 ml of LB. 350 pi of this overnight culture was then used to 
inoculate 5 ml LB in a 15 ml tissue culture tube. The cells were grown at 37°C on a 
microbiological shaker at 200 rpm until they reached mid log phase 
(A60onm=0.35-0.5). The cells were chilled on ice for 10 mins and kept at or below 4°C 
throughout the rest of the procedure. The culture was transferred to chilled centrifuge 
tubes and centrifuged at 3000 rpm for 10 mins to pellet cells. The pellet was 
resuspended in 1.5 ml of ice cold MgC^-CaCk buffer (see Table 2-3). The cells were 
pelleted again and resuspended in 200 pi of RF2 (see Table 2-3). Cells were 
immediately used for transformation.
2.4.6 Transformation protocol
An aliquot of frozen cells was allowed to thaw on ice prior to use. DNA was 
added to the cells and following gentle mixing the cells were incubated on ice for 30 
minutes. The cells were heat shocked at 42°C for 90 s before being returned to ice for 
a further 15 minutes, 800 pi of SOC medium4 at room temperature was added to the 
cells which were then incubated at 37°C for 40-60 minutes to aid recovery. The cells 
were pelleted for 2 mins at high speed and resuspended in 75 pi of sterile distilled 
water and then plated out onto selective media.
When competent cells from commercial suppliers were used instead of 
self-prepared ones the transformation was performed according to the manufacturers 
protocol.
Chapter 2 Materials and Methods
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2.5 Manipulations of DNA
2.5.1 Gel electrophoresis
Mini-gels ranging from 0.5-2%(w/v) agarose content were supplemented with 
0.05 pg/ml ethidium bromide for visualisation. IX TBE or IX TAE buffer (Table 2-3) 
was used for the preparation, the first for analytical purposes, the latter for extraction 
of DNA. Samples were loaded in a 4:1 volume ratio with DNA gel sample loading 
buffer (Table 2-3). A standard 1 kb ladder (Gibco-BRL) and DNA Molecular Weight 
Marker XIV (Boehringer) was used on all gels as a marker to identify the size of the 
separated bands. The gels were run at a constant voltage (typically 100 V) at room 
temperature until the bromophenol blue marker approached the end of the gels; DNA 
bands were located by viewing under UV light. Photographs were taken where 
appropriate on a UVP BioDoc~It™ System (Fisher Scientific).
2.5.2 Restriction digests
Analytical restriction digests contained 200 ng of DNA with 0.5-1 units of 
each enzyme along with the appropriate reaction buffer. Digests were earned out in a 
volume of 10 pi at 37°C for one hour.
Digests to obtain fragments for cloning contained 5-10 pg of DNA, 5-10 units 
of each restriction enzyme and the appropriate buffer. The digests were carried out in 
a volume of 50 pi at 37°C for at least 3 hours, preferably overnight. When double 
digests contained Ndel, this enzyme was added first and in small aliquots every 30 
minutes before adding the second restriction enzyme. This was done since Ndel is of 
limited stability.
2.5.3 Gel purification of DNA fragments
The restricted plasmid or DNA fragment was separated on a low melting point 
TAE agarose gel and the band excised. The DNA was isolated using a QIAquick Gel 
Extraction Kit (Qiagen Ltd. See Appendix III) as described in the manufacturer’s 
instructions. The resulting DNA was resuspended in 50 pi of sterile water. When 
visual inspection suggested a poor yield, the elution volume was lowered to 30 pi to 
yield DNA at an appropriate concentration.
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2.5.4 Alkaline phosphatase dephosphorylation
Alkaline phosphatase (Promega) was used to dephosphorylate restricted 
plasmid DNA. 1 pi calf intestinal alkaline phosphatase (CIAP) (10 U/pl) was added to 
the plasmid digest and digested as described above. This was only used to 
dephosphorylate vector DNA (not insert DNA).
2.5.5 DNA clean up methods
Sometimes it was necessary to purify further DNA from digested plasmid, 
insert DNA or PCR products in order to remove traces of restriction enzymes and 
other contaminating enzymes such as alkaline phosphatase. This was performed using 
the QIAquick PCR purification protocol (See Appendix III). The DNA was eluted 
into 30 or 50 pi of sterile water.
2.5.6 DNA ligation
The concentration of DNA was estimated by comparison with a known 
amount of molecular weight marker and known standard yields of DNA purification.
In the standard case approximately 0.5 pg of plasmid DNA and 1 pg of insert 
DNA was used per ligation reaction. DNA ligation reactions were carried out using 
1 pi T4 DNA ligase (1 U/pl) and 2 pi of the appropriate lOx reaction buffer along 
with plasmid and insert DNA. All ligations were carried out for 16 hours at room 
temperature in a final volume of 20 pi.
Ligations to produce deletion mutants were performed in a similar matter to 
the manufacturer’s instructions for use in the Exsite Mutagenesis Kit (Stratagene). To 
30 pi of purified PCR product (after Dpnl digestion) 100 pi dsfUO, 10 pi lOx cloned 
Pfu buffer and 5 pi rATP (10 mM) were added. 10 pi of that solution were withdrawn 
and 1 pi of T4 DNA ligase (4 U/pl) added. The ligation was carried out for 1 hour at 
37°C.
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2.6 Cloning by PCR
2.6.1 Primers for PCR
2.6.1.1 Primers for TOPO cloning
PCR primers were designed to amplify the desired gene from genomic DNA. 
No special restriction sites were introduced. The forward primer contained extra bases 
which encode for the Hisg-tag or the 3C protease cleavage site (see Table 2-8). The 
reverse primer contained the stop codon of the gene. The start codon of the gene was 
omitted from the primer after the extra bases.
2.6.1.2 Primers for conventional cloning
PCR primers were designed to incorporate two restrictions sites to facilitate 
cloning into the expression vector. The sites used were Kpnl and Nsil. Kpnl was used 
for the 5’ end of the gene and is located directly following the ATG start codon of the 
cloning vector pTB361 (see Table 2-8).
2.6.13 Mutagenesis primers
PCR primers were designed on the basis of the vector pTBLl '.HinhisG. The 5’ 
end of the reverse primers for the short forms was the stop codon. The forward 
primers started 5’ at the last required residue of the gene HinhisG running towards the 
5’ end of the gene. For the C-terminal domain the reverse primer 5’ end was the first 
residue of the C-terminal domain. The forward primer started at the 3’ end of the 
Hisg-tag going in 5’ direction of the tag. Both reverse primers were 5’ phosphorylated 
for following ligations (see Table 2-10).
2.6.1.4 Linker oligonucleotides
Two complementary oligonucleotides to produce DNA linkers were designed 
so that the double stranded form would have sticky ends (Table 2-9). These sticky 
ends are compatible with the restriction sites NdeI and Xhol, making it possible to 
clone it into a vector restricted with Nde I and Xhol.
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2.6.2 Genomic DNA
Genomic DNA from various bacterial organisms was used as DNA template 
for PCR reactions. Table 2-7 shows which strains were used and the source of the 
genomic DNA.
Table 2-7 Genome Strains
Chapter 2 Materials and Methods
Organism Abbreviation Strain Source
Bacillus subtilis BS 168 Alex Herbert, Glasgow 
University
Haemophilus influenzae Hin KW20 American Type Culture 
Collection (ATCC), USA
Mycobacterium tuberculosis Mtb H37Rv David Robinson/Glaxo 
Wellcome
Methanobacterium
thermoautotrophicum
Mth AH Brian Hanzelka, Ohio 
State University, USA
2.6.3 PCR reactions
2.6.3.1 PCR amplification o f genes from genomic DNA
PCR reactions were carried out using Vent DNA polymerase along with 
appropriate buffer. 2 units of enzyme were added per reaction along with 5 pi of 10X 
Vent reaction buffer, 1 pi of 10X dNTP mix (10 mM stock of each dNTP), 50 pmol of 
each primer, 100 ng of template DNA (genomic DNA, see Table 2-7) and also 
MgS04 in concentrations varying from 0-3 mM (final concentration). 50 pi reactions 
were set up in 0.2 ml PCR tubes without the polymerase. Polymerase was added after 
3 minutes of the initial denaturation step for hotstart PCR.
The following temperature profile was used for 30 cycles in a Biorad Gene
Cycler:
5 min @ 94° C (initial denaturation)
1 min @ 94°C
1 min @ 55°C (annealing temperature varied, see Table 3-2)
1 min @ 72°C
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A final elongation step of 5 minutes at 72°C was performed at the end of the 
amplification reaction to ensure that all amplified material was full length.
2.63.2 PCR for amplification o f deletion mutants (long PCR ’)
PCR reactions were carried out using Pfu turbo DNA polymerase along with 
the appropriate buffer. 2.5 units of enzyme were added per reaction along with 5 pi of 
10X cloned Pfu reaction buffer, 1 pi of dNTP mix (25 mM stock), 50 pmol of each 
primer (Table 2-10), 20 ng of template DNA (pTBLl :HinHisG). To enhance the 
amplification of these long DNA products the method of Tong PCR’ was used [Cheng 
et ah, 1994]. The final reactions contained 2%(v/v) DMSO and 8%(v/v) glycerol. 
50 pi reactions were set up in 0.2 ml PCR tubes.
The following temperature profile was used for 30 cycles in a Biorad Gene
Cycler:
2 min @ 95° C (initial denaturation)
30 sec @ 95°C
30 sec @ 60°C (annealing temperature, varied)
12 min @ 72°C
A final elongation step of 20 minutes at 72°C was performed at the end of the 
amplification reaction to ensure that all amplified material was full length.
2.6.33 Availing o f blunt end PCR products
To produce 3’ A-tails on blunt end PCR products the PCR reaction was treated 
with Taq DNA polymerase. For PCR amplifications with single bands, 1 pi Taq DNA 
polymerase was added to the PCR reaction. Agarose-gel purified PCR products were 
supplemented with the appropriate amount of 1 Ox Taq reaction buffer, 1 pi of dNTP 
mix (100 mM dATP) and 1 pi Taq polymerase. The reaction was incubated at 72°C 
for 20 minutes.
Chapter 2 Materials and Methods
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Chapter 2 Materials and Methods
2.7 Over-expression analysis
2.7.1 Over-expression studies
2.7.1.1 Quick test o f expression
A single colony of the over-expression clone was grown in 10 ml LB for about 
8 hrs at 37°C. Expression was then induced in 5 ml culture with the addition of IPTG 
to a final concentration of 0.8 mM. Samples were then grown for further 16 hrs at 
37°C and then harvested.
2.7.1.2 Time course o f expression
A 2 ml overnight culture, inoculated in LB, was grown overnight at 37°C. A 
10 ml culture was inoculated with 675 pi of this overnight culture. This was then 
grown to an Aeoonm of 0.6 before inducing expression with the addition of IPTG to a 
final concentration of 0.8 mM. 1 ml aliquots were removed at various time points and 
the Afioonm measured and plotted. These samples were pelleted and the cells 
resuspended in 10 pi of sample buffer for each 0.1 A unit. These were then subjected 
to SDS PAGE analysis to observe the band of over-expressed protein.
2.7.2 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
SDS-polyacrylamide gel electrophoresis was performed by the method of 
Laemmli [Laemmli, 1970], with a 5% stacking gel and 10 to 15% running gel 
(depending on the molecular weight of the protein of interest). The ratio of acrylamide 
to bisacrylamide in all PAGE experiments was 30:0.8 and polymerisation was 
induced by the addition of 0.03% (v/v) TEMED and 0.05% (w/v) ammonium 
persulphate. Samples were denatured by boiling for at least 5 minutes after dilution in 
SDS-PAGE sample buffer (Table 2-3). After electrophoresis the gels were stained for 
protein by the Coomassie blue method (see Section 2.7.3).
2.7.3 Staining for Protein
Gels were stained for protein with Coomassie blue for 30 minutes at 37°C. 
The Coomassie reagent consisted of 0.1% (w/v) Coomassie brilliant blue G250 in 
50% (v/v) methanol and 10% (v/v) glacial acetic acid. Destaining was carried out in
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10% (v/v) methanol and 10% (v/v) glacial acetic acid at 40°C until the background 
was fully destained and the bands clearly visible.
2.8 Protein Purification
2.8.1 Growth of cells for protein purification
The appropriate E, coli over-expression strain containing the over-expression 
constructs were inoculated from a glycerol stock into LB containing tetracycline and 
chloramphenicol and grown overnight at 37°C. The following morning, five flasks, 
each containing 500 ml of LB plus antibiotics5, were inoculated with 40 ml of this 
overnight culture and growth continued at 37°C to an Aeoonm of 0.5-0.6. The cells 
were then induced by adding IPTG to a final concentration of 0.8 mM and grown for a 
further 4-5 hours before harvesting in a MSE 2L centrifuge. The cell pellet was either 
used immediately or stored at -20°C until required.
2.8.2 Preparation of Cell Extract
Cells of the E. coli strains obtained from over-expression were thawed slowly 
on ice and resuspended in 20 ml of the appropriate lysis or resuspension buffer (see 
Table 2-11 and Table 2-12). The cell paste was subjected to three passes through the 
French press at 950 psi. 0.1 mg of DNAsel was added and the extract stirred at 4°C 
for 30 minutes before centrifuging at 18,000 rpm for 1 hour at 4°C.
2.8.3 Purification of E. coli HisG
The purification procedure of HisG from E. coli is described in Lohkamp et al. 
(2000). The purification of the Se-methionine labelled protein was identical except 
that 0.8 mM DTT was used instead of 0.4 mM.
2.8.4 Purification of HisG from Mth
Cells containing over-expressed HisG from Mth were resuspended and lysed 
in buffer A. To purify HisG from Mth a heat step was first earned out. The soluble 
lysate was incubated at 65°C for 30 min. The precipitate was removed by
5 Usually only tetracycline; chloramphenicol was omitted in pLysS strains to boost expression, but 
present for RIL or RP strains.
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centrifugation at 10 krpm for 1 h at 4°C. The pellet was discarded and the supernatant 
loaded onto a Q-Sepharose anion exchange column (30 ml bed volume, flow rate
1.5 ml/min) which was equilibrated with buffer B. The column was washed with two 
column volumes of buffer B. Protein was eluted with a 140 ml linear gradient of 
100% buffer B to 50% buffer C. HisG eluted between 64 and 100% buffer C 
(340-500 mM NaCl). These fractions were pooled and dialysed against buffer B. The 
protein solution was loaded on a reactive green 19 dye column (50 ml bed volume, 
flow rate 1 ml/min) that was equilibrated with buffer B. The column was washed with 
two column volumes of buffer B and bound protein was eluted stepwise in two 
column volumes at three different concentrations of sodium chloride (250 mM, 
500 mM and 1 M; 25%, 50%, 100% buffer C). HisG eluted in fractions at 500 mM 
and 1 M sodium chloride. The fractions containing HisG were pooled and dialysed 
against buffer B.
Table 2-11 Buffers for purification of Mth HisG
Buffer Constituents
Buffer A
(resuspension buffer)
50 mM Tris-HCl pH 8.5 
0.4 mM DTT
2 protease inhibitor tablets per 100 ml of buffer
Buffer B 
(wash buffer)
50 mM Tris-HCl pH 8.5 
0.4 mM DTT
1 pro tease inhibitor tablet per litre of buffer
Buffer C 
(elution buffer)
50 mM Tris-HCl pH 8.5 
0.4 mM DTT 
1 M NaCl
1 protease inhibitor tablet per litre of buffer
2.8.5 Purification of Hisx-tagged proteins
A 10 ml Ni-NTA agarose column was pre-equilibrated with at least 3 column 
volumes of Buffer A (Table 2-12) prior to loading the protein. The column was loaded 
at a flow-rate of 1 ml per minute and then washed with 3 column volumes of buffer B 
before eluting with a linear gradient of 0-100% buffer C. 2.5 ml fractions were
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collected at a constant flow-rate of 1 ml/min and the A280nm recorded on a chart 
recorder.
Table 2-12 Buffers for Ni-NTA column
Buffer Constituents Comment
Buffer A 
(lysis buffer)
50 mM NaH2P 0 4 pH 8.0
300 mM NaCl
10 mM imidazole
2 protease inhibitor tablets per 50 ml of buffer
pH adjusted with 
NaOH
Buffer B 
(wash buffer)
50 mM NaH2P 0 4 pH 8.0 
300 mM NaCl 
20 mM imidazole 
1 protease inhibitor tablet per litre of buffer
pH adjusted with 
NaOH
Buffer C 
(elution buffer)
50 mM NaH2P 04 pH 8.0
300 mM NaCl
250 mM imidazole
1 protease inhibitor tablet per litre of buffer
pH adjusted with 
NaOH
2.8.6 Storage of purified enzymes
The buffer containing the purified enzymes was carefully mixed with an equal 
volume of glycerol so that the solution contained 50% (v/v) glycerol. This stock 
solution was stored at -20°C.
2.9 Enzyme assay
2.9.1 Assay for ATP-Phosphoribosyltransferase (HisG)
The enzyme activity was determined by monitoring, in a 1 cm path length 
cuvette, the increase in absorbance at 290 nm at 25°C. The assay mixture contained 
150 mM KC1, 100 mM Tris-HCl pH 8.5, lOmM MgCl2, 5 mM ATP and 0.5 mM 
PRPP. The enzyme assay was carried out in a final volume of 1 ml.
To obtain kinetic parameters for wild type (WT) and mutant HisG from Hin, 
assays were carried out at five concentrations of ATP (0.05, 0.15, 0.5, 1, 2 mM) and
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PRPP (0.025, 0.05, 0.1, 0.15, 0.25 mM). The pH of the 25 mM ATP stock solution 
was adjusted to 8.5 with NaOH. Additional assays were performed with ATP 
concentrations up to 16 mM, but were not included in the analysis. The enzyme 
concentration of Hin WT and deletion mutant enzyme was 1.95 pM (see Section 3.4). 
Each measurement was earned out at least in duplicate. Individual data points were 
averaged and the statistical error included in the fit procedure. The data were fit to the 
Michaelis-Menten equation by least-square regression using Origin software to 
calculate kcat and Km- A molar extinction coefficient at 290 nm of 8=3600 M^cm"1 for 
PR-ATP was used [Smith and Ames, 1964].
Inhibition experiments with histidine were carried out as described above in 
presence of 500 pM histidine. The assay mixture including enzyme, ATP and 
histidine was incubated at 25°C for 3 minutes before the reaction was started by 
addition of PRPP.
Assays of BS HisG were performed as described above with fixed substrate 
concentrations (5 mM ATP and 0.5 mM PRPP) and an enzyme concentration of
1.47 pM. The enzyme was incubated in assay buffer together with the ATP for 10 min 
at the desired temperature. During incubation the absorbance at 290 nm was measured 
as a reference which was subsequently subtracted from the activity measurement. The 
assay was started by addition of PRPP. The temperature during the assay was 
controlled with a heating water bath.
Assays of Mth HisG and HisG-related protein were routinely carried out at 
65°C. The solution of Tris-HCl buffer, KC1 and MgCE was incubated at the higher 
temperature for 5 min before addition of ATP, PRPP and the enzyme.
2.9.2 Assay for short HisG and HisZ
The enzyme activity of the complex was determined as described above with 
the addition of 0.4 mM DTT to the assay mixture. Prior to measurements the reaction 
mixture (without the substrates) was incubated on ice for 1 hr.
2.9.3 HisIE enzyme activity
The activity of HisIE enzyme was monitored by measuring the increase in 
absorbance at 290 nm at room temperature in a 1 ml cuvette. This corresponds to the 
formation of the product Pro-FAR with a molar extinction coefficient at 290 nm of
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e=8000M‘1cm'1 [Martin et a l, 1971]. The assay mixture contained 50 mM Tris-HCl 
pH 8.5, 10 mM MgCk and 50-100 pM PR-ATP (final concentrations).
2.10 Crystallisation
2.10.1 Dynamic light scattering (DLS)
DLS experiments were performed to assess the monodispersity of the protein 
samples prior to crystallisation and to investigate the aggregation state of the 
enzymes. Experiments were carried out using a DYNA-PRO, 801 dynamic light 
scattering/molecular sizing instrument (Protein solutions, Buckinghamshire, UK). 
Usually protein solutions (1 mg/ml) were in 50 mM Tris-HCl, pH 7.5 and 100 mM 
KC1 but several other buffers and pTIs were also assessed. Experiments were carried 
out at 20°C and protein solutions were filtered using a 0.2 pm membrane filter.
2.10.2 Crystallisation screens
Various different sparse matrix screens [Jancarik and Kim, 1991] were used 
for crystallisation of enzymes (see Table 2-13). Screens were either purchased from 
the mentioned companies or prepared according to the composition given by the 
companies.
Table 2-13 Crystallisation screens
Trade Name Common name Company
Crystal Screen Magic 50 Hampton Research
Crystal Screen 2 B-Screen Hampton Research
Additive Screen 1-3 Hampton Research
Wizard I W-Screen Emerald BioStractures
Wizard II Z-Screen Emerald BioStructures
Cryo I Emerald BioStructures
Cryo II Emerald BioStructures
Structure Screen 1 M DI Molecular Dimensions
Structure Screen 2 MDII Molecular Dimensions
- N-Screen In house screen
- M-Screen In house screen
43
Chapter 2 Materials and Methods
2.10.3 Crystallisation methods
Crystallisation of protein was earned out by the method of vapour diffusion. 
Crystallisations were set up as sitting drops using Cryschem Plates (Hampton 
Research, Aliso Viejo, USA). The wells were sealed with Crystal Clear Sealing Tape 
(Hampton Research) and crystallisations were stored at 20°C.
For initial screening purposes 0.75 ml of well solution and a 2 pi drop was 
used. The drop contained 1 pi of well solution and 1 pi of protein solution. Refined 
conditions used 1 ml of well solution and a 4(2+2) pi drop volume unless otherwise 
stated.
To improve the diffraction quality of crystals small quantities of additional 
compounds were used to grow crystals. Additive Screens 1-3 from Hampton Research 
(a total of 72) were used according to the manufacturer’s instructions.
The Seed Bead Kit™ from Hampton Research was used for seeding crystals 
when necessary and used according to the manufacturer’s instructions.
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I. Appendix: QIAprep Spin Miniprep Kit (Qiagen)
This kit allows the rapid isolation of plasmid DNA by an alkaline lysis 
method. The DNA is bound to a silica based resin in the presence of high salt and 
following washing to remove contaminants can be eluted in low salt buffer. There is 
no need for organic solvent extractions and the DNA is of suitable quality for use in 
DNA sequencing and other molecular biological applications.
Step 1 Pellet 1.5-5 ml of an overnight culture
Step 2 Resuspend cells in 250 pi resuspension buffer PI
Step 3 Add 250 pi cell lysis solution (P2) and mix until a clear lysate is 
formed
Step 4 Neutralise by adding 350 pi potassium acetate solution (N3) and mix
Step 5 Spin to pellet insoluble material for 15 minutes at full speed in a 
microfuge
Step 6 Load supernatant on QIAprep column
Step 7 Centrifuge briefly and discard flow-through
Step 8 (Optional, only done when using endA+ strains) Wash with 0.5 ml PB 
buffer, centrifuge briefly and discard flow-through
Step 9 Wash with 0.75 ml PE buffer, centrifuge briefly and discard flow­
through
Step 10 Spin the column in a microfuge for 1 min to remove any residual 
buffer and elute DNA with 30 or 50 pi of sterile water (if plasmid was 
larger than 4 kbp the water was heated to 65°C).
II. Appendix: QIAquick PCR Purification Protocol (Qiagen)
This kit can be used as an alternative to organic solvent extractions and 
ethanol precipitations for the purification of PCR products from contaminating 
nucleotides, enzymes and primer dimers etc. or DNA from contaminating restriction 
enzymes or phosphatases.
The DNA is bound to a silica based resin in the presence of high salt and is 
eluted in low salt buffer in a similar manner to the previous protocol.
This protocol was used with Qiaquick columns from QIAquick Gel Extraction 
kit and buffers from the QIAprep kit.
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Step 1 Take 1 volume of restriction digest or PCR product and add 5 volumes 
of PB buffer.
Step 2 Load supernatant on QIAquick column
Step 3 Centrifuge briefly and discard flow-through
Step 4 Wash with 0.75 ml PE buffer, centrifuge briefly and discard flow­
through
Step 5 Spin the column in a microfuge for 1 min to remove any residual buffer 
and elute DNA with 30 or 50 pi of sterile water (if plasmid was larger 
than 4 kbp the water was heated to 65°C).
III. Appendix QIAquick Gel Extraction Kit (Qiagen)
Allows the purification of DNA from a TAE agarose gel.
Step 1 Separate DNA by electrophoresis on a TAE low melting point agarose 
gel and excise the relevant band
Step 2 Add 3 volumes of QG buffer to 1 volume of gel (100 mg ~ 100 pi).
Step 3 Incubate the sample for 10 min at 50°C to melt the agarose.
(Optional, only for DNA <500 bp or >4 kbp) Add 1 gel volume of 
isopropanol and mix
Step 4 Load supernatant on QIAquick column
Step 5 Centrifuge briefly and discard flow-through
Step 6 Wash with 0.5 ml QG buffer (preheated to 50°C), centrifuge briefly 
and discard flow-through
Step 7 Wash with 0.75 ml PE buffer, centrifuge briefly and discard flow­
through
Step S Spin the column in a microfuge for 1 min to remove any residual buffer 
and elute DNA with 30 or 50 pi of sterile water (if the plasmid was 
larger than 4 kbp the water was heated to 65 °C).
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Chapter 3: Cloning, Over-expression, and Mutational Analysis 
of HisG, HisIE and HisZfrom Multiple Microorganisms
3.1 Introduction
Milligram quantities of protein are required for structural investigations such 
as protein crystallography. Cloning of the target genes and subsequent over­
expression of the gene product is a convenient and relatively inexpensive method to 
obtain large amounts of protein that are naturally produced in very small quantities.
Here the aim was to over-express the first two (three), hisG, hisI(E), genes 
from several organisms. The sequence variation between organisms significantly 
increases the probability of obtaining soluble, well-behaved protein suitable for 
growing diffraction-quality crystals which are necessary for successful structural 
studies. Characterization of the same enzyme from different species also provides an 
opportunity to investigate the role of structural differences in function. In order to 
study the early steps of histidine biosynthesis in detail it was decided to clone and 
over-express the hisG and his IE  (or where applicable hisl and hisE) genes from 
several microorganisms. The genes, organisms, and reasons for selecting them are 
summarised in Table 3-1.
Table 3-1 Histidine pathway genes selected for cloning
Organism Gene Reason for selection
Bacillus subtilis (BS) hisG Contains short form of HisG and 
HisZhisZ
his IE
Haemophilus influenzae (Hin) hisG Pathogenic organism; similar to 
E. colihisIE
Mycobacterium tuberculosis 
(Mtb)
hisG Pathogenic organism; contains two 
genes for hisl and hisE rather than a 
bifunctional his IE
hisl
hisE
Methanobacterium 
thermoautotrophicum (Mth)
hisG Only bacterial genome known so far 
to contains two distinct hisG genesIlisG-related
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All cloned genes were tested for expression of soluble protein in E. coli using 
an IPTG-regulated T7 plasmid expression system.
3.2 Generation of over-expression constructs from B. subtilis,
H. influenzae and M. tuberculosis
3.2.1 Introduction
To generate over-expression constructs from B. subtilis (BS), H. influenzae 
(Hin) and M tuberulosis (Mtb) the ECHO™ Cloning System from Invitrogen was 
employed for ease of use and speed in performing multiple clonings simultaneously. 
All genes had a non-cleavable N-terminal Hisg-tag fused for rapid purification. The 
exceptions were Mtb hisl and hisE which had cleavable His6-tags included as they are 
small proteins and 6 extra charged residues could alter the properties of the enzyme 
more significantly.
Unfortunately the use of the ECHO™ Cloning System was very restricted and 
will be discussed in Section 3.2.5. Therefore a conventional cloning approach using a 
modified and well-characterized over-expression vector was employed (see Section 
3.2.6).
3.2.2 T7 expression vectors
T7 expression systems allow the efficient over-expression of a protein in a 
controlled manner in E. coli. The cloning vector has a promoter for T7 RNA 
polymerase located upstream from a multiple cloning site which is used to clone the 
insert DNA. T7 RNA polymerase is able to transcribe DNA five times faster than 
E. coli RNA polymerase and as it is specific for T7 promoters it results in induction of 
high level expression from such promoters only [Chamberlin and Ring, 1973; Golomb 
and Chamberlin, 1974]. This allows the specific expression of the gene product of 
interest. Bacterial strains for over-expression usually contain the gene for the T7 RNA 
polymerase integrated into the chromosome and are labelled (DE3). The bacterial 
strains used for expression purposes can carry a gene for T7 lysozyme which binds to 
and inhibits T7 RNA polymerase [Moffatt and Studier, 1987]. This is used as a means 
of controlling basal levels of protein expression prior to induction with IPTG. This is 
particularly important if the protein is toxic to the bacterial strain. The gene for the T7
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lysozyme is present on the pLysS plasmid [Studier and Moffatt, 1986], which also 
contains a chloramphenicol resistance gene and is transformed separately into the 
expression host.
In case the protein or gene is toxic to the host E. coli strain it can be useful to 
use a special over-expression strain such as C41(DE3) [Miroux and Walker, 1996]. 
This strain is a mutation of the well-characterised BL21(DE3) over-expression strain 
which was selected based on resistance to toxic genes or over-expressed proteins. It 
shows a delay in target mRNA production and an overall decrease in target mRNA 
levels.
Differences in the codon usage by different organisms can also profoundly 
affect the heterologous expression of proteins due to the presence of codons rarely 
used by E. coli. Genes encoding the tRNAs of codons rarely used in E. coli have been 
cloned into plasmids to help improve expression levels. Strains are available for rare 
Arg, lie and Leu tRNAs (RIL) and Arg and Pro tRNAs (RP) usage from Stratagene 
(BL21(DE3)RIL and BL21(DE3)RP respectively).
3.2.3 Amplification of his genes by PCR
The genes of interest were amplified by PCR Horn genomic DNA using Vent 
DNA polymerase. The oligonucleotides in the forward direction were designed to 
include a Hise-tag following the start codon ATG. The exception, his I  and hisE from 
Mtb, have a 3C protease cleavage site before the gene product. This cleavage site will 
then be fused to a N-terminal Hise-tag encoded for by the expression plasmid. In all 
cases the initiation codon of the gene was omitted from the oligonucleotides to avoid 
an alternative translational start beginning after the tag. For the genes with the 
cleavage site included, care was taken to avoid frameshifts in the subsequent 
recombination used by the ECHO™ Cloning System. Oligonucleotides for the reverse 
PCR direction were matched to the gene including the stop codon. The sequences of 
the used oligonucleotides are shown in Table 2-8.
PCR amplification of the different genes required different reaction 
conditions. The conditions which gave the best results concerning a single band and 
amount of amplified DNA are listed in Table 3-2.
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Table 3-2 Conditions for optimal PCR of histidine genes
Organism Gene Tm (°C) [MgS04]/mM Comments
B. subtilis hisG 62 0.5
hisZ 62 1.0
hisIE 62 0.5
H. influenzae hisG 62 1.0 Taq DNA 
Polymerase
hisIE 56 1.0
M. tuberculosis hisG 68 1.0
hisl 65 2.0
hisE 65 2.0
M. thermoautotrophicum HisG 60 1.0
H isGrel 55 2.0
TOPO cloning, which is part of the ECHO™ system, requires a single 3’ A- 
overhang and is not compatible with DNA amplification using proof-reading enzymes 
such as Vent DNA polymerase which generates blunt-ended PCR products. To permit 
cloning into TOPO vectors A-tails were generated by using Taq DNA polymerase to 
modify the PCR product from the initial amplification reaction.
3.2.4 Cloning of PCR products
3.2.4J TOPO® cloning
A schematic diagram of the TOPO reaction using the vector pUni/V5-His- 
TOPO with 5’ T-overhangs indicated is shown in Figure 3-1. Covalently bound to the 
T-overhang via a phosphate group is the enzyme topoisomerase I, which uses its DNA 
ligase activity to join free DNA ends together. The availability of substrate with a free 
3’ A-overhang (the PCR product) results in the enzyme completing its catalytic cycle 
resulting in the joining of the two lengths of DNA (vector and PCR product) and the 
subsequent release of the topoisomerase enzyme.
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4 s
i  i
Iopoisomcrasc I 
is released
Figure 3-1 Schematic diagram of TOPO reaction.
The TOPO reaction was performed according to the manufacturer’s 
instructions with the exception that the vector was diluted 1:10 as previous 
experiments had shown that diluting the vector in vector buffer still provided the user 
with a representative number of clones for analysis (pers. communication N. Hanlon). 
Comparable results were also obtained when the vector was diluted 1:10 with water. 
The reactions were transformed in PIR1 cells, plated on LB-agar plates and incubated 
overnight.
After purification of the plasmid analytical digests were performed on the 
pUni\hisX vectors to confirm the presence of the gene and also to identify the 
orientation of the gene in the vector, as TOPO cloning is not directional. For the 
subsequent ECHO cloning the 5’ end of the gene has to be located just downstream of 
the ribosome binding site (RBS) so that the gene can be expressed.
The digests were performed with restriction enzymes which cut the vector as 
well as the insert. Nsil and Sad  double digests were used for the His-tagged genes 
and single Xhol digests for the genes with the attached cleavage site. The recognition 
sequence of Nsil is included in the His-tag and Xhol is part of the 3C cleavage site. 
Sad  and Xhol are unique restriction sites in pUni and are located closely downstream 
and upstream respectively of the inserted PCR product (see Figure 3-2). DNA digests 
were analysed by agarose gel electrophoresis and DNA fragments of the expected size 
produced, confirming the presence and orientation of the cloned gene (data not 
shown). DNA digests were analysed by agarose gel electrophoresis and DNA 
fragments of the expected size produced, confirming the presence and orientation of 
the cloned gene (data not shown).
The TOPO cloning of Hin hisG proved to be difficult and despite repeated 
attempts no positive clones could be identified. Detailed analysis revealed the absence 
of 3’ A-overhangs on the PCR products as being responsible for the lack of positive
Topoisomcrasc I recognition sites
© © '_  V
S minutes at 
room temperature
3 ' phosphate I
m
TOW) TA Cloning- vector 7<u/-ampliticd PCR product Ligation complete
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TOPO clones and so the gene was reamplified using Taq DNA polymerase to ensure 
A-tails. This approached was successful and could prove useful for further cloning.
Uni1 Fo rw ard  prim ing site Kpn I _^__
351 GAGCTTAGTA CGTACTATCA ACAGGTTGAA CTGCTGATCA ACAGATCCTC TACGCGGCCG CGGTACC ATA
loxP site X h o  I RBS
421 ACT TCG TAT AGC ATA CAT TAT ACG AAG TTA TCG GAG GAA TTG GCT CGA GGA ATT GCC
TGA AGC ATA TGC TAT GTA ATA TGC TTC AAT AGC CTC CTT AAC CGA GCT CCT TAA CGG
Sac I,__________________ V5 epitope_____________
478 Cl AGG GCA ATT CGG GAG CTC GGT AAG CCT ATC CCT AAC CCT CTC CTC
G / E * 3 2 $ 2 S l e T  TCC CGT TAA GCC CTC GAG CCA TTC GGA TAG GGA TTG GGA GAG GAG
Arg Ala lie Arg Glu Leu Gly Lys Pro lie Pro Asn Pro Leu Leu
_____________ 6 x H is  tag______________  (Jni1 R e v e rse  prim ing site1
527 GGT CTC GAT TCT AGC CAT CAT CAC CAT CAC CAT TGA AGCTCGCT ATCAGCCTCG ACTGTGCCTT 
Gly Leu Asp Ser Ser His His His His His His ***
591 CTAGTTGCCA GCCATCTGTT GTTTGCCCCT CCCCCGTGCC TTCCTTGACC CTGGAAGGTG CCACTCCCAC
Figure 3-2 Sequence of pUni vector and characteristics in the vicinity of the 
inserted PCR product.
3.2.5 ECHO™ cloning
The ECHO™ Cloning System produces an over-expression construct by 
recombination of two vectors. One vector is pUni (donor vector) with the gene of 
interest cloned. The other is an acceptor vector which can have different promoters for 
different expression systems. The acceptor vectors used here are pCRT7-E (T7 
promoter) and pBAD/Thio-E (arabinose promoter and N-terminal GST fusion) from 
Invitrogen as well as a pET based vector with a N-terminal His-tag (courtesy of N. 
Hanlon, Glasgow University). Cre recombinase recombines the two vectors with the 
use of the internal lox sites in both vectors to give the desired recombinant over­
expression plasmid. A scheme of this reaction is shown in Figure 3-3.
Recombination reactions were set up according to the manufacturer’s 
instructions and transformed into DH5a and TOP 10 (only for pBAD vectors) 
competent cells. The pUni vectors containing the His-tagged genes were recombined 
with pCRT7-E and those containing the 3C cleavage site with both the pET vector 
and the pBAD vector.
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/ox* = loxP or loxH depending on acceptor vector
Figure 3-3 Scheme of recombination reaction in the ECHO™ Cloning System  
(Invitrogen).
Restriction digests of the purified plasmids confirmed that all the 
recombination reactions were successful and that occasionally multiple recombination 
events occurred (i.e. more than one acceptor and one donor recombine; data not 
shown).
The T7-based expression vectors were transformed into competent 
BL21(DE3)pLysS cells for expression studies. Expression of the pBAD vector can be 
induced with arabinose in TOP 10 cells so no further transformation was required.
No (over-)expression was detected for any of the T7-based over-expression 
constructs. Various different ways of improving expression (different temperatures, 
different IPTG concentrations, lower levels of antibiotic etc.) as well as different 
E. coli over-expression strains such as C41 were tested with no success. Furthermore 
the control pCRT7-E/Uni-CAT provided by Invitrogen showed no over-expression 
under any of the tested conditions whereas a positive control of a gene in the T7-based 
vector pTB361 showed over-expression. Despite extensive help from the Technical 
Service from Invitrogen the problem could not be resolved.
The pBAD based expression constructs were induced with arabinose and 
showed very low levels of over-expression. The failure of the ECHO Cloning System 
to produce acceptable results led to the development of an alternative cloning strategy 
for the over-expression of the hisX genes.
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3.2.6 ‘New’ cloning strategy
Following the experience with ECHO™ Cloning System an alternative 
approach for over-expression of the MsX genes was employed. It was decided to use a 
‘classic’ cloning strategy by sub-cloning the desired genes directly into the expression 
vector of choice. Since the existing pUnk/nxX gene constructs already carried the 
verified hisX genes it was decided to use these plasmids as the source for sub-cloning 
the hisX genes into an expression vector.
To use this approach an over-expression vector with compatible restriction 
sites to those in pUni:hisX was needed. Good candidates for restriction sites would be 
Nsil and Sacl for the His-tagged genes and Xhol and Sad  for the 3C cleavage site 
genes. These restriction sites would produce a fragment which includes the whole 
gene, including the His-tag or part of the 3C cleavage site respectively, and a small 
fragment of the pUni vector at the 3’ end. Furthermore the 5’ cloning site should be in 
close proximity of the RBS to ensure good over-expression. Unfortunately no existing 
T7-based over-expression vector could be found which fulfilled these criteria. It was 
decided to produce new over-expression vectors which could be used for subcloning 
with the existing pUni:/zwXclones.
3.2.7 Generation of new over-expression vectors
The over-expression vector pTB361, which was obtained courtesy of Dr M. 
Horsburgh, University of Glasgow, was used as the basis for the design of new 
expression vectors. It was chosen for expression of the hisX genes because it had been 
used in the laboratory with great success and shows high levels of over-expression. 
The aim was to introduce a polylinker into the multiple cloning site of pTB361 which 
includes restriction sites that are compatible with the pUni:/7AX vectors. Two different 
new vectors might be needed, one for the already His-tagged genes and one for the 3C 
cleavage site genes. For the latter sequences encoding a ITis6-tag and a 3C cleavage 
site would need to be introduced along with the linker. It was aimed to make the new 
vectors as universal as possible so that their use would not be restricted to the cloning 
of the his genes of interest.
A derivative of pTB361 with a gene already cloned into the multiple cloning 
site was digested with Ndel and Xhol. This had the advantage that any partial digests 
of the plasmid could be easily identified and so only completely digested vector DNA 
was agarose gel purified. Overlapping oligonucleotide linkers were designed so that in
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the double stranded form sticky ends complementary to Ndel and Xhol were 
produced. The sequence of the primers used to produce the linkers can be found in 
Table 2-9. Double stranded linkers were produced by mixing the two complementary 
oligonucleotides, heating the mixture above their annealing temperature and allowing 
it to anneal slowly to room temperature. This double stranded linker was then ligated 
into the digested pTB361 using a range of different linker concentrations in the 
reaction mix. The ligation was then transformed into competent DH5a cells. The 
plasmids purified from colonies obtained were tested for insertion of the linker by 
restriction digest. Digestion of the vector with Sacl confirmed the presence of the 
linker as this unique restriction site was newly introduced.
= = >  T 7  P r o m o t e r  - 5 5
S a c l
N s i l  X h o l
i 1 I F n — i
GGAGATATAC ATATGCATAA GTCAATAGAG CTCGAGTAGT ACTAATCTAG 
CCTCTATATG TATACGTATT CAGTTATCTC GAGCTCATCA TGATTAGATC
Figure 3-4 Vector diagram and sequence of pTBL1 (the diagram was produced 
with the program pDRAW).
Schematic diagrams of the two new vectors are shown in Figure 3-4 and 
Figure 3-5. The vector with the new restriction site only was named pTBLl and the 
plasmid with the additional His6-tag and 3C protease cleavage site was named pTBL2.
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= = >  T 7  P r o m o t e r
T7 P r o m o t o r
GGAGACCACA ACGGTTTCCC TCTAGAAATA ATTTTGTTTA ACTTTAAGAA 
CCTCTGGTGT TGCCAAAGGG AGATCTTTAT TAAAACAAAT TGAAATTCTT
N s i l  X h o l
iO GGAGATATAC ATATGCATCA T CAT CAT CAT CACCTCGAGG TACTCTTCCA 
CCTCTATATG TATACGTAGT AGTAGTAGTA GTGGAGCTCC ATGAGAAGGT
M H H  H H H  H L E V  L F Q
6 x  h i s  t a g  p r o t e a s e  c l e a v a g e
S a c I
X h o l___
i 1--- •
AGGTCCGAGC TCGAGTAGTA CTAATCTAGA GTCGACATTA TATTACTAAT 
TCCAGGCTCG AGCTCATCAT GATTAGATCT CAGCTGTAAT ATAATGATTA
G P S  S S S T  N L E  S T L  Y Y *  
s i t e
Figure 3-5 Vector diagram and sequence of pTBL2 (the diagram was produced 
with the program pDRAW).
3.2.8 Cloning of his genes into pTBLl and pTBL2
The hisX genes were cloned into pTBLl and pTBL2 as follows. The His- 
tagged genes were excised from pUni\hisX with the restriction enzymes Nsil and Sacl, 
whereas those with the 3C cleavage site were released with Xhol and Sacl. The 
vectors pTBLl and pTBL2 were prepared by restriction with the appropriate 
restriction enzymes The plasmid pTBL2 has two Xhol sites present and to eliminate
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any problems which may arise from the second Xhol site (which overlaps with the 
Sacl site see Figure 3-5) this vector was digested with Sacl followed by Xhol. Gel- 
purified fragments were ligated as appropriate and transformed into DH5a cells. The 
identity of recombinant clones was confirmed by restriction analysis and positive 
clones were then transformed in competent BL21(DE3)pLysS cells to test for over­
expression.
3.3 Generation of over-expression constructs from 
M. thermoautotrophicum
3.3.1 Introduction
Interestingly the genome of Mth contains two genes for HisG. To investigate 
the biochemical and structural differences between the HisG and HisG-related protein 
from Mth, both genes were cloned into the over-expression plasmid pTB361.
3.3.2 pTB361 plasmid
The expression plasmid used for these experiments is pTB361. No affinity tag 
for purification purposes was used as the genes are from a thermophilic organism and 
a heat step should be very effective for purification. The T7 promoter is located 
immediately upstream of the multiple cloning site and the restriction site Kpnl is used 
to clone the 5‘ end. The Kpnl site introduces an extra Val and Pro residue between the 
ATG start codon and the HisG protein. This cloning strategy was favoured over using 
the Nde I site which would not add any extra residues at the N-terminus but can be 
difficult to digest.
3.3.3 Amplification of hisG and HisG-related protein genes by PCR
Cloning into the expression vector pTB361 required the generation of 
restriction sites within the HisG and HisG-related protein DNA to facilitate cloning in 
the correct orientation and reading frame. The Kpnl site was used as the 5’ site and 
Xhol was used as the 3’ site. These two sites were generated by PCR using primers 
containing the appropriate restriction sites (Table 2-8).
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The genes were amplified from genomic DNA by PCR using Vent DNA 
polymerase. The Mth genomic DNA was obtained courtesy of Dr. B. Hanzelka, Ohio 
State University, USA.
3.3.4 Cloning of PCR product into pGEM
pGEM is a simple cloning vector with a multiple cloning site within the lacZa 
gene which permits screening of recombinant clones using blue/white colour 
selection. Blue colonies indicate no insert in the multiple cloning site whereas white 
colonies indicate an insertion because it disrupts the lacZa gene.
The multiple cloning site contains a restriction site for EcoRV which generates 
a blunt-ended linear vector. This can be used to clone blunt-ended DNA inserts, such 
as PCR products obtained with a proof-reading DNA polymerase.
Purified PCR product of the Mth genes was directly ligated into EcoRV 
digested pGEM. The ligation was transformed into competent JM109 cells which are 
suitable for the blue/white screening. The cells were plated on LB-agar plates 
supplemented with IPTG and X-Gal. White colonies were picked for analysis and 
purified plasmid analysed by restriction digestion.
3.3.5 Cloning into pTB361
pTB361 and the pGEM vectors with the hisG(rel) insert were digested with 
Kpnl and Xhol. After purification from agarose gel the hisG inserts were ligated into 
the digested pTB361. The ligation was transformed into competent DH5a cells. 
Purified plasmid was analysed by restriction digest for the correct insert and positive 
clones were transformed in BL21(DE3)pLysS for over-expression.
The level of over-expression of these constructs was poor. This was attributed 
to the presence of rare codons in the DNA sequence of the Mth genes. Therefore 
pTB36\\Mth-hisG (rel) was transformed in E. coli strains designed to increase over­
expression levels of genes with rare codons. The results are described in Section 4.2.
3.3.6 Generation of BL21 and C41 E. coli strains to increase over-expression
levels of genes containing rare codons
E. coli strains BL21(DE3) which increase levels of over-expression for genes 
containing rare codons are commercially available (Stratagene). These strains contain 
a vector, RIL or RP, for expression of rare codon tRNAs. The RIL plasmid encodes
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tRNA genes for Arg (AGG & AG A), lie (ATA) and Leu (CTA), whereas the RP 
carries tRNA genes for Arg (AGG & AG A) and Pro (CCC). Unfortunately these 
strains could not be used here as pTB361 is selective for tetracycline resistance and 
the commercially available strains contain tetracycline resistance on their genome. 
Therefore new strains with no tetracycline resistance had to be created.
Firstly, the plasmids RIL and RP were isolated from the commercially 
available BL21(DE3) strains. This was done with extra care as BL21 strains are 
endA+ which means that they contain endonucleases that can degrade the plasmids. 
Restriction analysis confirmed the identity of the plasmid and gel analysis prove that 
the plasmid preparation was free from degradation products. Purified RIL and RP 
plasmids were then transformed in BL21(DE3) and C41(DE3) competent cells6. 
Transformations were plated on LB agar plates containing chloramphenicol to select 
for the RIL and RP plasmids. Strains were named BL21(DE3)RIL, BL21(DE3)RP, 
C41(DE3)RIL and C41(DE3)RP.
3.4 Generation of mutants of HisG from H. influenzae
3.4.1 Introduction
Site-specific mutagenesis of proteins is a widely used technique to investigate 
the role of both individual residues and protein domains in the function of a protein. 
Both approaches were used here to investigate structure-function relationships with 
the HisG protein.
The C-terminal domain of HisG is involved in the formation of the hexameric 
form of the enzyme but no function beyond this structural role has been elucidated7. 
Therefore a deletion mutant was created with the C-terminal domain deleted (residue 
222-298 in Hin, corresponding to 223-299 in E. coli; named Hin HisGshort). 
Furthermore, a mutant with just the last 5 residues deleted (294-298 in Hin, 
corresponding to 295-299 in E. coli; named Hin HisG294) was also constructed as 
these residues appear to form the main interaction between the C-terminal domains 
(see Section 6.3 and 8,4). To investigate the binding and structural properties of the C-
6 Cells were made competent using the CaMg method and free o f additional plasmids such as pLysS.
7 This study was initiated before the structure o f HisG from Mtb confirmed the binding o f histidine at 
the C-terminal domain.
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terminal domain itself a deletion construct expressing the C-terminal domain alone 
was also made.
HisG from Hin was chosen to obtain the mutants as the vector constructs were 
readily available (see Section 3.2), the over-expression was very good and it is similar 
to the E. coli enzyme therefore facilitating the comparison of results. Furthermore the 
construct contains an N-terminal His6-tag for rapid purification.
3.4.2 Generation of deletion mutants
Deletion mutants were created by PCR of the whole plasmid. The primers 
were designed so that the part of the gene to be deleted was omitted from the 
amplification. Figure 3-6 shows a schematic flow diagram of how the deletion 
mutants were created.
Firstly, the template DNA is amplified by PCR. To amplify this 5.3 kbp DNA 
the method of long PCR was employed [Cheng et a l , 1994], which requires the 
addition of 2% DMSO and 8% glycerol to the PCR reaction mix as well as using 
PfuTurbo DNA polymerase. A number of other PCR protocols were tried initially but 
none were successful.
To fragmentize the template plasmid the restriction enzyme Dpnl was added to 
the PCR reaction. Dpnl will only digest DNA which is methylated and therefore does 
not digest the PCR amplified DNA. The PCR product was purified from agarose gel 
and ligated with T4 ligase. The ligations were transformed into competent DH5a cells 
and plated on LB-agar plates containing tetracycline. Plasmids were analysed by 
restriction digest with Nsil and Xhol and for the Hin HisGshort construct several 
positive clones were obtained, whereas only single clones were obtained for the Hin 
HisGcterm and Hin HisG294 constructs. Correct clones were identified by restriction 
analysis. The small size of the deletion (15 bp) produced by the Hin HisG294 
construct required a high percentage agarose gel to be run to visualise the difference 
between the wild-type and mutant DNAs.
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Template DNA
Oligonucleotide primer # 2  Oligonucleotide primer # \
(phosphorylafed)
PCR Step 1♦
Template dsDNA Linear mutagenesis primer-incorporating
PCR product with extended bases
Dpn I restriction enzyme, Step 2
Cloned Pfu DNA polymerase f
' = p e =
Dpn l-digested Cloned Pfu DNA polymerase-polished
template and hybrid DNA linear DNA
T4 DNA ligase Step 3
Recircularized PCR product
|  Step 4
Transform E. coli
Figure 3-6 Scheme of protocol to produce deletion mutants (adapted from 
Stratagene)
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I. Appendix: Schematic of vector pl)ni/V5-His-TOPO
R6K7 origin, bases 6-397
Uni1 forward priming site: bases 365-383
toxP site bases 418-451
TORO' Cloning site bases 480-481
V5 epitope: bases 500-541
6xHis tag bases 542 559
Uni1 reverse priming site, bases 563-584
BGH poiyadenylation sequence bases 582-790
T7 transcnption torminatlon region: bases 805-933
Kanamycin resistance gene: bases 1112-1906 (C)
kon promoter: bases 1905-2044 (C)
II. Appendix: Schematic of vector pCRT7-E
17 promoter; hose# 21-37 
17 promoter priming sile: buses 21-40 UvcH site: bases 65-0X
17 tntnscnplion icnninuinm region: buses 145-IV? 
Zeucin"* resistance gene: buses 272-735 
Ampicillin resistance gene: buses 739-1616 
pUC origin: buses 1761-2434
III. Appendix: Schematic of control vector pCRT7-
E/Uni-CAT
Unil forward priming site- ba.se*> 29X1-2999 
/««•/* site (in»m donor): bases 3034-3067 
17 iranscnpiion lenninulion region, buses 3114-3161 
/eoein'" resistance gene: bases 3241*3704 
Ampieillin resistance gene: bases 3708-45X5 
pUC origin: buses 4730-5403 
((*) indicates complementary sound
*The modified T is oilher a 3' overhang 
(pUni/V5-His-TOPO ) or paired with an 
A in pUm-Biunt/V5-His-TOPO
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Chapter 4: Over-expression, Purification, Crystallisation and 
Characterisation of Enzymes
4.1 Over-expression and purification of his-tagged enzymes from 
the histidine pathway
4.1.1 Over-expression
The level of over-expression was tested for each of the clones by the quick 
protocol described in Section 2.7.1. Over-expression was observed in all cases as 
proved by SDS-PAGE. A typical gel demonstrating the over-expression of Mtb Hisl 
and HisE is shown in Figure 4-1. It was difficult to obtain a clear band to show over­
expression of Mtb HisE on SDS-PAGE with Coomassie blue staining; this is due to
the small size of the protein.
Marker M A B C D E F
(kDa) -    ^
97.4
26.6
66.2
39.2
14.4
21.5
—  Hisl
— HisE
Figure 4-1 Over-expression of Mtb Hisl and HisE.
Lane Clone Lanes Clone
A Mtb Hisl 1 Over-night culture uninduced D
B Mtb Hisl 1 Over-night culture induced E
Mtb HisE 1 Over-night culture uninduced 
Mtb HisE 1 Over-night culture induced
with IPTG
C Mtb Hisl 2 Over-night culture uninduced F
with IPTG
Mtb HisE 2 Over-night culture uninduced
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Comparison of soluble and insoluble fractions showed that some of the 
proteins are over-expressed in inclusion bodies rather than as soluble protein. Table 
4-1 shows histidine pathway enzymes which expressed in a soluble form and as 
inclusion bodies. Enzymes with no significant amount of over-expression of soluble 
protein were not used any further in this work. All soluble enzymes were purified and 
crystallisation trials undertaken.
Table 4-1 Soluble and insoluble his enzymes obtained by over-expression in 
pTBLl and pTBL2
Organism Enzyme Soluble Inclusion bodies Comment
B. subtilis HisG >4 X
HisZ X
HisIE X
H. influenzae HisG X
HisIE X S
M. tuberculosis HisG X S
HisI X S
HisE S Some soluble, some 
inclusion bodies
4.1.2 Purification
All soluble his-tagged histidine pathway enzymes were purified in a one-step 
purification procedure using a Ni-NTA column. This resulted in almost pure protein 
as shown by SDS-PAGE. An example of the purification of BS HisZ is shown in 
Figure 4-2. Some minor contaminants are visible with a molecular weight of about 
70 kDa which result from nonspecific binding to the metal resin.
HisI and HisE from Mtb contained a 3C protease cleavage site for proteolytic 
removal of the his-tag. However the tag was not removed and enzyme including the 
tag was used for crystallisation and activity measurements.
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Marker M A B C D E F G H  I J K L  
(kDa)
97.4
66.2
39.2
26.6
21.5 ^
♦14.4 V *
Figure 4-2 SDS-PAGE of purification of B S  HisZ.
Lane
A Whole cell extract
B Extract after French press
Lanes
D Soluble fraction
E-L Fraction from Ni-NTA elution
C Insoluble fraction
4.2 Over-expression and purification of HisG and HisG-related 
enzyme from M. thermoautotrophicum
4.2.1 Over-expression
The genes encoding the HisG and the HisG-related protein of Mth contain 
several rare codons. Table 4-2 shows the percentage occurrence of rare codons in 
these genes and compares this with the codon usage in E. coli.
The table shows clearly that there will be a problem with the codons for Arg 
and especially lie. Therefore the strains containing the RIL plasmid should increase 
the over-expression substantially.
Plasmids pTB36\:Mth-HisG/HisGrel were transformed in the BL21 and C41 
RIL and RP strains to test for expression levels. Figure 4-3 and Figure 4-4 show SDS- 
PAGE analysis of over-expression of HisG and HisG-related protein in the different 
strains.
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Table 4-2 Rare codon usage in HisG and HisG-related protein of Mth
aa Codon
triplet
Mth HisG Mth HisG-related protein E. coli
rare codons/ 
all codons 
for aa
fraction of 
rare to all 
codons(%)
rare codons/ 
all codons 
for aa
fraction of 
rare to all 
codons(%)
fraction of 
all codons
(%)
Arg AGG 14/22 4.86 14/27 3.91 0.14
AGA 4/22 1.38 3/27 0.83 0.21
lie AUA 21/30 7.29 23/27 6.42 0.31
Leu CUA 0/27 0 1/28 0.27 0.41
Pro CCC 7/13 2.43 5/14 1.39 0.43
Figure 4-3 Over-expression of Mth HisG in different E. coli strains. SDS-PAGE 
of over-expression in BL21(DE3) strains (a) and C41(DE3) strains (b).
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Figure 4-4 Over-expression of Mth HisG-related protein in different E. coli 
strains. SDS-PAGE of over-expression in BL21(DE3) strains and C41(DE3) strains.
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For Mth HisG the highest levels of expression were obtained from both RIL 
strains with C41 giving the best results (see lane D in Figure 4-3 b). The HisG-related 
protein from Mth was expressed in the highest level in BL21(DE3)RIL (see lane E 
Figure 4-4). These results confirm the prediction that the RIL strains would give the 
best enhancement of expression. This is due to the frequent occurrence of the rare 
codon for lie (ATA) in both genes. The strains with the best results were used for 
subsequent large scale over-expression.
4.2.2 Purification of HisG
Because Mth is a thermophilic bacterium with an optimal growth temperature 
of 65°C; purification of the over-expressed HisG was attempted using a heat step. 
This should denature most of the host proteins but leave the thermostable HisG in its 
native form. However using an incubation at 75°C for 15 minutes, which was 
successfully used for glutamyl-tRNA reductase from Mth [Hungerer et al., 1996],
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resulted in the denaturation of the majority of the HisG protein. Therefore the 
temperature in the heat step was reduced to 65°C. This removed the majority of the 
host protein but the purity of HisG was not adequate for crystallisation and further 
purification was required. A Q-Sepharose anion exchange column was an effective 
second step followed by a dye column (reactive green 19) which had previously been 
used successfully in the purification of E. coli HisG [Lohkamp et a l , 2000]. The 
resulting pure protein was used for crystallisation, DLS experiments and enzyme 
assays.
4.2.3 Resolubilisation, refolding and purification of HisG-related protein
The HisG-related protein from Mth was mainly over-expressed in inclusion 
bodies. It was shown that the inclusion bodies could be resolubilised in buffer 
containing 3-5 M urea. Refolding of the enzyme was accomplished by dialysis against 
Tris buffer at pH 7.5 containing no urea. The correct folding of the HisG-related 
protein was proved by activity measurements in the HisG assay.
Preliminary experiments showed that the inclusion bodies can be partially 
purified by washing with buffer containing 30%(w/v) sucrose and 1% Triton-X-100. 
However further purification steps of the resolubilised protein are required to provide 
pure protein. A heat step, as employed in the purification of HisG, was not useful as 
the majority of the HisG-related protein was denatured by heat treatment.
4.3 Purification of PA5104
PA5104 was over-expressed in E. coli and cells for purification were provided 
by N. Patterson. The first purification step was performed as described for the his- 
tagged histidine pathway enzymes. However the his-tag had a 3C protease cleavage 
site which was removed by proteolysis with his-tagged 3C protease. After cleavage, 
the protein was subject to a second purification on a Ni-NTA column. This bound the 
protease, his-tag and some nonspecific binding proteins and PA5104 was eluted in the 
flow through. A gel showing the purification is shown in Figure 4-5. This proved to 
be the first successful application of the over-expression and purification system using 
the vector pTBL2 created during this work.
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Figure 4-5 Purification of PA5104.
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A Flow through o f the second Ni-NTA C Elution o f first Ni-NTA column (= load o f
column (pure PA5104) second column)
B Elution o f second Ni-NTA column (3C D Whole cell extract
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4.4 Dynamic light scattering (DLS)
DLS experiments were carried out to determine which combination of product 
and cofactor were appropriate to obtain a monodisperse enzyme solution. 
Monodispersity is not an infallible indicator that diffraction quality crystals can be 
obtained from a protein solution; instead it reflects the observation that monodisperse 
protein solutions have a much higher probability of producing crystals than those 
which are not [Ferre-D'Amare and Burley, 1997]. Furthermore DLS gives an 
indication of the molecular weight of the protein and hence provides information 
about the state of aggregation.
For E. coli HisG several conditions were tried (Table 1) and it was shown that 
monodispersity could not be achieved in the presence of any of the additives tested. In 
the presence of AMP the lowest value for polydispersity was obtained and the 
molecular weight was estimated to be 186 kDa. This is about 10% lower than the total 
Mw of six monomers and is consistent with the expected hexameric state of the
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enzyme. Other additives such as histidine and PR-ATP gave similar molecular 
weights and hydrodymanic radii but higher polydispersity.
Table 4-3 DLS of E. coii HisG
Additives hydrodynamic 
radius (nm)
polydispersity
(nm)
estimated 
Mw (kDa)
conclusion
none (no KC1) 7.3 0.3 369 polydisperse
None 6.9 1.0 321 polydisperse
AMP (0.4 mM) 5.5 0.7 186 polydisperse
Histidine (5 mM) 5.7 0.9 197 polydisperse
Histidine (5 mM) 
+ AMP (1 mM)
5.3 1.0 170 polydisperse
PRPP (1 mM) + 
ATP (5 mM) + 
MgCl2 (10 mM)
5.5 1.5 184 polydisperse
PRPP (1 mM) + 
ATP (5 mM) + 
MgCl2 (10 mM) + 
Histidine (5 mM)
5.6 1.6 190 polydisperse
None of the several conditions probed for the Mth HisG resulted in 
monodispersity (Table 4-4). The lowest polydispersity value was obtained in presence 
of histidine at pH 7.5. The calculated molecular weight of around 200 kDa in presence 
of inhibitors at low pH is in accordance with the calculated weight of 188 kDa for a 
hexamer. In the absence of the inhibitors histidine or AMP the polydispersity 
increased. In addition a higher value for the polydispersity was observed in the 
absence of MgCl2 and at higher pH values.
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Table 4-4 DLS of Mth HisG
Additives hydrodynamic 
radius (nm)
polydispersity
(nm)
estimated 
Mw (kDa)
conclusion
None 13.5 6.4 1621 polydisperse
MgCl2 (10 mM) 5.8 2.2 208 polydisperse
Histidine (5 mM) 
pH 7.5
5.7 1.1 205 polydisperse
Histidine (5 mM) 
pH 8.5
6.8 2.9 307 polydisperse
AMP (2 mM) 
pH 7.5
5.7 1.6 203 polydisperse
AMP (2 mM) 
pH 8,5
7.0 3.4 333 polydisperse
Table 4-5 DLS of Hin and BS  HisG
Enzyme hydrodynamic 
radius (nm)
polydispersity
(nm)
estimated 
Mw (kDa)
Conclusion/
comment
Hin HisG WT 5.8 0.6 207 polydisperse/
filter blocked
Hin HisG short 3.3 0.3 54 polydisperse
Hin HisG 294 5.3 1.4 165 polydisperse/
filter blocked
BS  HisG 3.2 1.6 50 polydisperse
4.5 Crystallisation
4.5.1 Crystallisation of E. coli HisG
Initially crystallisation experiments of HisG in the absence and presence of 
2mM AMP were performed at 20°C using the sitting-drop vapour-diffusion 
technique. An exhaustive set of conditions, comprising commercially available and 
local sparse-matrix screens [Jancarik and Kim, 1991] were tried. Initial crystals were
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obtained from various conditions mostly in the presence of AMP. Optimisation of 
these crystallisation conditions were most successful for a single condition which led 
to the final conditions of 1.3 M sodium tartrate, 50-200 mM MgCh, 100 mM citrate 
buffer, pH 5.6 and protein in the presence of 2 mM AMP (crystal form I). Typically, 
1 -2 pi of protein (10 mg/ml) were mixed with an equal volume of the reservoir 
solution. Crystals appear after 3-4 days and continued to grow as trigonal prisms up to 
a maximum size of 0.3 x 0.2 x 0.2 mm (Figure 4-3). A second crystal form was 
obtained using 1.36-1.44 M ammonium sulfate, 0-0.3 M sodium chloride, 100 mM 
HEPES buffer, pH 7.5 and protein in the presence of 2 mM AMP. More rounded 
crystals appeared after 4-5 days and grew to a maximum size of about 
0.2 x 0.2 x 0.2 mm (crystal form II, see Figure 4-6).
Figure 4-6 Crystals of E. coli HisG in presence of 2 mM AMP. a) crystal form I, b) 
crystal form II.
E. coli HisG was co-crystallised in various combinations of substrate and 
inhibitors (AMP, PR-ATP, histidine) using the conditions which yield crystal form I. 
Crystals were obtained in all cases where AMP or PR-ATP was present. The 
morphology of some of these crystals, especially in the presence of 2 mM AMP and 
5 mM histidine, was clearer than the ones obtained in the presence of AMP alone. 
Crystals grown in the presence of 2 mM PR-ATP (no AMP) showed similar 
morphology to the ones grown in the presence of AMP.
At a later stage of the project, sparse-matrix screening of crystallisation 
conditions was tried with E. coli HisG (10 mg/ml) in the presence of 10 mM AMP 
and 10 mM histidine. Several different crystal forms of HisG complexed with AMP 
and histidine were found. These were refined and one condition yielded crystals of
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limited diffraction quality (crystal form III) in 18% (w/v) PEG 3350, 0.2 M NaNCb, 
and 100 mM HEPES buffer pH 7.0 (not refined conditions).
4.5.2 Crystallisation of BS histidine pathway enzymes
Sparse-matrix screening was performed on HisG, HisIE, HisZ and a complex 
of HisG-HisZ. The probed screens resulted in no success for HisIE, HisZ and the 
HisG-HisZ complex. However various crystal forms were obtained for HisG at a 
protein concentration of 10 mg/ml in the presence of 10 mM ATP. One crystal form
was obtained from 2.5-4.5 M NaCl, 100 mM MgCb and HEPES buffer at pH 8.2
(Figure 4-7). As these crystals did not diffract to better than 3 A, crystallisations were 
performed using additive screens. However crystals obtained from these showed no 
difference in size and diffraction properties from the ones initially observed.
A second crystal form initially showed clusters of crystals which were grown 
in 2.0-2.4 M Na/K phosphate and Na acetate buffer at pH 4.6-5 (Figure 4-7). However 
using a seed-bead kit for seeding, single crystals were obtained. These were rod-like 
and usually very thin.
Figure 4-7 Crystals of BS HisG. (a) crystals of crystal form I and (b) a cluster of 
crystal form II.
Crystallisation of a HisG-HisZ complex was attempted with a molar ratio of 6 
HisG to 2 HisZ, based on preliminary data about the quaternary structure of L. lactis 
HisG-HisZ [Champagne et al., 2001]. A more recent investigation of the complex 
showed however that the true ratio is 4:4 [Bovee et al., 2002] which could explain 
why no crystals could be obtained for the HisG-HisZ complex.
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4.5.3 Crystallisation of Mth HisG
DLS showed that Mth HisG is monodisperse in the presence of histidine 
(Table 4-4). Therefore sparse-matrix screening was carried out in the presence of 
5 mM histidine at a protein concentration of 10 mg/ml.
Crystals of HisG from Mth were grown in 32-38% (v/v) MPD, 200-350 mM 
MgCb, 100 mM imidazole, pH 8.0 and protein in the presence of 5 mM histidine 
(Figure 4-8). The crystals show a trigonal prism morphology and are usually fairly 
thin.
Figure 4-8 Crystals of Mth HisG.
4.5.4 Crystallisation of PA5104
Sparse-matrix screening for PA5104 was carried out by N. Paterson. Various 
conditions produced crystals of which two were refined and produced crystals suitable 
for X-ray diffraction. Crystals of PA5104 were grown in 24-34% (v/v) PEG 400, 
200 mM MgCh, and 100 mM Tris-HCl buffer at pH 8.5 or 9.0 (crystal form I). The 
crystals appear to be rhombic, and could be nearly cubic, elongated or flat in 
appearance (Figure 4-9).
A second crystal form of PA5104 was obtained in 1.8-2.2M ammonium 
sulfate, 200 mM NaCl, and 100 mM cacodylate buffer at pH 6.5. In many cases the 
crystals appeared not to be single.
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Figure 4-9 Crystals of PA5104 (crystal form I), (a) flat crystals of PA5104 and (b) 
more ‘cubic’ crystals.
Figure 4-10 Crystals of PA5104 (crystal form II).
4.6 Kinetic properties of HisG
4.6.1 Hin HisG and truncation mutants
Enzyme assays were carried out using the method described in the literature 
without the use of pyrophosphatase [Blasi et al., 1971], To obtain kinetic parameters 
for both substrates, ATP and PRPP, the concentration of one of the substrates in the 
assay was kept constant while the other was varied. The resulting plots of rate versus 
corresponding substrate concentration were analysed using steady-state kinetics. The 
data showed some degree of co-operativity which indicate a more complex kinetic 
behaviour. This type of behaviour had been observed previously, especially in the 
presence of histidine [Tebar and Ballesteros, 1976]. However the Hill coefficient was 
within one standard deviation of 1 and therefore a more complex analysis was omitted 
here. The results for the steady-state analysis are shown in Table 4-6.
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Table 4-6 Kinetic parameters of Hin HisG and truncation mutants
Enzyme Substrate £cat (S'1) Km (pM) kcJ K M (M s'1) 106
Hin HisG WT ATP 1188±34 185±21 6.4±0.7
PRPP 1325±9 44±1 30.1±0.7
WT + histidine ATP 282±9 292±28 1.0±0.1
Mutant 294 ATP 521±26 334±46 1.6±0.2
PRPP 624±51 115±17 5.4±0.9
Short Hin HisG ATP 709±60 885±195 0.8±0.2
PRPP 769±51 147±17 5.2±0.7
For the Hin wild type (WT) enzyme the observed values of Km for ATP 
(185 pM) and PRPP (44 pM) are very similar to previously observed ones. The values 
for the E. coli enzyme were determined to be 70 pM and 30 pM respectively [Tebar 
and Ballesteros, 1976]. For the S. typhimurium HisG the data vary for ATP in the 
range 89-340pM and PRPP 28-52 pM [Sterboul et a l, 1977; Wainscott and Ferretti, 
1978]. Both Hin mutant enzymes show activity for the HisG reaction with higher Km 
and lower /ccat values for both substrates compared to the WT enzyme. Based on the 
Km values the binding affinity of both substrates decreases from the WT enzyme to 
Hin HisG294 and the short Hin HisG. However the catalytic efficiency, as reflected 
by kcJKui is within the errors identical for both mutants and substrates and by a 
factor of about 6 lower than that for the WT FlisG.
The results in Table 4-6 show that histidine is an inhibitor for Hin WT HisG as 
has been shown for other long forms of HisG [Martin, 1963]. No difference in activity 
could be detected for either Hin HisG mutant in presence of histidine (data not 
shown). This shows that histidine is not an inhibitor to the HisG mutants studied here.
The maximum rate for all Hin HisG forms studied here decreased at ATP 
concentrations above 5 mM (data not shown). Thus the enzymes are inhibited by 
higher concentrations of substrate ATP. It has been argued that this could be an effect 
of chelation of the required Mg ions by excess ATP [Dall-Larsen, 1988].
4.6.2 Thermophilic HisG from Mth
HisG from Mth showed almost no activity at room temperature. However, 
activity was observed at increased temperatures as expected for an enzyme from a
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thermophilic organism. The highest activity was observed at 65°C, the optimal growth 
temperature of the organism. Even at higher temperatures (up to 90°C) the enzyme 
showed activity which only slowly decreased with increasing temperature. The 
activity fell with decreasing temperatures so that at room temperature the enzyme is 
almost inactive.
Activity measurements were carried out with the HisG-related protein 
obtained from resolubilisation of inclusion bodies. Enzyme activity for the 
condensation of ATP and PRPP to form PR-ATP was observed based on the increase 
in absorbance at 290 nm. Again the highest activity was observed at 65°C with a 
decrease in activity at higher and lower temperatures. It should be mentioned that for 
both enzymes control reactions without the enzyme were carried out; these showed no 
increase in absorbance at 290 nm.
4.6.3 Short HisG from BS
Assay measurements were performed on the native short form of HisG from 
BS. Under standard assay conditions at 25°C no enzyme activity could be detected. 
However the formation of PR-ATP at 290 nm could be observed at increased 
temperatures demonstrating enzyme activity. Figure 2 shows the measured increase in 
absorbance at 290nm following the incubation of the enzyme at various temperatures. 
Enzyme activity can clearly be seen at temperatures above 30°C. Further evidence 
that true enzyme activity is observed is provided by the proportional increase in initial 
rate with increasing enzyme concentration. Additionally, control reactions with no 
enzyme or use of HisZ, as a control enzyme (since it does not catalyse the HisG 
reaction), showed no increased absorbance at 290 nm (data not shown).
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time /s
Figure 4-11 Activity of BS HisG at different temperatures. The change in 
absorbance measured at 290 nm is shown for 4 different temperatures (o  20°C, ■ 
30°C, A 40°C, ♦ 50°C). The insert shows the change of the initial rate with 
temperature (•).
4.7 Kinetics Discussion
Two different forms of HisG are found in bacteria which are distinguished by 
an extra 80 residue C-terminal domain. Sequence alignment and phylogenetic analysis 
of the equivalent N-terminal regions, omitting this C-terminal domain, shows no 
significant difference between the truncated inactive form and the active canonical 
form. Furthermore crystal structures of long forms of HisG have revealed that the 
active site is located in the core, between the first and second domain. The structural 
function of the C-terminal extension is to form a hexamer, with mainly the last 5 
residues being involved in forming an inter-subunit [3-sheet (see Section 6.3). 
Furthermore the C-terminal domain provides a binding site for the allosteric inhibitor 
histidine [Cho et al., 2003]. It seems that the C-terminal extension is solely involved 
in regulation of the enzyme. Therefore it is not clear why the short form of HisG is 
inactive and requires HisZ to form an active complex. To answer this question the two 
truncation mutants of a native long form of HisG from Hin were created. The first one 
lacks just the last 5 residues to investigate the disruption of the main interactions in
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forming hexamers. In the second mutant the full length C-terminal domain was 
truncated to match the length of the native short forms of HisG, so that the core of the 
two HisG forms can be compared.
Enzyme activity was observed for both of the truncation mutants of the long 
HisG. However the kcat for both mutants was half that of the WT enzyme and the 
specific activity was reduced by a factor of 6. Activity of the 294 mutant, the 
truncation where the last 5 residues are omitted, could have been expected as only the 
formation of the hexamer, which is shown to be an inactive state [Klungsoyr and 
Kryvi, 1971], is disrupted. DLS showed that the quaternary structure of the 294 
mutant is similar to that of the WT enzyme (Table 4-5). The lack of inhibition by 
histidine for this mutant is again caused by the lack of stabilisation of the hexameric 
form. However the short Hin HisG mutant would not necessarily be expected to be 
active as it corresponds to the native short HisGs which are inactive without HisZ. As 
shown by DLS (Table 4-5), the quaternary structure of the short mutant is a dimer 
which corresponds to the oligomeric state of the native short HisG and the proposed 
active form of the long HisG [Klungsoyr and Kryvi, 1971]. Based on the activity 
shown by the short mutant Hin HisG we can still not understand why the native short 
HisG is inactive. As there is no significant difference in primary, secondary, and 
quaternary structure between the two forms the answer might be found in the tertiary 
structure. Because of the other similarities, the difference is most likely to resemble 
that found between the tense and relaxed conformations of allosteric enzymes. The 
native short enzyme therefore would be in a tense conformation and the long enzyme 
in a relaxed conformation. Changing the tense conformation of the native short HisG 
into the relaxed form and hence restoring its catalytic activity could prove this. This 
idea was supported by the observation that with increasing temperature the enzyme 
activity of the native short HisG from BS could be restored. This can be explained by 
a thermal transition from the tense inactive conformation to the relaxed conformation. 
Similar activations of catalytic activities at increased temperature are found in 
enzymes of thermophilic organisms where the highest activity is usually found around 
the optimum growth temperature of the organism [Rees and Adams, 1995]. Here this 
was observed for the HisG and HisG-related protein from Mth. Based on these results 
it appears likely that HisZ is a “macromolecular catalyst” for the short HisG by 
forming a HisG-HisZ complex. In this complex the short HisG is in a relaxed form 
and can perform its catalytic reaction whereas in isolation it is in a tense, inactive
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form. Furthermore, because it is not essential for enzyme activity, the C-terminal 
domain of the long HisG seems only to perform regulatory functions. In organisms 
with short HisG and HisZ these regulatory functions must be performed either by 
HisZ, the HisG-HisZ complex or by another enzyme which has yet to be identified.
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Chapter 5: X-ray Data Collection, Processing and Scaling
5.1 Data collection and processing
Diffraction data from various crystals have been collected using the rotation 
method in-house using a rotating anode X-ray generator or at a synchrotron radiation 
source. Although there are various programs for data processing (d*trek [Pflugrath, 
1999], Mosflm [Leslie, 1992], DENZO [Otwinowski and Minor, 1997]) available 
DENZO has been mainly used in the course of this study and scaling of the data was 
done with program SCALEPACK. In some cases Mosflm and d*trek was used in an 
attempt to improve data statistics. Integration with Mosflm and subsequent scaling 
with SCALA can take absorption corrections into account. d*trek uses 3D-profile 
fitting to improve statistics on partially recorded reflections and the scaling procedure 
has various options of absorption correction. Furthermore both programs allow the 
use of more than one diffraction image in their auto-indexing routines which can 
improve the space group determination. When anomalous data were processed in 
order to be used in programs which allow local scaling, data were not merged with 
SCALEPACK.
Derivatised crystals were usually back-soaked with cryo-protectant or well 
solution prior to loop-mounting and cryo-cooling unless otherwise stated.
5.1.1 HisG from E. coli
5.LL1 Native (crystalform I)
Crystals of ATP-PRT (crystal form I) in presence of 2 mM AMP were used 
for data collection. The X-ray diffraction data were collected on beam line 9.6 at the 
SRS Daresbuiy Laboratory using a wavelength of 0.87 A  using a ADSC Quantum-4 
CCD detector. The crystals were radiation-sensitive, therefore cryocooling was 
essential. Crystals were loop-mounted in a cryoprotectant containing 15% (v/v) 
glycerol and cryo-cooled to 100 K using an Oxford Cryosystems cryostream. A native 
dataset to 2.7 A  resolution was collected using 1° oscillation frames (Figure 5-1). A 
total of 109° were collected in two wedges to maximise the completeness of the 
observed reflections. Data were processed with DENZO and scaled with
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SCALEPACK [Otwinowski and Minor, 1997]. From autoindexing using DENZO, the 
crystals were found to index in a primitive rhombohedral lattice, corresponding to 
space group R3, with unit-cell dimensions of a=b=133.6 A and c=114.1 A. Indexing 
with the higher symmetry space group R22 resulted in comparable merging R-factor 
statistics (Table 5-1). An assumption of one molecule per asymmetric unit for R7>2 
lead to an acceptable packing density, Vm of 2.95 A 3 Da'1 which corresponds to a 
solvent content of 58% [Matthews, 1968].
Figure 5-1 A typical diffraction pattern of ATP-PRT from E. coli. The data were 
collected on the beamline 9.6 at Daresbury synchrotron.
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Table 5-1 Statistics for the X-ray data processed in R32
<7min (A) Rsym (f) (//a) No. of unique 
reflections
Completeness (%) Multiplicity (%)
5.82 0.041 38.2 1099 95.6 6.3
4.62 0.061 39.1 1104 99.6 6.6
4.03 0.055 36.7 1098 99.9 6.7
3.66 0.050 32.2 1094 100.0 6.7
3.40 0.0.71 23.6 1079 100.0 6.7
3.20 0.120 14.5 1075 100.0 6.7
3.04 0.180 10.4 1092 100.0 6.7
2.91 0.293 6.4 1076 100.0 6.7
2.80 0.469 4.3 1077 100.0 6.7
2.70 0.668 3.1 1066 100.0 6.7
Total 0.049 18.0 10860 99.5 6.7
5.1.1.2 Native (crystal form II)
Crystal form II was found to diffract to 3.7 A  on the same beam line and under 
the conditions as described above; processing was also performed as described 
previously. The crystal symmetry was determined to belong to primitive 
rhombohedral lattice with unit cell dimensions of <3=6=132.6 A  and c= 113.8 A. The 
same space group and the similar unit cell dimensions indicate similar packing in the 
two ciystal forms. As the resolution of the data from these crystals was not as good as 
from crystal form I no further data were collected.
5.1.1.3 MAD
SeMet labelled ATP-PRT was crystallised under conditions similar to those 
used for crystal form I of the native enzyme. The concentration of sodium tartrate was 
reduced from 1.3 M to 1.1 M, the MgCl2 concentration was the same (50-200 mM). 
The crystals show a clearer morphology and grow to a larger size than their native 
counterparts (0.5 x 0.3 x 0.3 mm3); however the resolution of the diffraction was not 
improved.
Two independent three wavelength MAD data sets of Se-Met labelled protein 
were collected on a single crystal at ALS beam line 5.0.2 using a ADSC Quantum-4
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CCD detector (G. McDermott). First a fluorescence spectrum of the Se-Met labelled 
crystal was collected. The spectrum which shows a clear peak is shown in Figure 5-2. 
The three wavelengths used in the experiment were 0.9796 A (12656 eV) for the 
anomalous peak (f'), 0.9798 A (12653 eV) for the inflection point (f) and 0.9611 A 
(12900 eV) as a remote wavelength.
12600 12650 12700 12750
E / (eV)
Figure 5-2 Fluorescence spectrum of Se-Met labelled HisG crystal. Shown is the 
experimental fluorescence If (red) which is proportional to f \  its derivative dIf/dE 
(blue) and the theoretical f  (blue) and f  ’ (brown). The Kramers-Kronig transformation 
is used to determine the experimental f  (K-K, green).
All diffraction data were collected with 1° oscillation. The first data set 
consists of two 60° wedges collected continuously for each wavelength. The wedges 
were separated by 180° to collect the corresponding Friedel pairs of the observed 
reflections. The second data set was collected in two 80° wedges again separated by 
180°. Here the wedges were split in smaller units of 10° which were collected in 
alternation 180° apart. This method has the advantage that the Friedel pairs are 
collected in quick succession and possible shifts in the wavelength have a smaller 
effect on the anomalous differences. On the downside the crystal has to be rotated 
more often and possible inaccuracies in the oscillation can have a larger effect than in 
the first method described. All data were processed with DENZO and scaled with
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SCALEPACK [Otwinowski and Minor, 1997]. Statistics for the data processing are 
listed in Table 5-2.
Table 5-2 Crystallographic data and phasing of E. coli HisG
Data set Native AMP SeMet
Space group R32 R32
Unit cell (A) a=6=133.6 c==114.1 o=6=134.1 c=114.5
Resolution (A) 2.7 2.7
Wavelength (A) 0.87 (f ') 0.9798 (f ") 0.9796 0.9611
Unique reflections 10860 10851 10835 10846
Completeness (%)1 99.5 (100.0) 99.5(97.4) 99.6(98.3) 97.7(100.0)
Rmerge (%)'* 5.9 (79.6) 7.7 (78.8) 8.7 (87.4) 7.8 (72.6)
Multiplicity1 6.7 (6.7) 7.8 (6.3) 8.6 (7.0) 8.1 (7.3)
Mean <I/a(I)>1 18.0 (3.1) 13.0 (2.5) 13.9 (2.3) 14.2 (2.1)
1 Number in parenthesis represents values for highest resolution bin, 
Kncrgc | lobs " Evg 1 i ^  Evg
5.1.1.4 HisG complexed with histidine
Diffraction data from crystal form I, grown in the presence of 2 mM AMP and 
5 mM histidine, were collected on beam line BW7A at HASYLAB, DESY, Hamburg. 
A dataset with 1° oscillation and a total of 69 frames was collected with the data 
statistic shown in Table Table 5-3.
Crystal form III, grown in the presence of 10 mM AMP and 10 mM histidine 
diffracted to 3 A  at best. A complete data set was collected to 3.3 A. However 
diffraction was very diffuse with a high mosaic spread (up to 1.6°) which made data 
processing difficult. Autoindexing with DENZO suggested a primitive monoclinic 
lattice with cell dimensions of o=91.19A 6=113.58 A  c=101.58 A  and (3=113.74°. 
Systematic absences (0,2n+l,0) indicated space group P2\. Merging and scaling with 
SCALEPACK proved difficult with R-factors of individual frames all above 10% (up 
to 30%). Calculation of the Matthews coefficient suggests a hexamer in the 
asymmetric unit (asu). There is a possibility that the actual space group is PI rather 
than P2j. However the merging statistics are only slightly improved with an overall 
merging R-factor of 16.5% compared to 18.8% forP2i. Additionally a  and (3 refine to
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90.01° and 90.14° respectively in PI which suggests that the space group has two 90° 
angles.
5.1.1.5 Crystal form I  complexed with PR-ATP
Diffraction data were collected on beam line 9.6 at the SRS Daresbury 
Laboratory using a wavelength of 0.86 A  using a ADSC Quantum-4 CCD detector. 
Crystals were loop-mounted in a cryoprotectant containing 15% (v/v) glycerol and 
2 mM PR-ATP and cryo-cooled to 100 K using an Oxford Cryosystems cryostream. 
A dataset was collected using 1° oscillation frames with a total of 71 frames being 
collected. Data were processed with DENZO and scaled with SCALEPACK 
[Otwinowski and Minor, 1997]. The statistics for that dataset is shown in Table 5-3.
Table 5-3 HisG E. coli ligand structure statistics
Data set Native AMP Histidine
Space group R32 R32 R32
Unit cell (A) a=b= 133.6 c=l 14.1 a=b=133.0 c=113.2 a~b-\32.\ c=l
Resolution (A) 2.7 2.9 2.9
Wavelength (A) 0.87 0.8424 0.95988
Unique reflections 10860 8707 8521
Completeness (%)] 99.5 (100.0) 99.8 (100.0) 99.3 (99.9)
Rmerge (% )h2 5.9 (79.6) 5.6(52.1) 5.8 (58.1)
Multiplicity1 6.7 (6.7) 4.3 (4.2) 4.2 (4.2)
Mean <I/a(I)>1 18.0 (3.1) 20.2 (2.3) 16,9(2.0)
‘ Number in parenthesis represents values for highest resolution bin.
P -m crg e  "  2, | I0bs “ L v g  | /  2j Ia v g
5.1.2 HisG from Mth
5.1.2.1 Native
X-ray diffraction data on a crystal of Mth HisG were collected on beam line
9.5 at the SRS Daresbury Laboratory using a wavelength of 1.0 A  using a 165mm 
MAR CCD detector. Crystals were loop-mounted in dry paraffin oil and cryo-cooled 
to 100 K using an Oxford Cryosystems cryostream. A native dataset to 2.6 A  
resolution was collected using 0.5° oscillation frames. The smaller oscillation range
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was chosen because of the high mosaic spread of the crystal (up to 1.6°) and large unit 
cell dimensions. Data were processed with DENZO and scaled with SCALEPACK 
[Otwinowski and Minor, 1997]. From autoindexing in DENZO, the crystals were 
found to index in a primitive rhombohedral lattice, corresponding to space group R32, 
with unit-cell dimensions of a=Z>=T 12.10 A  and c=247.62A. Data statistics are 
shown in Table 5-4. The assumption of two molecules per asymmetric unit for R32 
leads to a packing density, Vm of 2.5 A 3 Da'1 which corresponds to a solvent content 
of 49.6% [Matthews, 1968]. Assuming only one molecule Vm is calculated as 
4.9 A 3 Da'1 with a solvent content of 74.9% which was considered less likely.
Table 5-4 Crystallographic data statistics for Mth HisG
Data set Native histidine
Space group R32
Unit cell (A) a=b=132.10 c=247.62
Resolution (A) 2.59
Wavelength (A) 1.0
Unique reflections 18179
Completeness (%)1 93.4 (84.9)
Rmerge (%)1>2 4.0 (26.6)
Multiplicity1 3.2 (1.6)
Mean <I/cr(I)>1 16.8(1.9)
1 Number in parenthesis represents values for highest resolution bin.
Knerge ~ S | IGbs “ Invg | I I0Vg
5.1.3 PA5104 from Pseudomonas aeruginosa
5.1.3.1 Native (crystal form 1)
One large crystal (approx. 0.5 x 0.2 x 0.2mm3) of crystal form I from the 
initial screen was loop-mounted and cryo-cooled to 100 K. The precipitant PEG 400K 
was sufficient as a cryoprotectant, so no further soaking of the crystals was required. 
A native dataset was collected on beam line 14.1 at the SRS in Daresbury (A. Riboldi- 
Tunnicliffe). 360 frames of 1° oscillation were recorded at a wavelength of 1.488 A  
using a ADSC Quantum-4 CCD detector. Most low resolution spots of the diffraction
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pattern were overloaded and spiked into neighbouring spots (Figure 5-4). However 
autoindexing with DENZO suggested a C centered orthorhombic or primitive 
monoclinic lattice. Data were processed with DENZO in the higher symmetry space 
group C222 with unit cell dimensions of <3=40.758 A 6=109.530 A c=93.730A. 
Scaling of the data with SCALEPACK was problematic. Further attempts to process 
and scale these data with d*trek and Mosflm/SCALA to allow absorption correction 
were equally unsuccessful.
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Figure 5-3 Chi2 and R m e r g e  vs oscillation.
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Figure 5-4 Diffraction pattern from PA5104.
To avoid the problematic overloads a smaller crystal, re-grown from the initial 
screen, was loop-mounted and cryo-cooled to 110 K for data collection in house on a 
Nonius FR591 rotating anode generator. 150 frames at 1° oscillation were collected 
with CuK« radiation at wavelength 1.54 A using a Macscience DIP2000 image plate 
system. Autoindexing with DENZO confirmed the lattice to be C centred 
orthorhombic with similar unit cell dimensions as seen before (a=40.527 A 
b= 107.951 A c=93.443 A). The data were processed with DENZO in C222 but again 
merging and scaling the data with SCALEPACK (and other programs) caused 
problems and was unsuccessful.
A third native dataset on PA5104 crystals was collected at the beam line BL
5.2 R (XRD1) at the ELLETRA synchrotron in Trieste. A medium sized, nearly cubic 
crystal (approx. 0.3 x 0.3 x 0.4mm3) was loop-mounted and cryo-cooled to 100 K.
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Data were collected at a wavelength of 1.0 A  using a 165mm CCD detector from 
MarResearch. Two datasets were collected, first one for the lower resolution range 
(360 frames at 1° oscillation) and then a high resolution range (720 frames at 0.5° 
oscillation). Autoindexing with DENZO confirmed the C centred orthorhombic 
lattice, so the datasets were processed in DENZO using space group C222. Both 
datasets merged and scaled independently, and together, without the problems seen 
previously using SCALEPACK. Systematic absences at (0,0,2n+l) suggested that the 
actual space group is C222i rather than C222. Data collection and scaling statistics for 
the low and high resolution as well as the combined data are shown in Table 5-5.
Table 5-5 Data collection and scaling statistics of PA5104
Data set Native all Native low res Native high res
Space group C222]
Unit cell (A) a=40.631 A  6=109.180 A  c=93.243 A
Resolution (A) 50 - 0.96 50-1.55 20 - 0.96
Wavelength (A) 1.0
Comment Anomalous Anomalous -
Unique reflections 126365 30358 126365
Completeness (%)J 100.0(100.0) 99.9 (99.4) 97.8 (100.0)
Rmerge (“/o)1*2 7.1 (35.7) 7.2(16.1) 5.9 (37.2)
Multiplicity1 13.2 (12.0) 14.1 (13.7) 13.3(12.1)
Mean <I/a(I)>1 22.6 (5.5) 30.5 (16.2) 28.7 (7.4)
1 Number in parenthesis represents values for highest resolution bin.
R n c r g c  ^  | L b s  _ L v g  | /  L v g
A comparison of the combined data with the previous, unsuccessfully scaled 
data is shown in Table 5-6.
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Table 5-6 Comparison o f PA5104 data collection and scaling statistics
Data set Native Native Native
Source ELLETRA DRS Rotating anode
Detector MAR CCD AD SC MAR DIP2000
QUANTUM
Wavelength (A) 1.0 1.488 1.54
Space group C222] C222i C222i
Unit cell (A) u=40.631 A £2=40.758 A a=40.527 A
£=109.180 A £=109.530 A £=107.951 A
c=93.243 A c=93.730 A c=93.443 A
Resolution (A) 50 - 0.96 100-1.38 50-2.6
Comment Anomalous Anomalous Anomalous
Degree 360 360 150
Rmago (%)'’2 7.1 (35.7) 7.1 (33.1) 13.0 (30.0)
2
X 1.0 1.6 3.2
Completeness (% / 100.0 (100.0) 82.5 (25.0) 96.5 (92.2)
Mean <I/a(I)>1 22.6 (5.5) 8.7 (2.1) 19.2 (8.8)
number of rejections / 4.48-10"3 17.33-10'3 51.60T0'3
total number of
reflections
1 Number in parenthesis represents values for highest resolution bin.
Rmerge ^ I Cbs " iavg | I 2* Invg
Assuming one molecule in the asymmetric unit, of the C222\ space group with 
<3=40.631 A  £=109.180 A  c=93.243 A , Vm is calculated to acceptable 2.41 A 3 Da'1 
with a solvent content of 48.66%.
5.1.3.2 S anomalous
The same crystal, which was used to collect the native dataset, was used to 
collect diffraction data at higher wavelength at the XDR1 beam line at ELLETRA. 
The crystal had to be re-centred after changing the wavelength and 720 frames with 1° 
oscillation were collected using a wavelength of 1.9 A. Data collected with this longer
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wavelength and high redundancy should be sufficient to solve the phases from sulphur 
anomalous scattering.
The data were processed without any problems in DENZO. Scaling with 
SCALEPACK proved impossible as seen before with high %2 values (above 5 on 
average) and high R-factors for each frame (above 10%). Furthermore the merging R- 
factors were 14% and above even for the lower resolution shells. For diffraction data 
measured with a high redundancy (on average above 15) and a low signal to noise 
ratio (I/a(I) on average higher than 20) much lower scaling statistics would be 
expected. Inspection of the data showed that a large number of reflections measured 
multiple times were significantly different. Table 5-7 shows the rejections for 
reflection (1,1,18) as a typical example. It shows that the intensity of the same 
reflection (not just the symmetry related ones) differs above the expected deviations 
from a Gaussian distribution. Radiation damage as a cause could be excluded as the 
intensities in later frames did not always show decreased intensities. Absorption 
effects are possible, however the observation that the deviations and the signs thereof 
seem to be independent of the film number and therefore rotation angle makes it less 
likely.
To account for possible absorption effects data were processed, scaled and 
merged with Mosflm/SCALA and d*trek as these allow corrections for these effects. 
Scaling with d*trek without absorption correction again gave high values for the R- 
factors while absorption correction could not be applied (the program could not 
account for the effects8). Scaling with SCALA using absoiption correction gave high 
values for R-factors too (above 10% in all shells).
To allow protein structures to be solved using sulphur anomalous scattering 
the data have to be measured with high accuracy as the anomalous signal is very low. 
An estimate for PA5104, which has 6 residues containing sulphur (2 Met and 4 Cys), 
gives an anomalous signal of about 1% for the wavelengths used here [Lemke et a l ,
2002]. Because of the scaling problems with large deviation between related 
reflections this small signal is unlikely to be detected reliably above the increased 
noise of the data obtained here. Therefore these data were not used any further.
8 Presumably the differences o f symmetry related and identical intensities were too large and not 
sufficiently systematic to calculate a correct absorption correction.
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Table 5-7 Rejections of reflection (1,1,18). The total %2 was 872.6 for an average 
intensity of <i>=22883 at a resolution of 5.13 A . Only fully recorded reflections of the 
first 360° of data are shown here.
h k 1 Rim Deviation/cr I a(I) Rejection probability
1 1 18 11 -4.7 2288.3 116.8 86
169 9.3 4434.7 131.4 100
1 -1 -18 0 1.2 3112.5 115.9 0
206 -9.4 1634.3 110.6 100
360 -1.4 2790.5 114.8 0
-1 -1 18 24 -5.5 2181.4 111.3 100
176 -4.8 2281.7 114.2 90
-1 1 -18 188 -7.9 1799.5 118.2 100
-1 -1 -18 191 -14.9 885.3 108.2 100
347 -2.2 2681.4 115.6 0
-1 1 18 26 -0.5 2892.8 116.8 0
180 -8.8 1710.3 111.0 100
1 1 -18 204 -12.7 1187.3 108.6 100
356 2.9 3326.7 115.4 1
1 -1 18 7 3.1 3465.2 154.8 1
162 -1.3 2791.2 125.3 0
5.1.3.3 Derivative
5.1.3.3.1 Pt derivatives
One crystal of PA5104 was soaked with 2mM  platinum ( II)  2,2':6',2"- 
terpyridine chloride dihydrate. A derivative dataset was collected on beam line XDR1 
at ELLETRA in Trieste (A. Riboldi-Tunnicliffe). Data were processed with DENZO 
and merged and scaled anomalously with SCALEPACK by Alan Riboldi-Tunnicliffe. 
Statistics of the data can be seen in Table 5-8.
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Table 5-8 Scaling statistics for PA5104 derivative data
Data set Pt Pt Hg Hg
Source ELLETRA SRS 9.5 SRS 9.5 SRS 9.5
Space group C222j
Unit cell (A) <3=40.551 a=40.594 £=40.588 £=40.609
6=108.460 6=109.062 6=108.946 6=108.802
c=93.320 c=92.937 c=92.901 c=93.076
Resolution (A) 2.20 2.06 2.06 1.75
Wavelength (A) 1.0 0.9341 1.0064 1.0050
Unique reflections 10906 13171 13151 21180
Completeness (%)1 83.8 (95.5) 99.0 (98.0) 99.6 (99.2) 99.6 (96.2)
Rmergc (%?* 3.9 (4.2) 5.2 (8.4) 8.0(16.5) 8.3 (58.5)
Multiplicity1 n/a 14.7 (14.4) 14.7 (12.3) 13.7 (7.2)
Mean <I/a(I)>* 16.9(18.7) 53.3 (32.3) 35.6(17.7) 25.8 (2.7)
Number in parenthesis represents values for highest resolution bin.
K-m crge | I 0bs ”  L v g  1 /  ^  L v g
A second Pt derivative dataset was collected on beam line 9.5 at the SRS in 
Daresbury. A crystal was soaked for 3 min in well solution containing 5 mM 
ammonium tetrachloroplatinate(II) and briefly back-soaked before being loop- 
mounted and cryo-cooled. Statistics of the data after processing with DENZO and 
scaling with SCALEPACK can be found in Table 5-8.
5.1.3.3.2 Hg derivatives
First one crystal was soaked in well solution containing 0.5 mM HgCE for 10 
minutes. A complete dataset was collected on beam line 9.5 at the SRS Daresbury.
A second ciystal was soaked for 15 minutes and a fluorescent scan on the Hg 
L-III edge recorded. Only a weak peak (in fact more a shoulder) was observed and the 
wavelength changed to be slightly lower wavelength than the start of the peak. A 
complete dataset was recorded. Scaling statistics after processing with DENZO and 
scaling with SCALEPACK are shown in Table 5-8.
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5.1.3.4 Wavelength dependency
To investigate possible absorption effects and scaling problems at higher 
wavelength of the PA5104 crystals 5 datasets were collected on one crystal using 5 
different wavelengths (0.7, 0.9, 1.1, 1.3, 1.5 A 9) at beam line 9.5 at the SRS 
Daresbury. The ciystal was approx. 0.15 x 0.4 x 0.4 mm3 in size and was loop- 
mounted so that the largest face was in plane with the loop. Collection of 180° with an 
oscillation range of 1° ensured that the path through the ciystal changed maximally 
with the phi rotation. With the increase of the wavelength the crystal-detector distance 
was shortened accordingly so that the resolution at the detector edge was constant. 
This kept the spot size and separation constant and identical parameter files could be 
used for processing and scaling. Therefore differences in processing and scaling 
statistics at different wavelength are solely wavelength dependent (ignoring radiation 
damage). Data reduction statistics as obtained from the programs DENZO and 
SCALEPACK for the five wavelengths are shown in Table 5-9.
Table 5-9 Scaling statistics for wavelength dependency of PA5104
Data set 1 2 3 4 5
Space group C222j
Unit cell (A) <2=40,541 a=40.560 o=40.570 o=40.565 o=40.576
6=108.508 6=108.557 6=108.582 6=108.585 6=108.595
c=92.963 c=93.008 c=93.029 £=93.026 £=93.041
Resolution (A) 2.05
Wavelength (A) 0.7 0.9 1.1 1.3 1.5
Unique reflections 13321 13291 13291 13291 13291
Completeness (%)! 99.7 (99.3) 99.4 (98.6) 98.9 (98.1) 98.2 (96.7) 97.3 (95.3)
Rmerge (%)1,2 5.8 (10.5) 5.9(10.6) 5.9(10.7) 6.7 (15.4) 6.8(17.8)
Multiplicity1 7.1 (6.3) 7.1 (6.3) 7.0 (6.6) 6.9 (6.7) 6.9 (6.8)
Mean <I/a(I)>1 32.3 (16.8) 33.0(17.6) 33.5 (17.4) 29.9 (13.4) 29.7 (12.2)
Rejections 134 145 149 225 59
1 Number in parenthesis represents values for highest resolution bin.
P-mcrgc ^ I lobs “ hvg I I ^  hvg
9 1.5 A was the longest wavelength used because o f the set-up of the beamline it was not easily possible 
to gain longer wavelengths.
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Figure 5-5 Chi2 and R m e r g e  for 0.7 and 1.5 A  vs. Phi oscillation.
The Rmerge and Chi2 of individual frames versus oscillation angle (frame) for 
the lowest (0.7 A) and highest (1.5 A) wavelength investigated are shown in Figure
5-5. No significant difference can be seen for the Chi2 values and RmCrge is marginally 
higher for the longer wavelength. Furthermore no difference in angular dependency 
can be seen, not even for the longest wavelength.
Rmerge after scaling and completeness versus wavelength are shown in Figure
5-6. A decrease in completeness with increasing wavelength can be observed. Rmerge 
increases at 1.3 A by about one percent and to a greater extent for the outer resolution 
shell. It is difficult to explain these results especially as the number of rejections does 
not increase substantially with increasing wavelength which could indicate absorption 
effects. A reason why no oscillation dependency for the longer wavelength compared 
to the previous observed data (see Section 5.1.3.1) was observed could be the size of 
the crystal. Here a smaller crystal was used compared to the previous data collection 
at comparable wavelengths.
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Figure 5-6 R m e r g e  and completeness vs. wavelength for PA5104.
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5.1.3.5 Native (crystal form II)
One crystal of crystal form II was loop-mounted and cryo-cooled to 100 K. 
Mother liquor containing 20% glycerol was used as a cryoprotectant. A native dataset 
was collected on beam line 9.6 at the SRS in Daresbury. 180 frames of 1° oscillation 
were recorded at a wavelength of 0.864 A  using a ADSC Quantum-4 CCD detector. 
Some of the diffraction spots were slightly blurred and in some frames an additional 
lattice was observed. This could have been due to a split or twinned crystal. However 
autoindexing with DENZO was successful and suggested a primitive monoclinic 
lattice. Data were processed with DENZO in the space group P2 with unit cell 
dimensions of a=69.533 A  £=67.175 A  c=84.222 A  and (3=111.932°. The data were 
merged and scaled with SCALEPACK. Systematic absences at (0,2n+l,0) suggest the 
space group of P2\. Data collection and reduction statistics are shown in Table 5-10.
Calculation of Vm with the above mentioned unit cell parameters gives two 
acceptable values. It is calculated as 2.8 A 3 Da'1 with a solvent content of 55% for 3 
monomers in the asu or 2 .1 A 3 Da"1 and 40% solvent for 4 molecules.
Table 5-10 Scaling statistics of PA5104, crystal form 2
Dataset PA 5104 crystal form2
Source SRS 9.6
Space group P2\
Unit cell (A) a=69.533 £=67.175 c=84.222
(3=111.932°
Resolution (A) 
Wavelength (A) 
Unique reflections 
Completeness (%)'
50-1.9 
0.864 
56322 
99.8 (99.9) 
9.0 (64.5) 
3.5 (3.2) 
14.0(1.9)
Rmerge (%)U  
Multiplicity1 
Mean <I/a(I)>1
^ N u m b e r  in  p a ren th es is  rep resen ts  v a lu es fo r h ig h est re so lu tio n  bin.
Rncrgc — 2 | lobs “ hvg | I 2 IaVg
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5.2 Calculation of structure factors from intensities
Files from SCALEPACK containing miller indices (h,k,l) and corresponding 
intensities (sea files) were transformed in mtz format using the CCP4 program 
SCALEPACK2MTZ [CCP4, 1994], Structure factors were calculated from these 
intensities using the program TRUNCATE [French and Wilson, 1978]. The overall B 
factor was calculated using Wilson statistics and twinning of the data was checked for 
by examining the distribution of centric and acentric reflections in the cumulative 
intensity distributions generated by TRUNCATE. Different datasets were combined 
in one reflection file (mtz format) with the CCP4 program cad [CCP4, 1994] and a 
free R column added. Solving of the phases for each structure is described within the 
appropriate sections.
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Chapter 6: Structure of HisG from E. coli
6.1 Introduction
HisG from E. coli was the first enzyme to be investigated structurally in this 
study. An over-expression clone was already available [A. Elwell unpublished results] 
and together with the S. typhimurium enzyme is the best studied [Dall-Larsen, 1988]. 
Initial crystallisation conditions, crystallographic characterization and prediction of 
the quaternary structure has been published earlier, based on earlier work in the 
laboratory [Lohkamp et al., 2000],
6.2 Solving the phases of E. coli HisG
The native crystals of HisG did not diffract to high resolution (see Section 
5.1.1) presumably due to the inherent flexibility of the protein. Solving phases using 
MIR one has to eliminate the problems of anisomorphism associated with this 
method. This can be especially problematic for cases where the protein is flexible as 
seen for HisG. To overcome the anisomoiphism, caused by using multiple crystals to 
solve the phases, other phasing methods such as SAD, MAD or SIRAS can be used 
which use data collected on a single crystal. MAD usually gives the most reliable 
phases as it uses at least three different wavelengths which give an anomalous and 
isomorphous signal. Therefore MAD phasing using Se-Met labelled protein was 
employed to provide phase information.
6.2.1 MAD phasing
Collection and processing of the MAD data sets is described in Section 5.1.1. 
The program SOLVE [Terwilliger and Berendzen, 1999] was used to find the Se sites 
from three wavelength MAD data. 11 out of the possible 13 Met (including N- 
terminal Met) of E. coli HisG were found with a Figure of Merit (FoM) of 0.62 and a 
Z score of 55.98 from resolution range 28-3 A. Phases from these initial 11 sites were 
refined with MLPHARE [Otwinowski, 1991]. This resulted in an overall FoM 0.43 
for the resolution range 30-2.7 A  (isomorphous differences) and 30-2.8 A (anomalous 
differences). These starting phases were further improved by solvent flattening with 
histogram matching using the program DM [Cowtan, 1994], which gave a readily
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interpretable electron density map. One more selenium site was identified during 
model building and was subsequently refined together with the other 11 sites in 
MLPHARE to improve the experimental phases. This resulted in a FoM of 0.44 and 
0.86 after DM for the resolution range 30-2.7 A (see Table 6-1).
Table 6-1 Phasing statistics for E. coli HisG
Wavelength (A) (f ')  0.9798 (f ") 0.9796 0.9611
Phasing power acentric/centric 0.94/0.72 1.68/1.00 0.62/0.49
Mean figure of merit 0.4378
6.2.2 Model building and refinement
The initial model of ATP-PRT was traced from a 2.7 A DM map using 
QUANTA [Accelrys Inc.]. Figure 6-1 shows the initial electron density obtained from 
DM together with a built Ca trace and one Se site.
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Figure 6-1 MAD solvent flattened electron density map of HisG. The Ca trace is 
shown in green and red with the electron density in purple. One identified selenium 
site is marked with a yellow sphere.
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Iterative cycles of model building in QUANTA followed by refinement using 
CNS [Brunger et a l, 1998] with experimental phases included as restraints were 
performed. First the model was refined using simulated annealing and torsion angle 
dynamics followed by group B-factor refinement. Once the model was more complete 
energy minimization refinement in CNS was used. One AMP molecule as well as 2 
tartrate molecules could be fitted to the electron density. The final refinement cycles 
were carried out using REFMAC5 [Murshudov, 1996] including TLS refinement 
[Winn et a l, 2001], Three segments were used for TLS refinement corresponding to 
the three domains of HisG (see Section 6.3.2). The quality of the electron density map 
and low resolution of the data allowed only two water molecules to be build and 
refined, hence these were omitted and no water molecules added to the final model. 
Table 6-2 shows the decrease in R- and free R-factor during the steps of refinement.
Table 6-2 R- and free R-factor during refinement
Refinement step R-factor /% free R-factor /%
Start ' ‘ 42.9 ”  “ 4A6
Simulated annealing (CNS) 31.1 39.3
B group refinement 28.6 36.0
Energy minimization (CNS) 26.4 33.0
B group refinement 24.0 31.2
Refmac5 with TLS 22.2 27.7
6.3 HisG model
6.3.1 Quality of the model
The final model of HisG with RWOrk "  22.1% and Rfree = 27.7% had rms 
deviation in bond distances of 0.017 A and bond angles of 1.9°. The geometrical 
parameters were either satisfactory or better than expected for a structure of this 
resolution as assessed by PROCHECK [Laskowski et a l, 1993]. No residues were 
found in disallowed regions of the Ramachandran plot. Table 6-3 shows a summary of 
the refinement statistics.
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Table 6-3 Refinement statistics of E. co li HisG with AIVIP
Refinement statistics
Resolution range (A) 81.65-2.70
Rworking (%) 22.2 (9975)
Rita (%)u 27.7 (883)
Number of atoms
Protein 2187
Nonprotein (AMP, tartrate) 42
R.m.s. deviation from ideal
Bond length (A) 0.017
Bond angles (°) 1.9
Ramachandran statistics
Most favoured 212
Additionally allowed 36
Generously allowed 6
Disallowed 0
1 number in parenthesis is the number o f reflections.
2 Rfrce was calculated with 8.1% of reflections.
6.3.2 Overall structure
The crystals were grown with AMP which stabilises the hexameric form of the 
enzyme. From preliminary crystallographic analysis the quaternary structure of the 
hexamer was predicted [Lohkamp et a l, 2000]. The HisG hexamer is formed via 
crystallographic symmetry from a single L-shaped monomer (Figure 6-2), which 
comprises the asymmetric unit. The monomer is separated into three clearly defined 
a/(3 protein domains, of which the first two are linked by a two-stranded antiparallel 
J3-sheet and form a cleft in which the active site is situated, while the third domain is 
connected to the first domain via an extended a-helix.
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Figure 6-2 Structure of E. co li HisG. A ribbon representation of E. coli ATP-PRT 
monomer coloured according to secondary structure. The beginning and end of the 
disordered loop are labelled and the missing residues represented as spheres. One 
molecule of AMP and two molecules of tartrate are represented in ball and stick. The 
N- and C-termini are labelled with N and C, respectively. This diagram was produced 
using RIBBONS [Carson, 1987].
The folding of each of the three domains is distinct (Figure 6-2). The first 
domain consists of residues 5-103 and 192-224. It contains a core of 4 parallel and 2 
anti-parallel [3-strands, with a strand order of 231465 (iT T T if), flanked by 4 a- 
helices, two on each side. The second domain consists of residues 103-191. The core 
is built of a twisted 5-stranded p-sheet, 4 strands parallel and 1 anti-parallel with a 
strand order of 32415 (TTTiT). The p-sheet appears to wrap around helix a4 on one 
side, with the opposite side covered by two short a-helices (a5 and a6). One of the 
most unusual features of the folds of both domain 1 and domain 2 is the interdigitation 
of the P-strands. In a/p proteins containing mainly parallel P-sheets, it is most 
commonly found that P-a-P motifs, where the two strands are adjacent, are the 
preferred building blocks. In ATP-PRT this feature is rare with only p7-a4-p8 of the
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second domain forming such a motif which is followed by a crossover connection 
forming a crevice where the AMP is located (Figure 6-2). Analysis of the two 
domains using DALI [Holm and Sander, 1995] reveals that they are not unique, 
together they form a "periplasmic binding protein" fold, sharing most structural 
homology to the glutamate receptor fragment (pdb accession code 1115; rms deviation 
4.0 A for 219 Ca atoms) and the transcription factor CysB (pdb accession code 1AL3; 
rmsd 4.9 A over 235 Ca atoms) (see Figure 6-3). The crevice between the two 
domains is the ligand-binding site in this fold and in ATP-PRT is undoubtedly the 
active site of the protein.
Figure 6-3 Superposition of E. coli HisG with glutamate receptor fragment.
Ribbon diagram of glutamate receptor fragment (1ii5) in blue superimposed on the 
structure of HisG from E. coli (red). Ligands glutamate (Glu) and AMP are shown in 
stick representation. This figure was prepared using PyMOL [DeLano, ]. All following 
figures were prepared using PyMOL unless otherwise stated.
Another feature of the first two domains and the periplasmic binding proteins 
is the 18 A long pair of anti-parallel P-strands, which connects domain 1 to domain 2. 
This is formed by the continuation of strand p5 into p6 and piO into p i l  which is 
interrupted by a P-bulge at Glu 186 on strand [310 and a larger extended bulge 
(residues Asp 100 - Gly 102) on strand p5. This inter-domain anti-parallel structure is 
held together by five main chain hydrogen bonds and a number of salt bridges at 
either end. The outer face of the two P-strands is characterised by predominantly 
positively charged residues while the inner face comprises small residues Cys, Ser, 
Ala and Gly. An exception is Tyr 189, which due to the twist of the sheet, packs at the 
back of the interface between domains.
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The interface between domains 1 and 2 buries 684 A2 of surface area with the 
bulk of the interactions made between helix a3 and helix a4. The relative position of 
the two helices seems to be oriented by the side chain of the highly conserved Glu 79 
in helix a3. This interacts with the beginning of helix a4 via an electrostatic 
interaction with the helix dipole and by forming two hydrogen bonds to the backbone 
amides of His 133 and Leu 134. The residues Leu 82, Tyr 131, Leu 134 and Tyr 189 
form the majority of the hydrophobic interactions at the interface, with hydrogen 
bonds formed by the side chains of both Arg 137 and Tyr 189 to Glu 78, and between 
the side chains of Tyr 131 and Asn 75. None of these residues is particularly 
conserved illustrating the high sequence variability of this enzyme, for example, in the 
first 150 amino acid residues there are only five invariant residues (4 glycines and 
Asp 57) (Figure 6-4). The only region of the structure where the sequence is 
conserved is in domain 2, residues 153-182, which contain the PROSITE ATP-PRT 
signature [Falquet et a l, 2002]. The core of this motif, residues 164-176, is similar to 
the 13 residue PRPP binding motif as found in type I PRTs (Figure 6-4 and Figure 
6- 10).
The third or C-terminal domain (residues 220-299) adopts a ferredoxin-like 
fold. This domain is linked to the first domain by the 22 residue helix a l  (residues 
204-225) which also serves as the last helix of domain 1. The C-terminal domain 
contains a 4 strand (3-sheet on one side flanked by two a-helices, forming a double 
pap motif, connected by an eight residue loop (residues 255-263) the majority of 
which is not resolved in the electron density map. By visual inspection of the 39 super 
families with this fold in the SCOP database [Lo Conte et a l, 2000], the C-terminal 
domain seems to be most similar to family 5, the Pn signal transduction proteins and 
family 20, the ‘ACT domain’ family10. This is consistent with its role in the regulation 
of the enzyme by histidine and tRNA binding [Flartman et a l, 1971; Smith et a l, 
1974; Sterboul e ta l, 1977].
10 ‘ACT domain’ stands for aspartokinase, chorismate mutase, TyrA domain
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Figure 6-4 Sequence alignment of representative HisGs. A sequence alignment 
of representative long (1) and short (2) forms of ATP-PRT from archaea, bacteria and 
yeast together with the secondary structure of the E. coli ATP-PRT, produced using 
ESPript (51). a-helices and p-strands are represented as helices and arrows,
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respectively, and (3-turns are marked with TT. The residues involved in binding PRPP 
are indicated with ▲ , the two residues shown to be involved in histidine binding with 
*, and the 13 residues similar to type I PRPP binding motif are marked with a blue 
line. The residues buried at the dimer interface are marked m in green, those buried 
at the trimer interface are coloured in red (S1 see text) and magenta (S2). This 
sequence alignment was created using the following sequences (Organism, 
SwissProt accession numbers or other source in brackets) HIS1_ECOLI (Escherichia 
coli, P10366); HIS1_SALTY (Salmonella typhimurium, P00499); HIS1_CAMJE 
(Campylobacter jejuni, Q9PM78); HIS1_SULTO (Sulfolobus tokodaii, Q970Z3); 
HIS1_METTH (Methanobacterium thermoautotrophicum, 027550); HIS1_CANAL 
(Candida albicans, P46586); HIS1_YEAST (Saccharomyces cerevisiae, P00498); 
HIS1JVIYCTU (Mycobacterium tuberculosis, 033256); HIS1_STRC0 (Streptomyces 
coelicolor, The Wellcome Trust Sanger Institute, SC01438); HIS1_THEMA 
(Thermotoga maritima, Q9X0D2); HIS1_LACLA (Lactococcus lactis (subsp. lactis), 
Q02129); HIS1_PSEAE (Pseudomonas aeruginosa, Q9HVW8); HIS1„STAAM 
(Staphylococcus aureus, Q99QW2); HIS1_SYNY3 (Synechocystis sp. PCC 6803, 
Q55503).
6.3.3 The HisG dimer and hexamer
The long ATP-PRTs of E. coli and Salmonella typhimurium have been shown 
to exist in an equilibrium between various oligomeric states [Klungsoyr and Rryvi, 
1971; Tebar et al., 1973; Parsons and Koshland, 1974]. The equilibrium is affected 
not only by the concentration of substrates and effector molecules but also by the 
protein concentration. The structure reported here is of the hexameric form of the 
enzyme, which is a trimer of dimers that are related to the monomer by 
crystallographic symmetry.
The dimer interface, which is on the crystallographic 2-fold axis, buries 
1192 A2 of surface area per subunit. The interface is formed between the exposed 
surface of the p-sheet from J31-(33 together with the loop and part of helix a2 from 
domain 1 interacting with strand p8 through to helix a5 of domain 2. The interface is 
made of predominantly hydrophobic side chain interactions with Leu 39, lie 40, Leu 
51, Val 53, Leu 61 and Val 66 from domain 1 interacting with Leu 151, Val 157, Ala 
161, Leu 163, Ala 179 and Ser 154 from domain 2. Two residues make significant 
hydrogen bonds at either end of the dimer interface. The invariant Asp 57 in domain 1 
hydrogen bonds with both the side chain and main chain amide nitrogen of Asn 152 in
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domain 2. In addition the side chain of conserved Asn 180 in domain 2 forms 
hydrogen bonds to the backbone carbonyl of Glu 37 and amide nitrogen of Leu 39.
Figure 6-5 HisG hexamer. A ribbon representation of the HisG hexamer viewed 
down the crystallographic 2-fold axis. Individual chains are coloured uniquely and 
molecules of the inhibitor AMP are shown in ball and stick representation. The 
surface is calculated using GRASP [Nicholls et al., 1993] and the figure composed 
using DINO [Philippsen, 2001].
The hexamer is formed from three dimers by the crystallographic 3-fold 
symmetry, confirming our previous quaternary structure prediction (Figure 6-5) 
[Lohkamp et al., 2000]. The protein interactions that form the trimer are almost 
exclusively restricted to the C-terminal domain (Figure 6-2 and Figure 6-5). Domains 
1 and 2 of the dimers contact via residues 33-38 and 173-178 with exclusively 
hydrophobic interactions, but in general there is a 6 A separation between the 
backbone atoms of these residues. A hole of about 15-20 A diameter is formed 
between the dimers and the trimers of the C-terminal domain (calculated from a
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molecular surface produced using GRASP [Nicholls el a l , 1993]). The trimer 
interface in the C-terminal domain is composed of two dissimilar surfaces (SI and S2) 
which bury 760 A2 and 790 A2 of accessible surface area at the interface respectively. 
The last eight amino acid residues (Figure 6-2) are critical for trimer formation, 
burying almost 70% of the SI buried surface area and forming five out of the six 
interfacial hydrogen bonds. The hydrogen bonds are formed between strand p i6 of SI 
and pi5 of S2, the last strand of the anti-parallel sheet of the C-terminal domain. In 
addition to this four hydrophobic residues from each monomer (Tyr 228, Met 230 
from strand pl2  and Leu 292 and Pro 293 from strand pi5) pack together to form a 
core around the three-fold axis of the trimer. There is also the possibility of a salt 
bridge being formed between Glu 295 from SI and Lys 227 from S2. None of the side 
chain interactions seems to be strictly conserved across the long ATP-PRT forms, 
again highlighting the sequence variability of the enzyme. Overall the buried surface 
area at the trimer interface is comparable to that at the dimer interface as is the 
number of hydrogen bonds; however from solution studies it is clear that the 
hexamers can be more easily dissociated into dimers than into monomers [Klungsoyr 
andKryvi, 1971; Tebar et a l, 1973],
6.3.4 AMP binding
AMP and ADP are competitive inhibitors of ATP-PRT with respect to both 
ATP and PRPP [Morton and Parsons, 1977]. Low levels of histidine synergistically 
enhance this inhibition which is also associated with formation of the hexameric form 
of the enzyme [Kryvi and Klungsoyr, 1971]. Specifically, histidine lowers the 
dissociation constant for AMP by 20-fold and ADP by 4-fold [Morton and Parsons, 
1977]. In the AMP-bound ciystal structure, one molecule is bound per monomer with 
the phosphoribosyl moiety interacting with domain 2 and the adenine ring positioned 
in the cleft between domains 1 and 2. The main interactions made by the AMP to the 
protein are via the phosphate and the ribose groups of the nucleotide (Figure 6-6). The 
monophosphate binds to a loop following strand p9 and the beginning of helix a6. 
Hydrogen bonds are made to the AMP phosphate by the backbone amides of Ser 172, 
Thr 173, Gly 174 and Thr 176, and the hydroxyls of Ser 172, Thr 173 and Thr 154. 
The dipole of helix a6 also provides additional electrostatic binding energy. The 2' 
and 3' hydroxyl groups of the ribose of AMP form hydrogen bonds to the side chains
109
Chapter 6 HisG from E. coli
of conserved residues Glu 156 and Asp 169. The only additional interaction is the 
guanidinium group of Arg 16 from the N-terminal domain, which stacks against the 
adenine ring of AMP. This orientation of AMP is markedly different from that 
reported for the His-AMP M. tuberculosis enzyme [Cho et al., 2003] (see Figure 8-2) 
due to the 2' and 3' hydroxyl groups of the ribose being coordinated by an non­
conserved aspartate (residues Asp 30 using M tuberculosis numbering) from an 
adjacent protein subunit.
C104
T173
S172
E156
D169
G153
Y131
C104
Figure 6-6 AMP binding in HisG. A stereoview of the AMP binding site with 
residues from the dimer related molecule coloured in orange. Hydrogen bonds 
formed between AMP and HisG are shown as green dotted lines. Residues D 169 to 
T 176 are part of a 13 residue PRPP binding motif. R 16 base stacks with the purine 
ring of bound AMP. This figure was prepared using WebLabviewer.
6.4 HisG with PR-ATP
Crystals of HisG co-crystallised with PR-ATP were essentially isomorphous 
to the ones in presence of AMP (see Section 5.1.1). Therefore phases did not need to 
be solved specially.
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6.4.1 Refinement
The model of HisG complexed with AMP was stripped of the AMP and used 
as an input model for rigid body refinement in REFMAC5. This was followed by a 
round of refinement with REFMAC5 including TLS refinement. The monophosphate, 
attached ribose and the purine ring of PR-ATP were clearly identified in a Fo-Fc 
difference map. The ribose and tri-phosphate stemming from the ATP was not seen in 
the density. Figure 6-7 shows an omit difference map of PR-ATP. This part was build 
and the complete structure further refined with REFMAC5/TLS [Murshudov, 1996; 
Winn et al., 2001].
Figure 6-7 Omitmap of PR-ATP and AMP. PR-ATP and AMP shown in stick with a 
Fo-Fc map contoured at 2ct and 1.75ct respectively. This figure was prepared using 
SETOR [Evans, 1993].
6.4.2 Quality of model
The model of HisG complexed with PR-ATP had a final RWOrk = 20.0% and 
Rfree = 27.2%. The rms deviation in bond distances was 0.018 A and for bond angles 
of 2.031°. The assessed geometrical parameters by PROCHECK [Laskowski et al., 
1993] were either satisfactory or better than expected for a structure of this resolution. 
The Ramachandran plot shows two residues (Ala 248 and Arg 250) just outside the 
additional allowed region (see Figure 6-8). These residues are part of a loop in the 
C-terminal domain where the electron density is poorly resolved. However density is 
for the loop and the Arg side chain is clearly seen. Table 6-4 shows a summary of the 
refinement statistics.
The model with PR-ATP superimposes on that with AMP with an rms 
deviation of 0.346 A.
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Figure 6-8 Ramachandran plot of E. co li HisG complexed with PR-ATP
112
o>
Chapter 6 HisG from E. coli
Table 6-4 Refinement statistics of HisG complexed with PR-ATP
Refinement statistics
Resolution range (A ) 50-2.9
Rworking (%)' 20.0 (7834)
Rfh* (%)1,2 27.2 (687)
Number of atoms
Protein 2193
Nonprotein (PR-ATP, 2 tartrate) 43
R.m.s. deviation from ideal
Bond length (A ) 0.018
Bond angles (°) 2.031
Ramachandran statistics
Most favoured 212
Additionally allowed 39
Generously allowed 1
Disallowed 2
1 number in parenthesis is the number of reflections.
2 Rfrec was calculated with 8.1% of reflections.
6.4.3 PR-ATP binding
HisG was co-crystallised with highly purified PR-ATP, produced by 
biotransformation using the E. coli enzyme (by S. Campbell). The structure is 
isomorphous with the AMP structure and only the phosphoribosyl-adenine (PR-A) 
part of PR-ATP is seen. PR-ATP is reasonably stable near neutral pH, however the 
crystallisation buffer was at pH 5.6, outside this range. Although 100 mM MgCl2 was 
present in the crystallisation, tartrate was used in a more than 10-fold higher 
concentration which could chelate the divalent cation. Either of these effects could 
result in the observed lack of order or degradation of the product in the crystals. The 
conformation of the PR-A structure is essentially the same as that of AMP-bound 
protein. However, there is a small (0.5 A ) concerted shift around the monophosphate 
binding loop (residues 170 - 185) together with a shift in the PR-A structure relative 
to the AMP molecule (Figure 6-9). The ribose ring of PR-A is shifted almost 1 A  
relative to AMP and the difference electron density (Figure 6-7). Due to this shift one
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hydrogen bond between Asp 169 and the ribose hydroxyls is lost. This is consistent 
with the proposal that PR-A is bound to the crystals and not AMP, which was 
excluded meticulously from all stages in the protein preparation.
Figure 6-9 PR-A(TP) binding compared with AMP binding in HisG. The structures 
of HisG with PR-A(TP) and AMP are shown in stick coloured according to the 
elements. The residues with green carbon atoms belong to the PR-A(TP) bound 
structure, the ones in cyan coloured carbons to the AMP bound structure. Hydrogen 
bonds between HisG and PR-A(TP) are shown in black dotted lines, the ones 
between AMP and HisG in grey dotted lines.
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6.5 Discussion
6.5.1 AMP inhibition at the PRPP binding site
The region of domain 2 involved in AMP binding (residues 164-176) is 
similar to the PRPP binding motif (Figure 6-10). Alignment of this motif with the 
type I PRPP binding motif reveals the main difference as two consecutive conserved 
aspartic acid residues (position 5-6 in PRPP motif) versus one in ATP-PRT (position 
6, Asp 169). Residue 169 is conserved as either Asp or Glu and is part of the PRPP 
binding motif, whereas the invariant Glu 156 is outside the motif (Figure 6-10). The 
13 residues in ATP-PRT possess a typical backbone conformation as seen for the 
PRPP binding motif in both type I PRTs and PRPP synthetases. In type I PRTs this 
loop is involved in binding of PRPP, confirmed by a crystal structure of orotate PRT 
with PRPP bound [Scapin et al., 1995]. This identifies this loop in ATP-PRT as the 
potential PRPP binding site. It is therefore surprising that AMP binds to this site 
rather than to the ATP binding site of the enzyme which had been previously assumed 
[Morton and Parsons, 1977]. The only other example of a feedback inhibitor binding 
to the PRPP binding site, rather than an allosteric site, is that of AMP to B. subtilis 
glutamine phosphoribosylpyrophosphate amidotransferase [Smith et al., 1994]. Figure 
6-11 shows a comparison of the PRPP binding site in orotate PRTs and ATP-PRT.
PRPP motif position 1  13
124 1 3 1
PRPP motif prosite (type I) 
Orotate PRT (S. typhimurium)
Anthranilate PRT (type I I I )
L I L l g g l L S S f x S  
VMLVDDVITAGTA
|xxxx|x|
1 56 16 9 176
ATP-PRT prosite (type IV) 
ATP-PRT (E. coli)
MxxxxxBxBxxfcdHbcxtHxBB
EVAPRAG LADAICDLVSTGATL
4-10aa
Figure 6-10 Alignment of PRPP binding motif.
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Figure 6-11 Comparison of PRPP binding site, (a) shows the PRPP binding site in 
orotate PRT from S. typhimurium (OPR1) and (b) the AMP binding site in E. coli 
HisG. The structures were superimposed using the monophosphate binding loop and 
adjacent helix (which includes the 13 residue PRPP binding motif). Residues from a 
symmetry related monomer (within the dimer) are shown with cyan carbon atoms, (c) 
shows the PRPP and a coordinated water (red) and Mg2+ ion (magenta) from the 
orotate PRT structure superimposed on the ATP-PRT structure. Hydrogen bonding is 
shown in grey dotted lines and possible ones for PRPP binding in yellow.
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6.5.2 Substrate binding sites
The modified PRPP binding site of ATP-PRT can be compared with those of 
several representative type I PRTs, namely Toxoplasma gondii HG-PRT, 
Trypanosoma cruzi H-PRT and S. typhimurium O-PRT (1FSG, 1TC2 and lOPR 
respectively, see Figure 6-11 and Figure 6-13). The binding of the PRPP to ATP-PRT 
requires Mg2+ although it has been shown that manganese can substitute functionally 
for magnesium [Bell and Koshland, 1971]. The structures of type I PRTs complexed 
with PRPP and Mg2+ show that four of the six coordination sites are occupied by 
PRPP, the 2' and 3' hydroxyl groups of the ribose and one each by the pyrophosphate 
moiety. The remaining two coordination sites are occupied by water molecules, one of 
which is bound to the protein. Comparison with these structures suggests that this 
arrangement will be found in ATP-PRT, the conserved water molecule binding to Glu 
156 and the backbone of Val 155. The terminal phosphate of PRPP in type I PRTs is 
normally coordinated by the protein backbone or by arginine or lysine side chains. In 
ATP-PRT the amide of Ser 154 may be involved but conserved residues from domain 
1 of the dimer related subunit, Lys 13 and Arg 54 are also in positions to play an 
important part in coordination (see Figure 6-11).
The orientation of bound AMP not only provides information about the PRPP 
binding but also the position of the adenine ring found in the substrate ATP and 
product PR-ATP. In bound PR-ATP the purine ring will be orientated in a way that 
the 5- and 6-membered rings swap positions compared with the bound AMP. This is 
possible as the only interaction of the ring is the base stacking with Arg 16 (Figure
6-6) and no hydrogen bonding or electrostatic interaction are involved. The ribose of 
ATP and the product are most likely to bind to conserved residues Cys 104 and Asn 
75, while the triphosphate, thought to require Mg2+ for binding, may be positioned in 
the cleft between domains 1 and 2.
6.5.3 Reaction mechanism and inhibition of HisG
Detailed studies on the reaction mechanism of ATP-PRT have been 
undertaken for both the E. coli and S. typhimurium enzymes [Kleeman and Parsons, 
1976; Morton and Parsons, 1976; Tebar and Ballesteros, 1976; Goitein and Parsons, 
1978; Dall-Larsen, 1988], The reaction proceeds via a steady state ordered Bi-Bi 
kinetic mechanism with the binding of ATP followed by PRPP, and PPi leaving first 
followed by PR-ATP (see Figure 1-4) [Morton and Parsons, 1976]. However, the
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observation that both AMP and ADP are competitive inhibitors with respect to both 
substrates has been difficult to reconcile with this mechanism [Morton and Parsons, 
1977], From the crystal structure it is clear that the reasonable assumption that AMP 
and ADP inhibit by binding to the ATP binding site of the free enzyme is in error. The 
monophosphate and ribose of AMP are instead bound to the PRPP binding site in 
domain 2, while the adenine ring binds in a position occupied by ATP in domain 1. In 
this way AMP can compete with PRPP as well as ATP for binding to the free enzyme.
The binding of PR-ATP in the active site further confirms the binding site of 
PRPP. Furthermore it confirms the overlapping of the purine ring position of AMP 
and the product. This validates the assumption that the purine portion of ATP binds 
there with the ribose-triphosphate occupying the cleft in domain one. However this 
part could not be resolved in the structure.
AMP interacts with domain 1 through base stacking of the adenine ring with 
Arg 16, presumably closing the enzyme active site and forming a conformation 
similar to that when PR-ATP is bound which is confirmed by the structure. In this 
conformation the enzyme seems to favour aggregation into an inactive hexameric 
form as has been shown by solution studies [Klungsoyr and Kryvi, 1971]. In this 
aggregated form, the binding sites for substrates are much less accessible to solvent as 
they are located on the inner surface of the hexamer (Figure 6-5). Therefore AMP and 
PR-ATP inhibit the enzyme by both conventional competitive inhibition with respect 
to the substrates and by forming a hexamer in which the active sites are closed and 
inaccessible.
6.5.4 HisG is a new class of PRTs: Extending the PRT superfamily
The structures of previous reported PRTs have been classified as type I, II and 
III on the basis of their folded structure. ATP-PRT has no structural similarity to these 
enzymes and therefore should be classified as a type IV PRT. A new type of PRT 
would have been expected, as beyond the PRPP binding motif there is no sequence 
similarity between ATP-PRT and any other PRTs. However, all structurally 
characterised PRTs with the PRPP binding motif have been found to possess a type I 
fold. Although it has been proposed that a PRPP binding motif is exclusive to PRTs in 
the nucleotide synthesis and salvage pathways [Sinha and Smith, 2001], the histidine 
biosynthetic enzyme structure reported here has a similar PRPP binding motif but is 
not homologous to the type I PRT family of enzymes.
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Figure 6-12 Comparison of different types of PRTs. One representative of each 
type of PRT coloured according to their secondary structure are shown in ribbon 
representation: type I - orotate-PRT (a), type II - quinolate-PRT (b), type III - 
anthranilate-PRT (c) and type IV ATP-PRT (d). Where available substrate, product or 
inhibitor are shown in stick as well as the two conserved acidic residues involved in 
PRPP binding.
The conserved 13 residue PRPP binding motif is common to type I PRTs 
(Figure 6-10). This motif is not found in the type II enzymes and is restricted in type 
III enzymes [Eads et al., 1997]. ATP-PRTs have a modified PRPP binding motif with 
one of the two conserved acidic residues, which are involved in binding the PRPP 
ribose, being found outside the motif (Glu 156). The backbone of the PRPP binding 
loop and helix a6 of ATP-PRT (residues 170-180) superimpose with a rmsd of 
between 0.5 A and 0.8 A on representative type I PRT structures highlighting the 
conserved nature of this motif and the common mode of binding of the
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monophosphate (Figure 6-13). Although the motif is found in the central strand of the
5-stranded P-sheet of ATP-PRT domain 2, as in type I PRTs, there is no structural 
similarity beyond this to suggest the domains are related. For example, in the direction 
of the (3-strands, the [3-sheets of the domains are inclined at an angle 20° from each 
other, while perpendicular to this, the planes of the two p-sheet are at an angle of up 
to 60° away from each other. These large structural differences affect the position of 
the two acidic residues associated with the PRPP binding motif (Asp 124 and Asp 125 
in S. typhimurium O-PRT; Glu 146 and Asp 147 in Toxoplasma gondii HG-PRT). In 
type I PRTs, these acidic side chains acids are adjacent and located at the apex of the 
central P-strand where they are in a position to bind the 2' and 3' hydroxyl group of 
the ribose respectively. ATP-PRT has only one residue, Asp 169, in an equivalent 
position which is situated 2.5 A away from the two acidic residues of the type I PRTs, 
however it is still in a position to bind to the 2' hydroxyl of PRPP. The residue 
adjacent to Asp 169 in ATP-PRT is hydrophobic and buried against helix a4; the 
binding of the 3' hydroxyl is instead accomplished by Glu 156, a residue at the 
beginning of helix a5 and outside the normal PRPP binding motif. The pairs of acidic 
residues in type I PRTs and ATP-PRT are separated by approximately 5 A and 
therefore are structurally equivalent.
Figure 6-13 Comparison of PRPP binding motif of HisG and type I PRT. Ribbon 
diagram of a comparison of the 13 amino acid PRPP binding motifs of E. coli ATP- 
PRT and a typical type I PRT, HG-PRT (1FSG). The residues used to superimpose 
the two structures are highlighted in yellow, the rest of the structure is coloured
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according to secondary structure. The ligands are represented in stick and coloured 
according to atom type. This figure was produced using DINO [Philippsen, 2001].
Although the different types of PRTs form distinct folds, they share a number 
of structural similarities that probably result from catalysing a common chemical 
reaction. All types consist of at least two domains of which one binds the PRPP and 
the other is responsible for the substrate-specific recognition. The PRPP binding 
shows a common feature of two conserved acidic residues which bind the two 
hydroxyl groups of the PRPP ribose as well as coordinating the divalent cation. In 
type I and III PRTs these residues are adjacent in sequence whereas in type II and IV 
they are separated by 21 and 13 residues respectively. In type I, IV and presumably III 
PRTs, the PRPP monophosphate is bound in a loop with a common backbone 
conformation while in type II positive side chains are involved. These structural 
similarities appear to represent common structural solutions for the binding of PRPP. 
However, the differences in overall fold and the lack of amino acid sequence identity 
both suggest that the 4 types of PRTs are the result of convergent evolution.
6.5.5 The C-terminal ‘regulatory’ domain
The C-terminal domain of the long ATP-PRTs has been implicated in the 
regulation of the enzyme by histidine and tRNA binding [Hartman et al., 1971; Smith 
et al., 1974; Sterboul et al., 1977], This domain shares no obvious sequence similarity 
with any other proteins, but has a ferredoxin-like [3ap|3af3 topology, which is 
common to a large number of proteins. Visual inspection of the ferredoxin-like super 
families in the SCOP database [Lo Conte et a l, 2000], revealed the C-terminal 
domain to be most similar to Pn signal transduction proteins and the ‘ACT domain’ 
family.
The ACT (aspartokinase, chorismate mutase, TyrA domain) domains are 
found typically at the N- or C-termini of enzymes involved in amino acid and purine 
biosynthesis either as a single domain or as a tandem repeat [Chipman and Shaanan, 
2001]. ACT domains are involved in oligomerisation, usually to form dimers and 
tetramers, with pairs of the regulatory domains forming an eight-stranded P-sheet with 
four helices on one side. Small effector molecules seem to bind between regulatory 
domains and in some cases cause feedback inhibition (e.g. serine in E. coli 3- 
phosphoglycerate dehydrogenase) [Schuller et a l, 1995]. This is consistent with the
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evidence from mutant studies which indicates that the C-terminal ATP-PRT domain is 
responsible for feedback inhibition by histidine and the binding to histidyl-tRNA 
[Hartman et al., 1971; Smith et al., 1974; Sterboul et al., 1977]. However, the overall 
fold and oligomerisation of the C-terminal domain of ATP-PRT show that it is much 
more similar to the Pn signal transduction proteins than to the ACT domains.
Figure 6-14 Comparison of C-terminal domain of HisG with Pn-like protein. (A)
Ca superposition of the C-terminal domain of ATP-PRT compared with the PM protein 
GlnK. ATP-PRT is shown in blue, overlaid residues of GlnK in magenta. The B-, C- 
and T-loop of GlnK are shown in yellow, orange and green, respectively. N- and C- 
termini are labelled with N and C, respectively. (B) Comparison of the quaternary 
structure of Pn protein GlnK (left) and C-terminal domain of ATP-PRT (right). The top 
pair of diagrams show a view down the 3-fold axis and the lower pair a side view. 
One subunit is coloured in blue, the other two according to their secondary structure. 
In GlnK the B-, C- and T-loops, which are involved in ATP binding, are shown in 
yellow, orange and green, respectively. Key residues involved in binding ATP in GlnK 
and ATP are shown in ball and stick representation. The equivalent binding cleft of 
ATP-PRT is shown with the conserved Thr 252 in ball and stick representation.
The Pn proteins form trimers with the 4 [3-strands forming a barrel around the 
3-fold axis, an arrangement exactly analogous to the two C-terminal domain trimers 
formed at either end of the ATP-PRT hexamer (Figure 6-5 and Figure 6-14). 
Functionally, Pn proteins have been shown to play a pivotal role in the coordination of 
carbon and nitrogen metabolism in plants, bacteria and archaea [Ninfa and Atkinson,
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2000]. They are known to bind various ligands including 2-ketoglutarate and 
glutamate and can be uridylylated and phosphorylated. Binding of effectors or 
covalent modification alters the conformation of Ph proteins, which then interact with 
receptors to induce various secondary effects such as changes in gene expression, 
protein modification and transport of nitrogen and carbon sources. A superposition of 
the C-terminal domain of ATP-PRT with the Pn protein GlnK [Xu et a l , 1998] using 
main chain atoms from the |3-sheet results in a rmsd of 1 A over 84 atoms (Figure
6-14b). However, conserved regions of sequence found in Pn proteins corresponding 
to three loops are in each case significantly shorter in ATP-PRT. The ‘B-loop’ in 
ATP-PRT is a turn, which contains two conserved residues Gly 285 and Ala 286, 
while the ‘C-loop’ is truncated by ten residues (Figure 6-14a). The ‘T-loop’ as in 
several of the Pn protein structures is not completely resolved (residues 256-264 are 
missing); however it does not contain any conserved tyrosine or serine that could be 
covalently modified [Arcondeguy et a l, 2001], and its size is not consistent with it 
interacting with other protein receptors [Jiang et a l, 1997]. A comparison of the 
C-terminal domain trimer with that of GlnK complexed with ATP [Xu et a l, 1998] 
reveals that the intersubunit pocket in which ATP binds is conserved. In particular 
Thr 29 (GlnK numbering), which makes two important hydrogen bonds to the adenine 
and ribose of ATP in GlnK, is highly conserved in ATP-PRT C-terminal domains 
(Thr 252, Figure 6-4). In contrast residues involved in binding the tri-phosphate 
moiety, two glycines from the ‘B-loop’ and Arg 103 from the ‘C-loop’ of GlnK are 
absent in ATP-PRT, suggesting that the domains do not bind ATP.
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Chapter 7: Structure Solution of HisG from Mth
7.1 Solving the phases of Mth HisG
7.1.1 Molecular replacement (MR) using E. coli HisG as a search model
Initially molecular replacement was attempted to solve the structure of HisG 
from Mth using the structure of the E .coli enzyme as a search model. A variety of 
search models were tried, using combinations of the first two domains, the monomer, 
a complete dimer, with no changes to the residues, systematically cutting residues to 
alanine through to a complete poly-alanine model. In addition various MR programs 
(AMoRe [Navaza, 1994], BEAST [Read, 2001], MOLREP [Vagin and Teplyakov, 
1997] and EPMR [Kissinger et al., 1999]) had been utilised and various resolution 
ranges of data had been assessed. Several reasons can be proposed to explain the 
difficulties in obtaining a correct MR solution using the E. coli HisG as a search 
model. One is the low sequence identity (38%) between the search model and the 
structure to be solved. Another is the coordinate error in the search model due to the 
low resolution and therefore high coordinate error of the E. coli search model. 
Furthermore, a conformational change between the histidine and AMP-bound 
structure cannot be excluded, making the search model inadequate. Finally, the search 
model is elongated in shape and symmetry equivalent molecules are closely 
associated within the hexamer. This significantly blurs the boundaiy between inter- 
and intra-molecular vectors necessaiy for conventional MR. Addition of (weak) phase 
information from derivatives was available (data not shown) and a phased MR search 
tried. However, despite the best efforts and use of considerable computing time, no 
solution was obtained.
The availability of the higher resolution HisG structure of Mtb initiated a new 
attempt to solve the Mth structure which was successfiil and is described in the 
following.11
11 At least one good thing...
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7.1.2 MR solution with Mtb HisG as search model
A 1.8 A  resolution Mtb HisG structure complexed with AMP and histidine 
(pdb entry 1NH8) was deployed as a search model in AMoRe. Using the monomer 
with all residues or as a poly-alanine model gave no clear solutions (data not shown). 
Because there are two monomers in the asymmetric unit (asu) for the Mth enzyme a 
dimer of 1NH8 was tried as a search model. Initially the dimer was built by 
superposition with the E. coli dimer which gave no solution. Then a dimer was built 
using the crystallographic symmetry of the Mtb enzyme. Here again the full model 
gave no distinct solutions over various resolution ranges.
A poly-alanine model of Mtb HisG dimer built in this way as a search model 
in AMoRe gave correct solutions. Various resolution ranges were probed and 
solutions for ranges 10-4 A  and 17.5-4 A  are shown in Figure 7-1. Though no single 
distinct peak could be seen in the rotation function, the correct solutions became clear 
after the translational search and even clearer after rigid body fitting in AMoRe. More 
than one solution is found with all search models corresponding to symmetry 
equivalent molecules. The solutions were visualised and inspected for packing within 
the unit cell using the molecular graphics program PyMOL and special attention was 
paid to any clashes with symmetry related molecules.
A modified model was built by editing the search model so that conserved or 
similar residues were kept but significantly different residues were mutated to Ala. If 
there were one to two residues missing in the alignment then the preceding and 
following residues were deleted from the search model. In case more residues were 
missing two residues were cut from the search model. The results of MR with this 
modified model are shown in Figure 7-1. The results here are not as clear as for the 
poly-alanine models and two incorrect solutions are in the top 6 results. However this 
model was used for further refinement and model building as it resembles the Mth 
enzyme the most.
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Figure 7-1 AMoRe results for Mth HisG
7.1.3 Model building and refinement
The modified HisG model from Mtb, rotated and translated according to the 
AMoRe solution file, was used as an input for rigid body refinement with REFMAC5 
[Murshudov, 1996]. The two chains of the dimer were split in 3 individual domains as 
rigid body groups. After 20 cycles of refinement in the resolution range 30-4 A the R- 
factors dropped by about 8% (see Table 7-1). Before model building the model was 
further restrained refined with REFMAC5 (40-3.5 A). To further improve these initial 
phases and remove model bias, solvent flattening with histogram matching was 
carried out using DM [Cowtan, 1994] and an initial map was calculated.
Solution Number
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Table 7-1 R- and free R-factor during refinement of Mth HisG
Refinement step R-factor /% free R-factor /%
Start (AMoRe model) 54.9 57.4
Rigid body (REFMAC5) 46.4 49.1
REFMAC5 (initial) 38.2 46.3
Simulated annealing (CNS) 33.3 38.1
B group refinement 30.4 35.5
Refmac5 with TLS 21.0 28.5
Iterative cycles of model building with QUANTA and refinement were carried 
out. Refinement for the incomplete model was accomplished with a cycle of simulated 
annealing, followed by grouped B-factor refinement, in CNS [Brunger et a l , 1998]. In 
early refinement stages density for histidine was found between C-tenninal domains 
within the hexamer (see Figure 7-2). Once the model was nearly complete, histidine 
was modelled and refinement was carried out with REFMAC5 using TLS parameters 
and NCS restrains. A total of 6 TLS groups were used for the 3 domains in the 2 
chains.
Figure 7-2 Electron density for histidine in Mth HisG. 2Fo-Fc electron density in 
early stages of the refinement (no histidine included) is shown at 1o contour level. 
Green and cyan carbon atom label symmetry related monomers. The position of the 
histidine in the final model is shown in grey.
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7.2 Mth HisG model
7.2.1 Quality of the model
The final model of Mth HisG had a final R- and free R-factor of 21.0% and 
28.5% respectively. The rms deviation of the bond lengths was 0.015 A  and of the 
bond angles 1.534°. Both chains have no residues outside the allowed region of the 
Ramachandran plot. The geometric parameters for the side and main chains are 
satisfactory or better than expected for this resolution as indicated by a PROCHECK 
analysis. A summary of the refinement statistics is shown in Table 7-2.
Table 7-2 Refinement statistics of Mth HisG
Refinement statistics
Resolution range (A) 47.7-2.65
Rworking (%) 21.0(13948)
28.5 (1373)
Number of atoms
Protein 4352
Nonprotein (Histidine, MPD, Tris, imidazole) 56
Water 99
R.m.s. deviation from ideal
Bond length (A) 0.015
Bond angles (°) 1.53
Ramachandran statistics
Most favoured 447
Additionally allowed 52
Generously allowed 1
Disallowed 1
! number in parenthesis is the number o f reflections 
2 Rfree was calculated with 8.2% of reflections.
7.2.2 Overall structure
The structure of HisG from Mth is shown in Figure 7-3. The overall fold is the 
same as observed for the E. coli enzyme. A more detailed comparison with other
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HisG structures is described in Section 8.4. The Mth enzyme was crystallised in the 
presence of histidine which stabilises the inactive, hexameric form. The two 
monomers in the asu form the dimer and the hexamer is formed via the 3-fold 
crystallographic symmetry.
a b
Figure 7-3 Mth HisG monomer and dimer. The monomer (chain A) is shown (a) 
and the dimer (b) in ribbons representation. The bound histidine is shown in stick 
representation.
7.2.3 The two monomers
The two monomers overlay with an rms deviation of 0.42 A  over all Ca 
atoms12 and with a maximum deviation of 2.0 A. Figure 7-4 shows the rms deviation 
over the whole peptide chain. A very marked deviation, including the maximum, 
occurs around residue 34 which is the loop before (3-strand 2 (see Figure 7-5). The 
first 80 residues are otherwise virtually identical. For the remainder of the chain there 
is a deviation of around 0.5 A  throughout. From inspection of the Ca trace of the two 
superimposed chains (Figure 7-5) it is clear that this difference is caused by a tilt of 
domain 2 and 3 with respect to domain 1. In chain B the domains are further apart, 
resulting in a more open L-shape than in chain A.
12 the coordinate error of the structure is 0.30 A
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residue number
Figure 7-4 Rms deviation between chain A and B of Mth HisG.
Figure 7-5 Overlay of chain A and B of Mth HisG. Ca trace of Mth HisG chain A is 
shown in red and overlaid chain B in green. The straight arrow shows the region of 
maximum deviation. The curved arrows show movement of the second and third 
domain in chain B compared to chain A and a nearly identical first domain.
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7.2.4 Histidine binding
One molecule of histidine is bound per subunit of HisG. The ligand binds 
between two adjacent C-terminal domains within the trimer of the hexamer (see 
Figure 7-6). Figure 7-7 shows the interactions involved in the histidine binding to Mth 
HisG, with the distances between protein atoms and those of histidine shown in Table
7-3. Most hydrogen bonds to the histidine originate from one subunit with 
predominantly main chain atoms being involved (Met 236, Gly 238 & Val 256) and 
the side chain of conserved residue Thr 240. Additionally two residues (Asn 220’ & 
Asp 276’) of a neighbouring subunit are involved in histidine binding. Besides the 
main chain interactions there are two side chains (Asn 220’ & Thr 240) involved in 
binding. One histidine side chain nitrogen (ND1) forms a hydrogen bond to a water 
molecule. A comparison of the histidine binding between the two chains A and B in 
Mth HisG shows that most interactions are conserved (Table 7-3). However the main 
difference is in the coordination of OXT which is either hydrogen bonding to the side 
chain nitrogen of Asn 220 (symmetry neighbour; chain A) or to the main chain 
nitrogen of Thr 237 (chain B). This means that the interactions of histidine with the 
neighbouring subunit can be reduced to two essential ones (side chain Asn 220 and 
main chain Asp 276).
a b
Figure 7-6 Trim er of C-terminal domain of Mth HisG with bound histidine. The
C-terminal domains, in ribbons representation, from the three different chains are 
shown in green, blue and magenta, (a) shows the view from the centre of the 
hexamer, (b) a side view. Bound histidine is shown in stick representation and 
coloured by element. In addition, the conserved residue Thr 240 is shown in sticks.
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Figure 7-7 Histidine binding in Mth HisG (chain A). Histidine is shown in stick 
(thick) representation and carbon atoms in green. Two HisG subunits are shown in 
stick (thin) representation, the symmetry equivalent one with carbon atoms in cyan. 
Hydrogen bonds between histidine and the protein are shown in grey dotted lines.
Table 7-3 Protein-histidine interactions in Mth HisG (chain A). In parentheses are 
shown the numbers for chain B; italics denote symmetry related residue of the trimer 
within the hexamer; values in grey denote distances too long for hydrogen bonding.
histidine atom protein residue atom distance /A
ND1 h 2o 2.34 (2.80)
NE2 Asp 276 O 2.83 (2.87)
N Asn 220 OD1 2.90 (3.17)
Gly 238 O 2.76 (2.91)
Thr 240 OG1 2.85 (2.73)
0 Met 236 N 3.05 (3.12)
Val 256 N 3.08 (2.82)
OXT Asn 220 ND2 2.95 (3.51)
Met 236 N 3.05 (3.05)
Thr 237 N 3.26 (3.00)
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7.3 Discussion
7.3.1 Histidine binding
A comparison of the histidine binding of HisG in Mth and Mtb is shown in 
Figure 7-8. Overall the mode of histidine binding is identical in the enzyme from 
these two species. This is not surprising because most hydrogen bond interactions are 
by main chain atoms. Hydrogen bonds involving the two side chains residues (Asn 
220 & Thr 240) are conserved as well. The side chain interactions of Thr 240 (in 
Mth), is highly conserved throughout the (long) HisG family and is found at a 
conserved position within the Pn-like C-terminal domain (see Section 6.5.5 and Figure
6-14). The residue at position 220 (here Asn) from the neighbouring subunit is 
conserved in size but not in charge as either His or Asp/Asn. The latter, with one 
hydrogen donor and one acceptor, are ideal for hydrogen bonding to the amino acid 
portion of histidine. In other species, like E. coli, where this residue is a histidine, 
only one hydrogen bond is possible but this does not seem to compromise the 
specificity13. Overall this shows that histidine binding in HisG relies on two side chain 
interactions with a conserved Thr and one other residue as a possible hydrogen 
bonding partner.
The histidine model in the Mth HisG structure (pdb code 1NH8) is incomplete 
with the oxygen (OXT) of the carboxylic acid being omitted. It is unclear if the atom 
is absent by mistake or whether it is not resolved in the electron density. No 
comparison of this part of the histidine is therefore attempted.
13 A ciystal structure o f E. coli HisG with histidine could prove this proposal. Unfortunately crystals 
grown in presence o f histidine and AMP did not diffract beyond 3 A and the collected data set was veiy 
difficult to scale and no solution has been obtained to date.
133
Chapter 7 Structure o f Mth HisG
Figure 7-8 Comparison of histidine binding between HisG from Mth and Mtb.
The top panels show histidine binding of Mth with carbon in green (a) and Mtb with 
carbon in cyan (b). Residues involved in histidine binding are labelled. The bottom 
panel (c) shows the two structures superimposed. Hydrogen bonds are shown in 
grey dotted lines (dark for Mth, light for Mtb).
Bound histidine is completely buried between the neighbouring subunits of 
HisG within the trimer. In comparison the histidine binding site in the E coli enzyme 
is open and accessible (see Figure 7-9). Upon histidine binding the pocket closes with 
the conserved Thr residue moving towards the histidine and the ‘T-loop’ closing the 
binding pocket (which is not resolved in the E. coli structure). The C-terminal domain
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in the E. coli structure is therefore in a favourable orientation to bind histidine which 
is consistent with the observation that AMP and histidine bind and inhibit HisG 
synergistically.
Figure 7-9 Histidine binding pocket. The buried histidine in the Mth structure is 
shown in the left panel (a), the open pocket in the E. coli structure in the right panel 
(b; histidine is shown in stick, taken from the Mth structure). The histidine binding 
portion of one subunit (green) of both structures is aligned. The conserved Thr 
residue from the neighbouring subunit (magenta) is shown in stick representation.
7.3.2 Quaternary structure
Conformational changes and the effect on the quaternary structure will be 
discussed in Section 8.4.
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Chapter 8: Comparison of HisGs
8.1 Significance of the disulfide bridge in Mtb HisG
The structure of apo Mtb HisG revealed a disulfide bridge between Cys 73 
from domain 1 and Cys 175 from domain 2, which was confirmed by cysteine 
modification experiments. This disulfide bond was not observed in the structure 
obtained in the presence of histidine and AMP. Cysteine modification experiments in 
the presence of inhibitors showed less accessible cysteines possibly due to hexamer 
formation. A potential role for this bond in regulation was proposed [Cho et a l,
2003]. This hypothesis is investigated in more detail in terms of structure and 
sequence alignments.
Sequence alignment shows that Cys 73 is unique to the Mtb enzyme (see 
Figure 6-4) and no cysteine residue is found in the surrounding area of position 73 
(position 78 in E. coli). Cys 175 (position 189 in E. coli) is conserved among the 
Mycobacterium spp. and found in a small number of other organisms. Again, no 
cysteine can be found in the vicinity of position 175 to function as a substitute in the 
other organisms. This suggests that if there is a functional role for this disulfide bond 
it is an Mtb specific feature.
Investigation of the HisG structures of E. coli and Mth showed that no 
structurally equivalent cysteine residues could form a disulfide bond as observed in 
Mtb. A comparison of residues in the position of the disulfide bridge, by superposition 
of apo Mtb HisG with other HisGs, highlights the variety of interactions made 
between the corresponding residues (Figure 8-1). In the E. coli enzyme a hydrogen 
bond is formed between Glu 78 and Tyr 189 while solely Van der Waals interactions 
are observed in the Mth HisG between Val 75 and Leu 179. This shows that the two 
regions of the structure are in close contact although the nature of the interactions is 
not conserved. This does not support the hypothesis of a conserved regulatory 
function proposed for the disulfide bond.
Nevertheless the disulfide bridge observed in the apo Mtb HisG has a 
significant impact on the structure. The distance between the Ca atoms is the shortest 
in this structure at 7.2 A , compared with 8.6 A  in the Mtb histidine+AMP ternary 
structure and the binaiy structures of AMP E. coli (10.7 A ) and histidine Mth (9.5 A ).
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The formation of the disulfide bond moves strand (310 and helix a3 closer together. 
Furthermore it stabilises the relative position of domain 1 to domain 2 beyond the 
more flexible interactions formed by the equivalent residues in the other species (also 
see Section 6.3.3).
Figure 8-1 Possible disulfide bond in HisG. Backbone representation in the vicinity 
of the disulfide bond, shown in stick, as observed in apo Mtb HisG (blue). 
Superposed are other HisG structures with equivalent residues shown in stick: green 
-  his+AMP Mtb; red: AMP E. coir, magenta: his Mth.
These observations show that a disulfide bond within HisG is not a conserved 
feature of the enzyme and therefore is unlikely to be involved in regulation. The 
disulfide bridge is more likely to be an artefact in the Mtb HisG formed by oxidation 
of cysteine residues which are structurally close and favourable positioned to form the 
bond. Formation of the disulfide bridge is likely to be physiologically irrelevant and 
most likely not to occur at all especially under reducing conditions. As a result the apo 
Mtb HisG structure has to be treated with caution, as structural differences may be the 
result of the formation of the disulfide bond and not due to the absence of inhibitors.
8.2 AMP binding in HisG
The binding of AMP in the E. coli enzyme, as observed in this study, differs 
significantly from the binding seen in the Mtb structure (see Section 6.3.4, Figure 8-2
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and [Cho et al., 2003]). Furthermore, based on the Mtb structure, it was proposed that 
AMP binds in the ATP binding site rather than the PRPP binding site as shown in this 
study.
Figure 8-2 AMP binding in E. coli (a) and Mtb HisG (b). The structures are shown 
in the same orientation, superimposed on the PRPP binding motif. Hydrogen bonds 
are shown in grey dotted lines (Mtb - in red 3.7 A long). Residues from a 
neighbouring subunit (trimer) are shown in purple.
A comparison of the AMP binding of the E. coli and Mtb (AMP+histidine) 
HisG enzyme shows that the binding of the monophosphate and the position of the 
purine ring of AMP are similar in both structures, however the orientation and binding 
of the ribose differ significantly (Figure 8-2).
The monophosphate binding differs slightly because in Mtb structure 
additionally 05 from the ribose is hydrogen bonding to the loop of the PRPP binding 
motif, rather than the phosphate oxygens only. However the residues involved in the 
coordination are the same in both enzymes. In the E. coli enzyme the ribose interacts 
with residues from the extended PRPP motif of the same subunit (see Section 6.3.4 
and Figure 8-2 a) whereas in the Mtb structure the ribose hydroxyl groups hydrogen 
bond to side chains of a neighbouring subunit (Asp 30’ and to a lesser extent 
Asp 33’ 14; see Figure 8-2 b). The two Asp residues are part of the ‘regulatory’ loop 
(see Section 8.3) which is very variable in sequence in HisG and neither residue 
involved in the binding is conserved beyond the Mycobacterium spp.. It would seem 
unlikely that residues from a neighbouring subunit of the trimer (not the dimer) are
14 Residue numbers from neighbouring, symmetry equivalent subunits are marked with *.
a
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involved in specific binding of one of the substrates, ATP, especially if it is assumed 
that the active form is a dimer. The purine ring of AMP in the Mtb structure is in a 
comparable position but is flipped 180° and tilted by about 30° along its long axis of 
the plane compared to the one in the E. coli enzyme (see Figure 8-3 a, b). In the 
E. coli HisG the ring base stacks with Arg 16 whereas in Mtb the ring nitrogens form 
hydrogen bonds (see Figure 8-2). However the bonds to the conserved residue Asp 70 
(Asn 75 in E. coli) are water-mediated and the direct bond of N6 is with a non­
conserved residue Tyr 116 (Tyr 131 in E. coli). Arg 16 is conserved among almost all 
species, but substituted by Ala or Ser in Mycobacterium spp.. The lack of stabilisation 
of the purine ring by the base stacking Arg could be the reason why AMP is found to 
adopt a different binding mode in the Mtb structure from that in the E. coli structure. 
However it is very unlikely that HisG in the few organisms without this feature will 
have a different substrate and inhibitor binding site from that present in the majority 
of organisms. It is more likely that the different binding mode of AMP is in part the 
result of the conformation of the protein induced by histidine inhibition permitting at 
least two conformations of the AMP. This explanation accounts for the poorly 
resolved electron density seen for AMP in the Mtb structure [Cho et al., 2003].
Figure 8-3 AMP and PRPP binding in HisG. In the same orientation, superimposed 
on the PRPP binding motif, AMP binding in E. coli (a) and Mtb HisG (b) is shown in 
stick representation as well as S 0 4 binding in apo Mtb HisG structure (c). Hydrogen 
bonds are shown in grey dotted lines. PRPP present in orotate PRT from S. 
typhimurium (OPR1) is superimposed in (c) as shown in Section 6.5.1. Residues 
from dimer and trimer related subunits are shown with cyan and purple carbon atoms 
respectively.
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A comparison of the AMP binding site in the various HisG structures with the 
PRPP binding site of orotate PRT (as described in Section 6.5.1) gives further insight 
into the PRPP binding of the HisG (Figure 8-3). The apo Mtb enzyme has a sulphate 
ion located in a position that corresponds to the 1-(3-phosphate of the PRPP in the 
(orotate) PRT structure. The distance between the sulphate and the 1-(3-phosphate is
2.3 A in this approximation. The binding is accomplished by the side chains of 
residues Lys 9 and Arg 49 and main chain nitrogen of Ala 139. Both basic residues 
are highly conserved. In some organisms, like E. coli, Lys 9 (position 14 in E. coli) is 
substituted with a structurally equivalent Lys found one amino acid towards the C- 
terminus (Lys 13 in E. coli). Arg 49 (Arg 54 in E. coli) is conserved as Arg or Lys 
amongst all species with the exception of yeasts. In the AMP-inhibited E. coli 
structure these residues are found in a similar position and orientation to those in the 
apo Mtb structure; however in the two histidine-inhibited structures from Mtb and Mth 
these residues are much further away from the pyrophosphate binding site. Therefore 
the large structural change, caused by the inhibitor histidine, not only closes the 
hexamer (see Section 8.4), but significantly disrupts the pyrophosphate binding site. 
Therefore part of the action of the inhibitor can be explained by the proposal that the 
substrate PRPP cannot bind in this conformation.
8.3 A ‘regulatory’ loop in HisG
Upon binding of histidine a major structural change and repositioning of the 
10 residue long loop (residue 29-39 in E. coli numbering) connecting helix a l  and 
strand J32 from the neighbouring subunit can be observed (see Figure 8-4). This loop 
will therefore hereafter referred to the ‘regulatory’ or ‘R-loop’. In the presence of 
AMP alone, as seen in the E. coli enzyme, the ‘R-loop’ forms hydrophobic 
interactions with a6 on the dimer-dimer interface. When histidine is bound, the ‘R- 
loop’ folds towards the PRPP binding site between domain 1 and 2. In the Mtb 
structure complexed with AMP and histidine, the ‘R-loop ‘ forms interactions with the 
AMP as described above. In the Mth histidine binary complex the ‘R-loop’ is even 
closer to the PRPP binding site and overlaps with the substrate binding sites therefore 
sterically hindering the binding of these. This results in a number of additional 
interactions of the ‘R-loop’ with the neighbouring subunit; these are formed between 
a charged residue from one of the subunits (Arg 12, Asp 30’ and Ser 161, Mth
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numbering -  Arg 16, Gin 33’ and Ser 172, E. coli numbering) with backbone atoms 
from the neighbouring subunit. Additionally a hydrogen bond is formed between 
Gin 41’ (Glu41’ in E. coli) of the neighbouring subunit and Glu212 (Arg 224 in 
E. coli) from the C-terminal domain. In terms of the E. coli numbering, only Arg 16 is 
well conserved; however for most charged residues which are not highly conserved 
and involved in the interactions a structurally equivalent residue with similar 
properties can be found (e.g. Glu 225 rather than Arg 224 in E. coli). From this we 
can conclude that, upon histidine binding, the dimer-dimer interactions of the ‘R- 
loop’, connecting a l  and {32, change from hydrophobic to charged, forming a stronger 
link and tighter assembly within the hexamer.
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Figure 8-4 AMP binding and binding site in HisG. (a) shows the superposition of 
HisG trimers from E. coli (red), Mtb (AMP+histidine; green) and Mth (histidine; 
magenta) aligned at the PRPP binding motif of one subunit, (b) shows a close up and
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(c-e) the individual structures in the same colour code and with individual residues 
and AMP shown in stick representation. The loop between a1 and |32 from a 
neighbouring subunit is marked by arrows in (b). Hydrogen bonds are indicated by 
grey dotted lines.
8.4 Changes in the quaternary structure of HisG
Four HisG structures have been determined so date, E. coli AMP binary15 (this 
study), Mth histidine binary (this study), Mtb apo and Mtb AMP and histidine ternary 
[Cho et a l, 2003]. These structures represent all hexameric forms of the enzyme. 
Therefore it is not practicable to discuss conformational changes upon inhibitor 
binding in terms of individual changes within the monomer or even dimer. For this 
reason the overall hexameric assembly and its changes will be examined first before 
the effects on monomer and dimer level will be discussed.
8.4.1 The HisG hexamer
The hexameric structure of the four different HisGs is shown in Figure 8-5. 
The conformation of the hexamer changes from “most open” to “most closed” on 
progression from apo, AMP-bound, AMP plus histidine-bound to histidine-bound. 
This is reflected by the overall dimensions of the oligomer which alters from 
95 x 100x 115 A , 100 x 90 x 110 A , 95 x 9 5 x l 2 0 A  to 95x95 x l 2 5 A  for the 
respective hexamers. The active site is located on the interior of the HisG hexamers 
(see Section 6.3.3). Access to the inside of the hexamer is restricted to a significant 
cavity at the dimer-dimer interface with a diameter of about 20 A , and a smaller 5 A  
diameter opening on the trimer interface along the 3-fold axis which is exclusive to 
the apo form. The larger cavity is seen in the AMP-bound structure with similar 
dimensions but a slightly modified shape. In the AMP- and histidine-bound fonn the 
cavity is almost closed with a diameter about 5 A , while the cavity is essentially 
completely closed in the histidine-bound structure. There is almost no break on the 
surface of the histidine-bound HisG which makes it the most compact hexamer. This 
observation is underlined by the sum of buried surface area which is listed in Table
8 - 1.
15 The E. coli PR-A binary structure will not be taken into account here, as it is basically isomorphous 
with the AMP binary structure.
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a
b
Figure 8-5 Surface representation of HisG hexamers. a) apo Mtb, b) E. coli AMP 
binary, c) Mtb AMP+histidine ternary d) Mth histidine binary. The surfaces of the 
hexamers are coloured according to the subunits and shown in three different views:
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middle -  along the (non-)crystallographic two-fold axis, left - rotated around 60°, right 
- along crystallographic 3-fold axis.
Table 8-1 gives the buried solvent accessible surface areas for the dimer, 
trimer and dimer-dimer interactions. In the apo HisG hexamer the largest surface area 
buried is at the dimer interface with little contribution made by dimer-dimer 
interactions. The C-terminal domains are almost fully solvent accessible with the 
exception of the p-sheet formed between strand [315 and p i6 from a neighbouring 
subunit. This suggests that the dimer in the apo hexamer resembles most closely the 
active dimer of HisG. Comparison of the differences in buried surface areas for the 
different dimers show the conformational change is not restricted to the C-terminal 
domain, even though this domain is the main contributor to the hexamer interactions. 
For all the hexamers studied, the contributions from dimer-dimer interactions, outside 
the C-terminal domain and helix ct7, are small (about 100 A 3). The histidine-inhibited 
structure represents an exception with about 400 A 3 buried on each side of domain 1 
and 2. Additionally it represents the only structure in which interactions between a top 
and bottom subunit from neighbouring dimers are made. Interestingly the histidine- 
bound structure represents the most compact and closed conformation with the most 
surface area buried. This would suggest that it would be the most stable and therefore 
best inhibited structure. In addition, it shows the most complete surface, making the 
active sites in the centre of the hexamer the least accessible. This is in apparent 
contradiction to the finding that AMP and histidine inhibit HisG synergistically which 
would suggest the most closed conformation should occur in the presence of both 
inhibitors. However, the slightly open conformation of the AMP binary complex, 
especially with access to the histidine binding site between the C-terminal domains, 
explains the synergism well (see Section 7.3). On the other hand it cannot be excluded 
that the histidine-inhibited HisG structure is more compact than expected as it was 
solved from a thermophilic organism and enzymes from these organisms tend to be 
more stable than their mesophilic counterparts.
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8.4.2 The HisG monomer and dimer
A comparison of all HisG dimers is shown in Figure 8-6. The structures were 
superimposed on the first two domains of one monomer to observe the conformational 
change of the C-terminal domain and the relative position of the monomers within the 
dimer to each other. In general very little conformational change upon inhibitor 
binding can be seen between the first two domains. This is reflected by the low rms 
deviation between the structures, namely 1.0-1.6 A  for the Ca atoms of the first two 
domains (see Figure 8-6). The conformational changes between the structures are 
listed here.
apo — AMP binary (Figure 8-6 a)
Veiy minor conformational changes are seen between the monomer upon 
AMP binding. The rms deviation increases only slightly from 1.4 A  to 1.7 A  when the 
whole structure is aligned rather than just the first two domains. However a small 
rotation of the C-terminal domain away from the 3-fold axis can be observed. The 
dimer interface is similar for the two structures and described for the E. coli enzyme 
in Section 6.3.3. Three hydrogen bonds are conserved on the dimer interface between 
the structures of which side chain oxygen Asp 57 to main chain Asn 152 is maintained 
in all structures discussed here. Asp 57 is conserved in all species and seems to be 
crucial for the formation of the dimer. Furthermore it acts as two anchor points16 
around which confoimational changes take place. In the AMP-bound structure the 
second monomer is rotated about 3° along the dimer interface. This results in the 
tighter packing of the C-terminal domains giving a more compact hexamer.
apo -  histidine binary (Figure 8-6 b)
Upon histidine binding a significant change in the monomer can be seen with 
the C-terminal domain rotating 35° around the end of helix a l  towards the 3-fold axis 
and the interior of the hexamer. The dimer interface is almost completely altered and 
the second monomer rotated about 40° around the Asp 57-Asn 152 axis (note the 
movement of helix a3) to give a more open, elongated dimer which in turn results in a
16 N.B. There are two anchor points due to the (non-)crystallographic 2-fold symmetry relating the two 
monomers within the dimer to each other.
147
Chapter 8 Comparison o f HisGs
10 A  longer hexamer. Interactions at the dimer interface which occur on the inside of 
the hexamer (i.e. between the ‘R-loop’ connecting a l  and (32 and helix a6 from the 
neighbouring subunit) are broken upon histidine binding and a new interface is 
formed on the outside of the hexamer between (38 and a2. Because the rotation of the 
C-terminal relative to the first two domains is virtually in the opposite direction the 
monomer rotation the C-terminal domains remain close to the 3-fold axis and the 
hexamer stays intact.
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apo -  AMP+his (1.0/198)
AM P-his (1.3/193)
AMP-AMP+his (1.6/192)
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his-AMP+his (1.4/254)
Figure 8-6 Conformational change of HisG monomers and dimers. HisG dimers 
of apo Mtb (blue), E. coli AMP binary (red), Mth histidine binary (magenta) and Mtb 
AMP and histidine ternary (green) are shown in ribbons representation superimposed 
on the first two domains of the top monomer. The right figure shows a view along the
2-fold (non-)crystallographic axis and the right one a view 90° rotated around the 3- 
fold crystallographic axis. Panels a-f shows all possible permutations. The numbers 
besides the pictures give the rms deviation in A calculated over the stated number of 
Ca atoms.
apo -  AMP & histidine ternary (Figure 8-6 c)
The conformational changes upon binding of AMP and histidine are 
comparable with those which occur when only histidine is bound. However the 
domain and monomer rotations are not as pronounced as in the histidine-bound 
structure with the C-terminal domain rotating about 20° and the second domain about 
30°. Therefore the histidine-bound hexamer shortens 5 A when AMP is bound.
AMP binary -  histidine binary (Figure 8-6 d)
The binding of AMP and histidine, although both causing the formation of an 
inhibited hexamer, have different effects on the monomer and dimer of HisG. The 
C-terminal domain is rotated about 40° upon binding of histidine compared to binding 
of AMP. Not only is the C-terminal domain rotated around the end of helix a7 but a l  
itself rotates in a concerted fashion by about 3°. Additionally the second monomer is 
rotated about around 40° along the Asp57-Asnl52 axis. This results in a less
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elongated hexamer than the Mth histidine-bound form and a narrower hexamer than in 
the E, coli AMP complexed HisG.
AMP binary -  AMP & histidine ternary (Figure 8-6 e)
Binding of histidine to HisG already complexed with AMP again shows 
changes on monomer level with helix a l  tilting about 3° and the C-terminal domain 
about 27° both in a concerted manner towards the 3-fold axis. Again the second 
monomer in the dimer is rotated outwards by about 30° which overall results in a 
longer more compact hexamer.
Histidine binary -  AMP & histidine ternary (Figure 8-6 f)
When AMP binds to the histidine binary enzyme complex the C-terminal 
domain shifts about 3.5 A  perpendicular to the strands of the ferredoxin-like P-sheet 
away from the 3-fold axis. The second monomer rotates about 10° back towards the 
3-fold axis. This shortens the hexamer by 5 A.
Conformational changes upon inhibitor binding can be summarised mainly as 
changes in the C-terminal domain and the orientation of the monomers within the 
dimer. Upon histidine binding the largest changes in conformation are observed with 
the C-terminal domain tilting towards the 3-fold axis and the second monomer 
rotating outwards elongating the dimer and hence the hexamer. Binding of AMP on 
the other hand has smaller effects with little change at the monomer level and only 
slight changes in the monomer orientations within the dimer. However these are large 
enough to change the hexamer conformation considerably, especially at the trimer 
interface between the C-terminal domains.
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Chapter 9: Structure of PA5104 from Pseudomonas 
aeruginosa
PA5104 was cloned and initially purified and crystallised by Neil Paterson 
during a 4th year project which I supervised. Reported here are the crystallographic 
part of this project and the solution of the structure which was carried out by myself.
9.1 Solving phases of PA5104
9.1.1 Attempts to solve phases
9.1.L I  Direct methods
Given diffraction data to beyond 1 A, the first attempt to solve the phase 
problem is by direct methods. The application of two methods used in this work are 
described.
Direct methods are based on the linear relationship between phases as 
expressed in triplet (or quartet) invariants. The probability distributions of these 
invariants are significantly broadened for increasing number of atoms N  (the variance 
is proportional to N~m for triplets and Af1 for quartets) and therefore only reliable and 
practicable for structures with limited N. Phases can be calculated and refined with the 
tangent formula, derived from minimizing the phase probability distribution, or the 
minimal function as used in the program ShakeTi’Bake. Furthermore computing time, 
especially for structure factors, increases rapidly with N. Therefore solving 
macromolecular structures with direct methods is challenging methodological as well 
as computational.
9.1.1.1.1 Shake’n’Bake (SnB)
SnB [Miller et a l 1994] has been successfully used to solve protein structures 
ab initio with 1183 non-hydrogen atoms (about 100 aa). PA5104 with 196aa therefore 
represents a significant challenge to this method of structure solution.
First the structure factors (F) were converted in normalised structure 
amplitudes (E) with the program DREAR [Blessing and Smith, 1999]. Attempts to 
run SnB with the default parameters and arrays suggested for the amount of atoms and 
given resolution failed, because computational arrays limits were exceeded. Therefore
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the sampling grid was broadened to reduce the size of the required arrays. SnB used 
about 150 days of computing time on an origin 200 server using one MIPS R10000 
processor. The resulting distribution of R-factors is shown in Figure 9-1. The 
distribution is monomodal which indicates that no correct solution was found using 
this approach. The computational expensive calculations with SnB did not allow 
further improved attempts to solve the structure with varied parameters17.
50.7 50.8 50.9 51.0 51.1 51.2 51.3 51.4 51.5 51.6 51.7
R-factor /%
Figure 9-1 R-factor distribution result from SnB. The main panel shows the 
monomodal distribution of R-factors obtained for PA5104. The insert shows the 
bimodal distribution for a successful example. Here the R-factor represents the value 
for the minimal function.
9.1.1.1.2 ACORN
ACORN is a program for solving protein structures ab intio when atomic 
resolution data (<1.2 A) are available. It uses trial phases, obtained experimentally or 
by MR, which then are modified by iterative cycles of dynamic density modification 
and application of the Sayre equation until a solution is obtained [Foadi et al., 2000], 
A positive solution is usually indicated by a correlation coefficient for medium E- 
values (CCS) of higher than 15% (and/or a significant increase from starting values). 
Here, initially in the absence of any phase information, trial phases were tried to be
17 The structure was solved otherwise, whilst SnB was still running.
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obtained by MR. Prior to using ACORN, normalised structure amplitudes were 
calculated with the program ECALC [CCP4, 1994],
Positioning of a random atom using MR-ACORN yielded CCS of below 5.5%. 
This can be expected for a protein structure with no heavier metal ion present. (N.B. 
initially it was not known that no metal ion is present, however the lack of any 
significant anomalous signal in the diffraction data collected at 1 A wavelength was 
indicative. However a significant absorption effect was observed. To rule out the 
presence of any metal ions in the protein, an X-ray fluorescence scan was recorded at 
Station 9.5, Daresbury SRS, which showed no significant metal contribution).
A more successful approach is a MR search with a 2lldary structure element, 
especially an a-helix [pers. communication J. Foadi]. Various theoretical a-helices of 
variable lengths were tried which are available from the CCP4 library. This is justified 
as secondary structure prediction and CD-spectroscopy showed 11-28% a-helical 
contribution for PAS 104. However none of these search models yielded a CCS of 
greater than 6.0%. More extensive MR searches, at the expense of computing time, 
usually yielded a slightly higher CCS (about 0.5%) but were still unacceptably low. 
Changes in the classification of Es very rarely improved the CCS. The use of single 
theoretical p-strands and turns of varying lengths resulted in CCS in ACORN of about 
5.5%. Multiple p-strands extracted as sheets from high resolution structures (both 
parallel and anti-parallel) improved the CCs slightly (up to 1%), but still failed to give 
a positive solution.
Furthermore Fe-S clusters were probed as well as whole or parts of protein 
structures. These structures were identified with a similarity search based on the 
secondary structure prediction (pyruvate kinase - pdb code 1A3W, cutinase/serine 
esterase - 1AGY, surface glycoprotein - 1CID, ribonuclease - 1DY5, and 
immunoglobulin -1 VGE). None gave a positive solution.
Because tryptophan is the amino acid with the largest scattering matter and the 
amino acid sequence of PA5104 contains 7 tryptophan residues an attempt to use just 
a tryptophan ring for the MR in ACORN was made as was adding a tryptophan to a 
secondary structure element. However all these attempts were unsuccessful.
Further examples and combinations of secondary structure elements 
themselves or in combination with other amino acids could have been probed. 
However, this would not only be time consuming but success in solving the structure
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would not be guaranteed. (N.B. currently it is not possible to place more than one 
fragment in MR-ACORN) Therefore phase information had to be determined 
experimentally.
9.1.1.2 Sulphur SAD/MAD
Collection of high redundant data at higher wavelength (1.5 A  and higher) 
should allow the location of sulphur atoms with anomalous differences [Dauter et al., 
1999]. Therefore a data set was collected using the wavelength of 1.9 A  to maximise 
the anomalous signal. Unfortunately neither these data nor other data, collected at 
longer wavelength, could be used due to scaling problems (described in Section 
5.1.3). Therefore it was initially tried to obtain sufficient anomalous signal from the 
data set collected at a wavelength of 1 A. Neither the program SOLVE [Terwilliger 
and Berendzen, 1999] nor an anomalous Patterson search with SHELX [Sheldrick, 
1997] yielded a useful anomalous scatterer site. The latter sites did not refine in 
MLPHARE and SHARP. Results from SOLVE and subsequently RESOLVE had a 
low Figure of Merit (FoM) of below 0.15 and 0.60 respectively and a low ‘score’ of 
below 10. A further indication that these data did not contain enough anomalous 
signal was obtained from the SOLVE data analysis which indicated a signal-to-noise 
ratio of below 1 in all cases.
The data collected investigating the wavelength dependent diffraction of 
PA5104 crystals at wavelength 1.5 A  were used as a SAD data set. Again no correct 
solution could be found with the above mentioned approach.
Because data sets were collected at various wavelengths to investigate possible 
absorption effects these could be used to obtain phase information by using them as a 
MAD experiment. However no correct solution was found using SOLVE due to lack 
of anomalous signal, especially signal-to-noise ratio. This was because the data sets 
were not collected for this approach and therefore insufficient data of the required 
high redundancy were available.
9.1.1.3 Derivatives
Independently two Pt derivatives of PA5104 were obtained as well as two Hg 
derivatives (one collected at the L-III edge and therefore called ‘peak’, the other near 
the peak, called ‘normal’) and used to solve the structure of PA5104 by MIR. Heavy 
atoms sites were searched for in SHELX and SOLVE. No sites were found using
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SHELX. SOLVE determined 2 weak Hg sites (occupancy about 0.1), which were 
consistent between the two Hg data sets and both refined in MLPHARE. Further sites 
with very low occupancy (below 0.05) could be identified but did not refine in 
MLPHARE. No further sites could be determined manually using difference Fourier 
maps18. The MIR was therefore reduced to a SIR problem.
Both Hg data sets (peak/4normal’) were independently and together refined 
against the native data set in MLPHARE19. This resulted in a FoM of 0.28 for both 
data sets and 0.19 and 0.10 for the individual data sets respectively. The occupancies 
for the two sites were 0.18/0.12 and 0,10/0.06, The hand of the sites was confirmed 
based on the FoM after MLPHARE and DM. To avoid overestimating the phases, as 
two equivalent heavy atom sets and sites were used, only the peak data were used 
subsequently. The phasing statistics for this derivative are shown in Table 9-1. 
Following density modification and phase extension to 1.5 A with DM the FoM 
increased from 0.15 to 0.60. Visual inspection of the resulting maps showed very little 
connected density (see Figure 9-11) and no obvious secondary structure elements, so 
that no initial model could be built. Therefore it was attempted to use the phases as a 
starting point for ARP-WARP, first in MIR mode with the aim of improving the input 
phases, and then to auto-build the structure. However this approach was not 
successfiil and the R- and free R-factor failed to decrease below 40%.
Table 9-1 Phasing statistics for PA5104 Hg peak derivative
Rcuiiis isomorphous 0.86/0.941
anomalous 0.94
Figure of merit 0.36/0.161
mean 0.19
Phasing power 0.51/0.621
1 centric/acentric
18 SOLVE should have done that already. However maps were calculated with FFT (CCP4) and 
investigated further.
19 Refinement in MLPHARE always included isomorphous as well as anomalous data.
156
Chapter 9 Structure o f PA5104
9.1.2 SIR(AS) phasing and solving of phases
Even the phases obtained from the SIRAS experiment described in the 
previous section were not correct enough to solve the structure. However they should 
be reliable, as the sites refined correctly in MLPHARE with two independent data 
sets, and therefore should still be better than random. Thus the phases can be used in 
ACORN(-PHASE) as trial phases. The density modified phases together with the 
atomic data were the input for ACORN and resulted in a solution with a CCs of 43% 
and a R-factor of 33.1%. This clearly indicates a correct solution. Figure 9-2 shows 
the improvement of the CCs with phasing cycles. An equivalent graph of an 
unsuccessful trial is shown in the same scale for comparison (Figure 9-3).
50
0 10 20 30 40
Cycle
Figure 9-2 Changes in correlation coefficient CCS for successful ACORN  
calculation. The solution is evident from the asymptotic behaviour of CCS and 
increase over 15%. The result was obtained using atomic resolution data with SIR 
density modified phases.
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I***********************
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Cycle
Figure 9-3 Changes in CCS for unsuccessful ACORN calculation. No (correct) 
solution is found which is indicated by no increase in CCS. The example shown is the 
result of an ACORN calculation with a theoretical a-helix as a MR search model.
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9.1.3 Model building and refinement
The map obtained from ACORN was used in ARP-WARP for automated 
model building in the resolution range 20-1.5 A. The R- and free R-factor was about 
35% for the starting model and dropped to 16.2% and 20.4% respectively after model 
building and refinement. ARP-WARP built a continuous polypeptide from residue 3 
to 195 including side chains and some additional dummy atoms. The terminal 
residues, to complete the model, were fitted manually using QUANTA [Accelrys 
Inc.]. Clear density was seen for some PEG molecules and octahedral coordinated 
Mg2+ ions. Additional water molecules were added and refined using ARP-WATER. 
Multiple side and main chain conformations were built manually in QUANTA. The 
final refinement cycles were carried out in the resolution range from 20-0.96 A  in 
REFMAC5. The refinements included riding hydrogens and isotropic B-factor 
refinement. The R- and free R-factor changes in each refinement step are given in 
Table 9-2.
Table 9-2 R-factor and free R-factor during the refinement of PA5104
Refinement step R-factor Free R-factor Phase error i° Phase error /°
/% /% (20-1.75A) (20-1.5A)
“S IR ...
After DM 
ACORN 
ARP-WARP 
ARP-WATERS 
REFMAC5
9.2 PA5104 model
9.2.1 Quality of model
The final model of PAS 104 had an R-factor of 11.5% and a free R-factor of 
13.9%. The rms deviation of the bond lengths was 0.031 A  and of the bond angles 
2.93°. All residues are within the allowed regions of the Ramachandran plot (see 
Figure 9-4). All geometric side and main chain parameters are satisfactory or better
n/a n/a 79.1 n/a
n/a n/a 73.8 75.4
33.1 n/a 26.2 27.3
16.2 20.4 14.8 14.2
15.5 19.9 n/d n/d
11.5 13.1 used as reference
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than expected for this resolution as indicated by a PROCHECK analysis. A summary 
of the refinement statistics is shown in Table 9-3.
Figure 9-4 Ramachandran plot for PA5104.
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Table 9-3 Refinement statistics of PA5104.
Refinement statistics
Resolution range (A) 20.0-0.96
R-working (%)' 11.5(113589)
Rfr»c(%)''2 13.1 (6334)
Number of non-hydrogen atoms
Protein 1664
Nonprotein (PEG, Tris) 79
Mg2+ ions 4
Water 489
R.m.s. deviation from ideal
Bond length (A) 0.031
Bond angles (°) 2.93
Ramachandran statistics
Most favoured 153
Additionally allowed 10
Generously allowed 0
Disallowed 0
* number in parenthesis is the number o f reflections.
2 Rfree was calculated with 5% of reflections.
9.2.2 Overall structure
The structure of PA5104 is comprised of two all-p domains (Figure 9-5). 
These two domains are linked with a three residue 3io-helix, the only helix present in 
the structure. Both domains are similar in fold, showing the barrel-like double 
stranded (3-helix structure with two antiparallel p-sheets.
The first domain consists of residues 1-11 and 118-196 and therefore contains 
both N- and C-termini. The 9 p-strands, p i and pl2-bl9, form two antiparallel sheets 
with strand order 1 17 14 19 12 and 13 18 15 16 respectively. This represents a jelly 
roll topology with the addition of strand pi. The short 3io-helix is assigned to this 
domain.
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Figure 9-5 The structure of PA5104 solved at atomic resolution. Two ribbons 
presentation of the PA5104 monomer coloured according to the secondary structure. 
The top panel shows a top view and the middle panel a view from the side. The 
bottom panel shows a topology diagram prepared with the program TOPS [Gilbert et 
al., 1999].
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The second domain contains residues 12-117 which includes strands 10 P- 
sheets, 02-011. The two antiparallel P-sheets are build of strands 2 3 4 11 6 9 and 5 
10 7 8 respectively. Again this shows the typical jelly roll topology with addition of 
strands p2-3. The barrel of this domain is open and has a cleft in centre which is filled 
with a PEG molecule (see Figure 9-6). The molecule is bound in a region of the 
protein with high sequence similarity among different species. This gives an 
indication for the location of an active site or small molecule binding site which will 
be discussed below (Section 9.4.3).
Figure 9-6 Surface representation of PA5104. Shown is a ribbon representation of 
PA5104 and the semitransparent surface as calculated with PyMOL. The PEG 
molecule binding in the cleft of the second domain is shown in stick representation.
Each domain shows a fold typical for cupins (from Latin ‘cupa’ for small 
barrel), therefore the whole protein is a bicupin. A 3D search against the SCOP 
database shows that the first domain is most similar to lectins/glucanases, seed storage 
proteins, and regulatory proteins of the AraC family (e.g. 1MAC, 2PHL, and 1ARC 
respectively). The second domain was determined to be most similar to the fold of 
glucose permease-like proteins, seed storage proteins and phosphomannose isomerase 
(e.g. 1F3G, 2PHL, and 1PMI respectively). Overall the fold resembles closest to the 
bicupin phosphomannose isomerase (see Figure 9-7).
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Figure 9-7.Comparison for bicupins PA5104 and phosphomannose isomerase.
A ribbon representation of phosphomannose isomerase (pdb code 1PMI) in green 
and PA5104 in green superimposed.
9.3 Structure of 2nd crystal form of PA5104
Before the structure of PA5104 was solved a data set was collected on a 
second crystal form. The structure of this crystal form was solved once the atomic 
resolution structure was available.
9.3.1 Molecular replacement
MR was carried out with the refined structure of PA5104 as a search model in 
AMoRe. The rotation function showed four clear solutions (see Figure 9-8) based on 
the CC and R-factor. Four monomers were placed with translation search and the 
position and orientations were refined. The change of CC and R-factors when 
additional monomers are included is given in Table 9-4.
11
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Solution Number Solution Number
Figure 9-8 AMoRe rotation function results for PA5104. The left panel shows the 
CC and the right the R-factor for the top 15 peaks. The first four solutions are clear 
solutions as the CC is above and the R-factor below the background of false 
solutions.
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Table 9-4 CC and R-factor for MR in AMoRe,
monomer CC /% R-factor /%
1 24.1 52.8
2 39.7 4 7  7
3 53.6 42.5
4 60.0 40.6
9.3.2 Model building and refinement
The model from the AMoRe result was first refined using rigid body 
refinement in REFMAC5 [Murshudov, 1996]. Iterative cycles of manual model 
building in QUANTA [Accelrys] and refinement in REFMAC5 with TLS [Winn et 
a l , 2001] were carried out. Each monomer was treated as one TLS group and in the 
initial steps of the refinement NCS restraints were imposed. Solvent molecules were 
added using the automated procedure in ARP-WARP. The R-factor statistics of the 
refinement steps are given in Table 9-5.
Table 9-5 R-factor and free R-factor during the refinement of PA5104 (crystal 
form 2)
Refinement step R-factor /% Free R-factor /%
Rigid body 36.5 36.5
REFMAC5 + TLS +NCS 24.1 28.3
With waters 19.3 24.2
REFMAC5 + TLS 18.1 23.6
9.3.3 Quality of the model
The model was refined to an R-factor of 18.1% and a free R-factor of 23.6% to 
1.9 A resolution. The geometrical parameters for main and side chains were 
acceptable or better than expected for this resolution as analysed by PROCHECK 
[Laskowski et a l, 1993]. The rms deviation for bond lengths was 0.016 A and 1.436° 
for bond angles. All residues were in the core or additionally allowed region of the 
Ramachandran plot. A summary of the refinement statistics is shown in Table 9-6.
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Table 9-6 Refinement statistics of PA5104 (crystal form 2)
Refinement statistics
Resolution range (A) 46.63-1.90
Rworking (%) 18.1 (46893)
R-frce (%)U 23.6 (4707)
Number of atoms
Protein 6159
Nonprotein (glycerol, sulfate) 127
Cl" ions 8
Water 361
R.m.s. deviation from ideal
Bond length (A) 0.016
Bond angles (°) 1.436
Ramachandran statistics
Most favoured 598
Additionally allowed 50
Generously allowed 0
Disallowed 0
1 n u m b er in  p a ren th es is  is th e  n u m b er o f  re flections.
2 R free  w as  ca lcu la ted  w ith  8 .4%  o f  re flec tio n s
9.3.4 The structure of PA5104 from a 2nd crystal form
Overall the fold of the four NCS related monomers in the second crystal form 
of PAS04 is the same as in the atomic resolution structure. The four monomers are 
arranged as two ‘dimers’ in the asymmetric unit (asu) (Figure 9-9). They interact via 
the bottom of the barrel of the first domain. Although the main interactions are 
hydrophobic, there are a significant number of hydrogen bonds. The majority of the 
latter occurs between main chain atoms of the ‘dimer5 related sheets in which the 
respective last strands ran antiparallel to each other. Similar interactions and ‘dimer’ 
formation can be seen in the atomic resolution structure of PAS 104 with symmetry 
related molecules.
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Figure 9-9 PA5104 structure from the second crystal form. Shown in ribbon 
representation are the 4 monomers in the asu coloured according to the chain The 
top two monomers and bottom two form a ‘dimer’ via the first domains.
It is questionable whether the ‘dimers’ observed here are physiologically 
relevant as DLS showed that the molecule is monodisperse as a monomer. However 
other cupins form real dimers which can depend on substrate binding, e.g. the 
regulatory protein AraC. This forms a barrel-barrel dimer, as seen here, in absence of 
arabinose and a dimer via its second, a-helical, domain in the presence of arabinose 
[Soisson et al., 1997]. It remains to be proved if PA5104 can form homo-dimers upon 
substrate binding or if it can dimerise with another protein of a cupin fold via this 
mode.
The four monomers are very similar with rms deviations between the Ca 
atoms of 0.50 A, 0.52 A, and 0.45 A between chain A and chain B, C, and D 
respectively. The main differences are in domain two in the loop between strands 03 
and 04 (around residue 35, see Figure 9-10). Chain C shows additional differences in
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the position of strand p2 (see Figure 9-12) and the loop connecting this strand with p3 
could not be resolved in the electron density.
residue number
Figure 9-10 Rms deviation between the four monomers of PA5104.
9.4 Discussion
9.4.1 (Problems) solving the structure
Processing of, and extracting anomalous signal from, data collected on 
PA5104 crystals using wavelengths of 1.5 A and longer proved to be extremely 
difficult and sometimes even impossible (see Section 5.1.3). Therefore the structure 
could not be solved using sulphur SAD. The precise reasons for this are still unclear, 
but absorption effects or radiation damage seem to be the most likely causes. 
However no radiation effects have been observed as judged from preliminary 
refinement of data collected on one crystal using different wavelengths (0.7 A and
1.5 A) which show no differences in refinement statistics and electron density 
difference maps.
All attempts to solve PA5104 using ACORN in MR mode with theoretical 
models failed. Various reasons can be found to explain this observation. First of all, 
no a-helix is found in the structure of PA5104 which is the preferred search model for 
use in ACORN. This is due to the compact scattering matter and orientation which 
helps to find a correct position in the MR routine [pers. comm. J. Foadi]. p-strands or 
P-sheets are more difficult to position and therefore a solution of the structure is less
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likely. Furthermore p-elements show more structural diversity which makes it 
difficult to find a closely matched structure that can be placed with MR. Simulations 
have shown that a correctly placed 4 residue p-strand (20 atoms) taken from the final 
model has enough scattering matter to solve the structure. However the fragment and 
even larger ones (e.g. a 8 residue p-strand) could not be placed correctly in the MR 
emphasising the importance of the correct positioning of the starting model and the 
problem in doing so. Further simulations were performed with correctly positioned 
Trp residues from the final model to investigate and justify the use of single amino 
acids in the MR search. It was shown that at least 3 complete Trp residues (42 atoms) 
are needed obtain a correct solution, 2 complete Trp residues (28 atoms) and 3 Tip 
rings only (30 atoms) gave no positive solution. This shows that Trp residues are not a 
good choice as a starting model to solve the phases, especially because of the problem 
of obtaining correct orientations for multiple Tip residues and different possible side 
chain conformers. Furthermore it shows that even after correct positioning of the 
search model the success of ACORN does not depend on the overall size of the model 
(20 atoms in a sheet were successful, but 30 in 3 Trp rings were not) but on its 
compactness.
Attempts at solving the structure of PA5104 a priori with direct methods 
(SnB) proved too much of a challenge for a protein of this size and failed using the 
approach described in Section 9.1.1.1.1. However, using experimental phases 
combined with phase refinement using the Sayre equation in ACORN proved to be 
successful. This approach was still not straight forward as the phase error for the 
initially obtained SIRAS phases was approximately 80° (see Table 9-2) and no 
solution could be obtained using ACORN. Only after improving the phases using 
density modification by solvent flattening (which reduced the phase error by 5%) was 
it possible to solve the phases using ACORN. Calculations with the modified phases 
restricted to 1.8 A  resolution showed that extending the phases to 1.5 A  was not 
required to get a positive result. The high phase error of the SIRAS phases is reflected 
in the poor electron density maps obtained at this stage, which did not allow any 
model building or solution by ARP-WARP. The density lacked connectivity and no 
secondary structure elements could be identified, a fact which was not supported by 
the lack of a-helical elements in the structure as these can be easier to identify than (3- 
sheets. However it seems noticeable that higher density is observed for the peptide
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bonds at this stage (Figure 9-11 a). The phase error was reduced to about 27° after 
successfully using ACORN (Table 9-2). This resulted in an electron density map of 
high quality which only marginally improved in the following automated model 
building and refinement (Figure 9-11 b-d).
Figure 9-11 Electron density maps of PA5104 at different stages of phasing.
Two representative strands are shown in stick representation with electron density 
maps contoured at 2a. The maps have been phased after the SIRAS phasing 
(solvent flattened with DM) a), after ACORN b), after ARP-WARP c) and the final 
phases d).
9.4.2 Comparison of structures from the two crystal forms
A superposition of the four monomers of the second crystal form with the 
atomic resolution structure is shown in Figure 9-12. Overall the rms deviation of Ca 
atoms between the atomic resolution structure and the other four monomers is 1.52 A, 
1.48 A, 1.63 A and 1.78 A for chain A, B, C, and D respectively. The difference
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within the individual domain is smaller, so superimposition of both domains of chain 
A on the relevant domains of the atomic resolution structure gives an rmsd of 0.29 A 
(excluding the difference described below).
Figure 9-12 Superposition of PA5104 monomers. Ca trace of the high resolution 
structure (red) with the four monomers from the second crystal structure (green-chain 
A, blue-chain B, magenta-chain C and cyan-chain D). The monomers were 
superimposed on the second domain only with exception of the loops between strand 
P2 and p3, and p3 and p4 (indicated by thin arrows). The first loop shows a different 
conformation in all four monomers of the second crystal structure compared to the 
atomic resolution structure. The second loop is not resolved in chain C and strand p2 
is tilted towards the centre of the barrel. The first domain in the atomic resolution 
structure is rotated with respect to the four monomers in the other structure (indicated 
by the boxed arrow).
The main difference between the structures is the loop between strands P3 and 
p4 in the second domain. In the atomic resolution structure this is open and close to 
the loop connecting the two domains whereas in the second crystal form the loop is 
moved towards the inside of the barrel in all monomers. This closes the ‘active’ site 
from the top but still leaves it open from the side (where the PEG is bound). 
Additionally in chain C of the second crystal form strand P2 is rotated towards the
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inside of the barrel. The following loop itself is not resolved in the electron density 
map which indicates flexibility in this part of the structure. The two observed 
conformational changes could indicate possible movements in the second domain 
upon binding of substrate.
There are no large differences between the structures in domain 1. However a 
different position of the two domains towards each other can be seen between the 
atomic resolution structure and the second crystal form. In the first the whole domain 
is rotated away from the second domain by 3°. Figure 9-13 shows the movement in 
more detail.
Figure 9-13 Rotation of the two domains in PA5104. A Ca trace of the atomic 
resolution structure (grey) superimposed with chain A of the second structure. The 
second domain (blue) was fixed and the first domain (red) rotated around the axis 
marked by the arrow by 3°. The hinge residues of strand p i2  are marked in green.
9.4.3 Active site and function
The active site or effector binding site is located in the barrel of domain 2 in 
PA5104. Five independent active site structures are available, one from the high 
resolution structure and four from the second structure. Superposition of the active 
sites show that very little conformational change is observed between the structures 
even though different small molecules are found to be bound in it (Figure 9-15). In the
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high resolution structure a PEG molecule is bound, whereas in the second structure 
glycerol molecules and a sulphate ion are bound. The active site differs in all 4 
monomers of the second structure. A number of water molecules are found to be 
coordinated in the active site too, of which only one is seen in all 5 structures. This 
water is hydrogen bonding to Arg 41, Ser 43 and Asn 110. All residues involved in 
contacts to bound molecules are conserved among species (Figure 9-14).
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p-strands are represented as helices and arrows, respectively, and p-turns are 
marked with TT. This sequence alignment was created using the following 
sequences (Organism, SwissProt accession numbers or other source in brackets) 
PSEAE_PA5104 (Pseudomonas aeruginosa, NP_253791); PSESY„AF326719 
(Pseudomonas syringae, AAK15635); PSEPU_PP5053 (Pseudomonas putida; 
P24696); BRUSU_BRA0933 (Brucella suis, NP_700100); BRUME„BMEII0364 
(Brucella melitensis; NP_541342); SINME_SMc00667 (Sinorhizobium meliloti, 
NP_386811); AGRTU_AGR_L_1834 (Agrobacterium tumefaciens, NP_356706); 
MESLOjmlr8324 (Mesorhizobium loti, NP_108443); RHIHR__riorf43 (Rhizobium 
rhizogenes, NP_066624); BORPA_BPP1062 (Bordetella parapertussis, NP_8 8 3 3 8 3 ); 
YERPE__YP01975 (Yersinia pestis, NP_405532); ECOLl_YDJR (Escherichia coli, 
P76214).
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Asp108 Asp1
Gly 52
Asp10 AspIC
Asp1
A rg  61
Figure 9-15 Active site of PA5104. a-d shows the active site in stick representation 
of the four chains of the second crystal structure and e of the high resolution 
structure. Hydrogen bonds between the protein and water or other molecules bound
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in the active site are shown in grey dotted lines, f shows possible conserved 
interactions of PA5104 with N-formyl-L-glutamate.
The availability of the five different and independent active sites and their 
interactions with small molecules by conserved residues makes it possible to suggest 
potential substrates for PA5104 and therefore indicate its possible function. As 
PA5104 is part of the hut operon and all enzymes of the pathway are identified it 
seems likely that the protein is somehow involved in regulation of the pathway. 
Therefore the first candidates to be considered as substrates have to be intermediates 
in hut pathway 2. Superposition of the active sites and bound molecules therein 
showed that the substrates for HutF and HutG2 (N-formimino-L-glutamate and N- 
formyl-L-glutamate respectively) both could be fitted in the active site. The 
interactions of PAS 104 made with the small molecules in the 5 structures can be 
maintained upon binding of these substrates (Figure 9-15 f). The two intermediates 
are very similar with only the formimino group replaced by a formyl group in the later 
intermediate. However the possible interactions of this part of the molecule with the 
guanidinium group of Arg 41 makes it more likely to be formyl-glutamate as it can 
serve as a hydrogen donor for the oxygen of the formyl group. The observation that 
expression of HutF and especially HutG2 both can be induced by their substrates 
respectively suggests that a protein binds either both or just one of the intermediates 
which then somehow activates expression of the respective Hut enzyme. As revealed, 
PAS 104 could serve that function by binding formyl-glutamate which in turn causes a 
conformational change within the protein similar to the one observed between the 
high resolution structure and the structure of the second crystal form. This 
conformational change then might enable PAS 104 to form a dimer comparable to the 
ones observed in other regulatory proteins, e.g. AraC (see Section 9.3.4). Because 
PAS 104 itself has no typical DNA binding domain like a (3-a-J3 motif, it is unlikely 
that the protein itself will bind to DNA to induce expression. It seems more likely that 
it will then bind to another, yet to be identified, protein which can bind to DNA or it 
disrupts DNA binding of another protein to DNA. Formation of a protein-PA5104 
complex by either means can then result in induction of expression of the respective 
Hut enzyme.
There are however other functions and observations to be considered in the 
determination of the function of PA5104 in addition to those solely based on the
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structures determined here and sequence alignments. First it cannot be excluded that 
glutamate, the end product of the hut pathways, can be bound in the active site as it 
shares a common scaffold with the two intermediates formimino-glutamate and 
formy 1-glutamate. In case of binding of glutamate, PA5104 could function as a sensor 
reflecting the glutamate level within the cell. Additionally there is a minor possibility 
that a molecule could bind which is unrelated to any of the hut pathway intermediates 
or the end product, especially since there are a number of conserved hydrophobic 
residues in the active site. In the binding theory outlined above only Phe 53 and to a 
lesser extent Phe 56 form van der Waals interactions with the substrate but conserved 
Trp 17 has no function in the binding. Finally, ORFs similar in sequence to PA5104 
are present in organisms which have no genes encoding any of the Hut enzymes and 
therefore lack the ability to utilise histidine. One example of such an organism is 
E. coli with gene ydjR being similar to PA5104 (see Figure 9-14). The amino acid 
sequence of ydjR shows that the residues for binding to hut intermediates, as outlined 
above, are conserved even though no hut pathway is present in E. coli. However the 
gene is found in a region of the genome where genes of the arginine degradation 
pathway are encoded. As glutamate is an end product in arginine catabolism it is 
possible that the protein encoded by ydjR functions as a glutamate binding protein as 
suggested above for PA5104. The determination of the structure of PA5104 suggests a 
series of experiments to elucidate the function and mode of action of PA5104. 
Important initial experiments would involve isothermal titration microcalorimetry to 
assess binding of potential ligands.
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Chapter 10: Conclusions
10.1 HisG
10.1.1 Substrate binding sites and reaction mechanism
The structures of HisG determined in this work and those recently published 
by [Cho et al., 2003], allow the substrate binding sites to be defined and provide a 
basis for formulating a reaction mechanism. The PRPP binding site was initially 
identified in the second domain of HisG by comparison of the AMP HisG structure 
with type I PRT structures. This comparison was conducted by superposition of the 
PRPP binding motif, characteristic for type I PRTs, with the modified PRPP binding 
motif found in HisG. The PRPP monophosphate binds to the £P-loop’ of the PRPP 
binding motif and the ribose hydroxyls hydrogen bond to conserved residues Glu 156 
and Asp 169. In combination with the apo Mtb HisG structure, where a sulphate ion is 
bound near the active site, the pyrophosphate binding site was identified to be on the 
dimer interface with the conserved basic residues Lys 13 and Arg 54 from the 
neighbouring subunit and a Mg2+ ion being involved in the binding.
The binding site for the purine ring of the substrate ATP was shown to be 
located between domains 1 and 2 in the same position as observed in the HisG 
structure complexed with product PR-ATP. Because the ribose-triphosphate part of 
PR-ATP was not resolved in the electron density map, no exact description of this 
binding site can be given. However, domain 1 shows a conserved, negatively charged 
pocket where the triphosphate, mediated via Mg2+ ion(s), can bind. This would 
suggest that at least two Mg2+ ions are required for the catalysis, one for the binding 
of PRPP and one or more for the binding of ATP.
The catalytic reaction requires the Cl carbon of PRPP to be orientated in the 
proximity of the N1 of the adenine ring of ATP. In the model outlined above the 
distance of the modelled Cl to N1 of the product PR-ATP is 3.5 A. However, no 
catalytic residue which could abstract a proton from or polarise the Cl of PRPP can be 
identified since there are no conserved, charged residues in the vicinity. The closest 
interactions possible are with the backbone carboxyl of Leu 170 and the guanidium 
group of Arg 16 which are 4-4.5 A  distant. It seems more likely that the reaction
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mechanism proceeds via an oxocarbonium intermediate. The pyrophosphate is 
abstracted from PRPP first to produce the positively charged intermediate, which can 
be stabilised by interaction with the backbone carbonyl of Leu 170. The reaction is 
completed by the electrophilic attack of C l+ on the favourably orientated N1 of the 
purine ring of ATP. This mechanism can be reconciled with the observed ordered 
mechanism of HisG. ATP has to bind first because if PRPP were to bind first it would 
be hydrolysed and the oxocarbonium intermediate would not be particularly well 
stabilised. A second piece of evidence is that pyrophosphate has been shown to be 
released first. Further evidence has been provided experimentally by investigation of 
kinetic isotope effects in the HisG catalysis which showed the possibility of an 
oxocarbonium intermediate [Goitein et al., 1978]. Additionally type I PRTs were 
shown to catalyse the transfer of the phosphoribosyl group via an oxocarbonium 
intermediate [Scapin e ta l,  1995].
10.1.2 Mode(s) of inhibition
Inhibition of HisG by histidine, AMP and PR-ATP was shown to be concerted 
with a change in aggregation state of the enzyme from the active dimeric form to yield 
different, inhibited, hexameric conformations. The hexameric crystal structure of 
HisG explains this observation since the active sites are buried in the interior of the 
hexamer and made less accessible for the substrates. The hexamer is particularly 
compact and closed in the presence of inhibitors histidine, and AMP plus histidine, 
but comparatively open in the presence of AMP. This explains in part the synergistic 
effect between AMP and histidine and the lower Kx for histidine compared with AMP.
The competitive inhibition of AMP with respect to both substrates was 
impossible to reconcile with the assumption that AMP binds to the ATP binding site 
although this is the interpretation made from the ternary Mtb AMP and histidine HisG 
structure. However, the AMP-complexed HisG structure presented here allows the 
correct interpretation of the substrate binding sites, explaining the experimental 
observations with the ribose-monophosphate of AMP competing with the PRPP 
binding site and the purine ring of AMP competing with the ATP binding site. This 
mode of inhibition also holds for the product PR-ATP. Additionally the PR-ATP- 
inhibited structure is slightly more compact indicating stronger binding of the product.
Histidine binds in an intersubunit pocket between neighbouring C-terminal 
domains in the hexamer, resulting in a close contact between these domains and
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ordering of the T-loop\ Surprisingly the histidine R-group forms only a single 
hydrogen bond to the carbonyl of Ser 28S. Despite this the site has been previously 
shown to be highly specific for histidine [Morton and Parsons, 1977]. When histidine 
is bound, the hexamer is more elongated than when AMP or no inhibitor is present. 
This elongation is accompanied by a change in the dimer interface, with the dimers 
opening towards the outside so that the PRPP binding site on the dimer interface is 
disrupted. Therefore histidine not only inhibits by hexamer formation but also by 
disordering the substrate binding site. In the AMP-bound HisG structure the histidine 
binding pocket is exposed to solvent and in a favourable conformation to bind 
histidine which can explain the synergism between the binding of AMP and histidine.
10.1.3 The C-terminal ‘regulatory5 domain
The C-terminal domain of HisG can be described as a regulatory domain, not 
only because of the similarity with regulatory Pn signal transduction proteins, but 
because it provides the binding site for histidine and, in particular, is involved in the 
formation of inactive hexamers. Furthermore HisG mutants lacking the C-terminal 
domain showed activity, ruling out any involvement of the domain in catalytic 
activity. Although the C-terminal domain would not have been expected to play a role 
in substrate binding or catalysis, the native short form of HisG, without the C-terminal 
domain, is itself inactive and needs to form a hetero-complex with HisZ to display 
activity. This observation is even more surprising as there are no obvious differences 
in the sequence between the long and short form of HisG, apart from the C-terminus. 
Experiments showed that the native short HisG can be activated by thermal energy, 
presumably by a conformational change from a tensed, inactive form to a relaxed, 
active form. This same transition occurs on formation of the HisG-HisZ complex 
although there is no structural information on how this change occurs.
Finally, given the importance of Pn proteins in coordinating nitrogen and 
carbon assimilation in microorganisms and plants, the presence of a structural 
homologue as a domain of HisG is very interesting. This domain in HisG forms 
trimers in response to ADP and AMP which are signals of low energy levels and 
adopts a different trimer conformation on binding histidine. The enzyme could 
therefore act as a signalling molecule interacting with discrete receptor proteins to 
indicate the cellular levels of histidine. Alternatively the domain may have been 
acquired by gene fusion and now only functions as a small molecule-binding protein,
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which regulates the activity of the enzyme. This might explain the presence in a 
number of bacteria and archaea of the short form of ATP-PRT in which the regulatory 
domain is absent and regulation is achieved by oligomerisation with HisZ, a histidyl- 
tRNA synthetase paralogue [Bovee et al., 2002].
10.2 PA5104
Crystals obtained from PAS 104, an unidentified protein in the hut operon of 
organisms with histidine utilisation pathway 2, diffracted to better than 1 A. Therefore 
solution of the structure was attempted by direct methods using the programs SnB and 
ACORN. The structure, with 196 amino acids, proved too much of a challenge for 
SnB due to its size. Employment of ACORN, used in MR replacement mode, with 
various secondaiy structure elements and combinations as search models did not give 
a positive solution either. This failure is due to the lack of a-helices, the preferred 
search model in ACORN, or any heavy atoms in the structure. In addition, similarity 
searches and secondaiy structure prediction failed to identify PA5104 as a bicupin and 
an all-(3 structure. This could have focused the attempts with ACORN to various 
forms of [3-sheets but would have been computationally veiy time-consuming with no 
guarantee of a solution. For these reasons it was necessary to obtain experimental 
phase information on PAS 104. Diffraction data were collected at longer wavelengths 
to obtain anomalous signal from sulphur atoms for SAD phasing, but these data could 
not be scaled satisfactory for this approach, presumably due to absorption effects. 
Consequently, heavy atom derivatives of PA5104 were collected which proved to be 
difficult as the heavy atom complexes tested had severe effects on the diffraction 
quality of the crystals. However, it was possible for one derivative data set to locate 
two Hg sites with occupancies of just above 0.1 and to obtain some anomalous signal 
because the data were collected near the absorption edge of Hg. The acquired phase 
information was insufficient to allow manual or automated model building. 
Nevertheless, these phases were reliable and better than random, which allowed phase 
refinement using the Sayre equation in ACORN-PHASE to solve the structure of 
PAS 104.
One of the cupin domains of PAS 104 is closed, whereas the other has a crevice 
in the centre of the barrel. Conserved residues, of which most show interactions with 
small molecules from the crystallisation conditions, form the surface of the cleft. This
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allows the identification of possible substrates for the binding site. Glutamate or its 
derivatives, which are the last two intermediates in the hut pathway, were recognised 
as possible candidates. Binding of the pathway intermediates could suggest a possible 
role of PA5104 in the regulation of expression of HutF and HutG2 by their substrates 
respectively.
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Purification, crystallization and preliminary X-ray 
crystallographic analysis of ATP-phosphoribosyl- 
transferase from Escherichia coli
ATP-phosphoribosyltransferase (ATP-PRT) from Escherichia coli Received 5 May 2000
has been purified and crystals were obtained by the vapour-diffusion Accepted 11 August 2000
method using sodium tartrate as a precipitant. Dynamic light
scattering was used to assess conditions for the monodispersity of
the enzyme. The crystals are trigonal, space group R32, with unit-cell
parameters a = b = 133.6, c =  114.1 A  (at 100 K), and diffract to 2.7 A
on a synchrotron X-ray source. The asymmetric unit is likely to
contain one molecule, corresponding to a packing density of
2.9 A 3 D a"1. A  model for the quaternary structure is proposed
based on the crystallographic symmetry.
1. Introduction
In microorganisms and plants, histidine is 
synthesized in ten steps by the enzymes of the 
histidine pathway. Eight enzymes are encoded 
on eight genes (hisG flEJAH FBC D ) often 
arranged as one operon (his operon). Three of 
the enzymes are bifunctional (hisIE, hisD, 
hisB) and two form a multienzyme complex 
catalysing one reaction {hisH, hisF) (see, for 
example, Alifano et al., 1996). The pathway 
leads from 5-phosphoribosyl 1-pyrophosphate 
(PRPP) and ATP to histidine.
The initial substrates o f the histidine 
pathway, PRPP and ATP, play a key role in 
intermediary and energy metabolism. 
Furthermore, they link the histidine pathway 
to the biosynthesis of folates, purines, pyrimi­
dines, pyridine nucleotides and tryptophan.
The first enzyme of the pathway, ATP- 
phosphoribosyltransferase (ATP-PRT; E.C. 
2.4.2.17) encoded by the hisG  gene, catalyses 
the condensation of ATP and PRPP to form 
/V'-5'-phosphoribosyl-ATP (PRATP). In addi­
tion to its catalytic function, it has been shown 
to be involved in several aspects of the regu­
lation of histidine biosynthesis (Ames et al., 
1961). ATP-PRT binds to the his operon and to 
histidyl-tRNA and is feedback inhibited by the 
end-product o f the pathway, histidine (Voll et 
al., 1967). Owing to these regulatory functions 
and the connection o f the histidine pathway to 
other biosynthetic and metabolic pathways, 
ATP-PRT plays an important part in the 
regulation of growth.
From the primary structure o f ATP-PRT, the 
molecular weight is deduced as 33 367 Da for 
the 299 amino acids. Experimentally deter­
mined molecular weights in the literature 
describe various oligomeric states of ATP- 
PRT. Ultracentrifugation and gel separation
have shown that the enzyme is in equilibrium  
between its active dimeric form, inactive 
hexameric form and higher aggregates 
(Klungspyr & Kryvi, 1971; Tebar et al., 1973). 
The hexameric form is stabilized by histidine, 
AMP, PRATP, high concentrations of ATP and 
high enzyme concentration (Klungs0yr & 
Kryvi, 1971; Kryvi & Klungspyr, 1971). The 
second substrate PRPP seems to dissociate 
higher aggregates, resulting in an increase in 
the concentration of dimers (Tebar et a t ,  1973).
The secondary structure of ATP-PRT has 
been investigated using CD spectroscopy 
(Kryvi, 1973). At that time it was proposed to 
consist o f about 33% a-helix and 20-30%  
/3-sheel, with no change observed when the 
inhibitors AM P and/or histidine were bound. 
Furthermore, it was proposed that the first 120 
residues of ATP-PRT contain a nucleotide- 
binding fold arranged in a pafktfiflafiafi 
pattern (Argos et al., 1983). To our knowledge, 
no comparison of ATP-PRT with other phos- 
phoribosyltransferases (PRT) of which struc­
tures are now known has been made (see, for 
example, Focia et a l ,  1998).
In common with a number of amino-acid 
biosynthetic pathways, the histidine pathway is 
present in bacteria, fungi and plants but absent 
in mammals. This makes it a good target for the 
development o f antimicrobial and antifungal 
drugs as well as herbicides (Mousdale & 
Coggins, 1991). A  variety of selective inhibitors 
for the histidine pathway are known and are 
used commercially as herbicides (Mori et al.,
1995). These herbicidal compounds all inhibit 
imidazoleglycerol-phosphate dehydratase, the 
product of the hisB  gene. Knowledge of the 
structure o f ATP-PRT will help with the 
understanding of its function and will provide a 
basis for the development o f antimicrobial 
drugs and herbicides.
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Table 1
D y n a m ic  l ig h t- s c a t te r in g  m e a s u r e m e n ts  o f  E. coli A T P - P R T  in  th e  p r e s e n c e  o f  d i f f e r e n t  a d d it iv e s .
T h e  h y d ro d y n a m ic  ra d iu s  re p re s e n ts  th e  m e d ia n  p a r tic le  size p re s e n t in th e  sa m p le  ce ll. T h e  p o ly d isp e rs ity  value 
in d ica te s  th e  s ta n d a rd  d e v ia tio n  o f  th e  sp re a d  o f  p a r tic le  sizes a b o u t th e  r e p o r te d  av e ra g e  ra d iu s . A  rise in p o ly d isp e rs ity  
in re la t io n  to  th e  a v e ra g e  ra d iu s  re p re se n ts  g re a te r  sp re a d  in th e  size d is tr ib u tio n . T h e  e s tim a te d  M w is ca lcu la ted  from  
th e  h y d ro d y n a m ic  ra d iu s  (R,i) u s ing  an  e m p irica lly  d e r iv e d  re la t io n sh ip  b e tw e e n  th e  R „  a n d  M „ v a lu e s  fo r a n u m b e r o f  
well c h a ra c te r iz e d  g lo b u la r  p ro te in s  in b u ffe re d  so lu tio n . A ll e x p e rim e n ts  w e re  c o n d u c te d  in  50  mJM T H s-H C I b u ffe r at 
p H  7.5 in th e  p re se n c e  o f  100 m M  KCI un less  o th e rw ise  s ta te d . S am p les  c o n ta in in g  P P R P  a n d  A T P  w e re  in c u b a te d  a t 
ro o m  te m p e r a tu re  fo r  10 m in  to  fo rm  PRA TP.
A d d itiv es
H y d ro d y n am ic  
ra d iu s  (n m )
P o ly d isp ers ity
(n m )
E s tim a te d  
M „  (k D a ) C onclusion
N o n e  (n o  KCI) 7.3 0.3 369 P o lyd isperse
N o n e 6.9 1.0 321 P o lyd isperse
A M P  (0.4 m M ) 5.5 0.7 186 P o lyd isperse
H is tid in e  (5 m M ) 5.7 0.9 197 P o lyd isperse
H is tid in e  (5  m M ) + 
A M P  (1 m M )
5.3 1.0 170 P o lyd isperse
P R P P  (1 m M ) + 
A T P  (5  m M ) + 
M gC I2 (10  m M )
5.5 1.5 184 P o lyd isperse
P R P P  (1 m M ) + 
A T P  (5  m M ) + 
M gC l2 (10  m M ) + 
h is tid in e  (5 m M )
5.6 1.6 190 P o lyd isperse
2. Enzyme purification
ATP-PRPP from E. coli was overexpressed 
in E. coli B834(DE3)pLysS to 30-40% of the 
total cellular protein using a T7 RNA poly­
merase expression system (Studier & 
Moffatt, 1986). Cultures were grown in LB 
medium at 315 K to an optical density of 0.6 
at 600 nm. Overexpression of protein was 
induced by addition o f IPTG to a final 
concentration of 0.4 mM. Bacterial growth 
was continued for 4 h prior to harvesting the 
cells.
The cells (5.3 g wet weight) suspended in 
20 ml of 50 mM Tris-HCl pH 7.5 containing 
0.4 mM DTT and two protease inhibitor 
tablets (EDTA-free; Boehringer-Mann- 
heim) per 100 ml (buffer A ) were broken by 
two passes through a French pressure cell at
6.5 MPa. This material was then diluted with 
40 ml buffer A  and centrifuged at 
18 000 rev min-1 for 1 h. ATP-PRT was 
purified from the resulting cell-free extract. 
All subsequent steps were performed at 
277 K.
The supernatant was applied to a D E A E -  
Sephacel anion-exchange column (21 x  
14 cm diameter, flow rate 60 ml h-1 ) equili­
brated in 50 mM Tris-HCl pH 7.5 containing 
0.4 mM DTT and one protease inhibitor 
tablet per litre (buffer B). The column was 
then washed with the same buffer until the 
•^280nm of the eluate was less than 0.3. 
ATP-PRT was eluted with a linear gradient 
of 0-500 mM KCI in 700 ml buffer B (flow 
rate 30 ml h-1) and 10 ml fractions collected  
and assayed as described in Martin et al. 
(1971). Fractions containing ATP-PRT 
activity were pooled and dialysed overnight 
against buffer B.
The protein was loaded on a dye column 
(Reactive Green 19, Sigma; 8.5 x  2.1 cm 
diameter, flow rate 40 ml h-1) equilibrated 
in buffer B. The column was then washed 
with 50 ml buffer B and ATP-PRT was 
eluted with a linear gradient (250 ml) of 
200-950 mM KCI in buffer B. The flow rate 
was 40 ml h-1 and 10 ml fractions were 
collected and assayed. Fractions containing 
ATP-PRT activity were pooled, dialysed 
overnight against buffer B and concentrated 
by ultrafiltration. At this stage, the enzyme 
precipitated at high concentrations, but no 
substantial amount of enzyme was lost 
owing to its irreversible precipitation.
The concentrated enzyme solution was 
applied to a Sephacryl S200 (superfine 
grade) column (170 x 1.5 cm diameter, flow 
rate 15 ml h-1) that had been equilibrated 
with buffer B  containing 500 mM KCI. The 
enzyme was eluted with buffer B containing 
500 mM KCI (flow rate 10 ml h-1, 10 ml 
fractions). Fractions containing ATP-PRT 
activity were dialysed against buffer B 
containing 50%(v/v) glycerol prior to long­
term storage at 253 K.
3. Dynamic light scattering
Experiments were carried out using a 
DYNA-PRO 801 dynamic light-scattering/ 
molecular-sizing instrument (Protein Solu­
tions, Buckinghamshire, England). Protein 
solutions (1 mg ml-1) were in 50 mM 
Tris-HCl pH 7.5, but several other buffers 
and pHs were also assessed. Dynamic light- 
scattering experiments were carried out to 
determine which combination of product 
and cofactor were appropriate to obtain a
monodisperse enzyme solution. M ono­
dispersity is not an infallible indicator that 
diffraction-quality crystals can be obtained 
from a protein; instead, it reflects the 
observation that monodisperse protein 
solutions have a much higher probability of 
producing crystals than those which are not 
(Ferre-D’Amare & Burley, 1997). Dynamic 
light-scattering experiments on ATP-PRT 
were performed using several conditions 
and in the presence of different inhibitors 
(Table 1). It was shown that monodispersity 
could not be achieved in the presence of any 
of the probed additives. The lowest value for 
polydispersity was obtained using 0.4 mM 
AMP, with a resultant molecular weight 
estimated as 186 000 Da. This is about 10% 
lower than the M w of six monomers, but 
consistent with the expected hexameric state 
of the enzyme. Other additives, such as 
histidine and PRATP, gave similar molecular 
weights and hydrodynamic radii but higher 
polydispersity. Furthermore, the solubility of 
the enzyme was found to be greatly 
increased in the presence o f AMP (from  
about 5 mg ml-1 in buffer to at least 
20 mg ml-1). In the light of these results, 
crystallization trials were carried out in the 
presence and absence of AMP.
4. Crystallization
The enzyme was stored in 50%(v/v) glycerol, 
which was removed by exhaustive dialysis 
against 50 mM Tris-HCl pH 7.5 containing 
0.4 mM DTT. The enzyme was concentrated 
to 11 mg ml-1 in 50 mM Tris-HCl pH 7.5, 
0.4 mM DTT and 2 mM AMP using 
Centricon-10 centrifugal concentrators 
(Amicon, Stonehouse, Gloucestershire, 
England).
Crystallization experiments were 
performed at 293 K using the sitting-drop 
vapour-diffusion technique. A n exhaustive
Figure 1
A  c r y s ta l  o f  A T P -P R T  f ro m  E. coli. T h e  c r y s ta l  is 
a p p r o x im a te ly  0 .3  x  0 .2  x  0 .2  m m  in  s iz e  ( c ry s ta l  
fo r m  I) .
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Table 2
Statistics for the X-ray data processed in R32.
5. X-ray analysis
Sj «.ym ( /) (H o)
No. of unique 
reflections
Complete­
ness (%)
Multi­
plicity (%)
5.82 0.041 38.2 1099 95.6 6.3
4.62 0.061 39.1 1104 99.6 6.6
4.03 0.055 36.7 1098 99.9 6.7
3.66 0.050 32.2 1094 100.0 6.7
3.40 0.071 23.6 1079 100.0 6.7
3.20 0.120 14.5 1075 100.0 6.7
3.04 0.180 10.4 1092 100.0 6.7
2.91 0.293 6.4 1076 100.0 6.7
2.80 0.469 4.3 1077 100.0 6.7
2.70 0.668 3.1 1066 100.0 6.7
Total 0.049 18.0 10860 99.5 6.7
set of conditions, comprising commercially 
available and local sparse-matrix screens 
(Jancarik & Kim, 1991; Cudney el al., 1994), 
were tried. Initial crystals were obtained 
from various conditions, mostly in the 
presence of AMP. Optimization of these 
crystallization conditions was most 
successful for a single condition which led to 
the final conditions of 1.3 AT sodium tartrate, 
50-200 mAf MgCl2, 100 mM  citrate buffer 
pH 5.6 and protein in the presence of 2 mM  
AMP (crystal form I). Typically, 1-2 pi of 
protein (10 mg ml-1 ) was mixed with an 
equal volume of the reservoir solution. 
Crystals appeared after 3-4  d and continued 
to grow as trigonal prisms to maximum 
dimensions of 0.3 x 0.2 x 0.2 mm (Fig. 1). A  
second crystal form was derived using 
1.36-1.44 AT ammonium sulfate, 0-0.3 AT 
sodium chloride, 100 mAT HEPES buffer pH
7.5 and protein in the presence o f 2 mAT 
AMP. Round-shaped crystals appeared after 
4-5 d and grew to maximum dimensions of 
about 0.2 x 0.2 x 0.2 mm (crystal form II).
Figure 2
A  typical diffraction pattern from ATP-PRT collected  
beam line 9.6 at Daresbury synchrotron.
The X-ray diffraction data 
were collected on beamline
9.6 at the SRS, Daresbury 
Laboratory using a wave­
length of 0.87 A  and a ADSC  
Quantum-4 CCD detector. 
The crystals were radiation 
sensitive and therefore cryo- 
cooling was essential. Crys­
tals were loop-mounted in a 
cryoprotectant containing 
15%(v/v) glycerol and cryo- 
cooled to 100 K using an 
Oxford Cryosystems Cryostream. A  native 
data set to 2.7 A  resolution was collected 
using 1° oscillation frames from crystal form 
I (Fig. 2). Data were processed with 
D E N Z O  and scaled with SC A LE PA C K  
(Otwinowski & Minor, 1997). From auto- 
indexing in D E N ZO , the crystals were found 
to index in a primitive rhombohedral lattice 
corresponding to space group R3, with unit­
cell parameters a = b = 133.6, c = 114.1 A. 
Indexing with the higher symmetry space 
group R32 resulted in comparable merging 
R-factor statistics (Table 2). For R32, only 
one monomer per asymmetric unit leads to 
an acceptable packing density VM of 
2.95 A 3 D a-1 , which corresponds to a 
solvent content o f 58% (Matthews, 1968).
Crystal form II diffracted to only 3.7 A; 
from a single frame, processing was 
performed as described above. The crystal 
symmetry was determined to be primitive 
rhombohedral, with unit-cell parameters 
a = b = 132.6, c = 113.8 A. Because of the 
similar unit-cell parameters and the identical 
lattice, we presume that crystal 
form II also belongs to space 
group R32.
So far there are two different 
types of PRT structures known 
and another one predicted. 
Several reported structures, e.g. 
uracil PRT, show the type I 
fold of a five-stranded /J-sheet 
surrounded by three or four a- 
helices (and a hood domain) (see, 
for example, Tomchick et al., 
1998). Quinolinate PRT comprises 
a type II fold with two domains: a 
mixed ar//J N-tcrminal domain and 
an faa 6 barrel C-terminal domain, 
similar to known ( /to r)#  barrels 
(Eads et al., 1997). Anthranilate 
PRT is predicted to give a typical 
(/k*)8 barrel fold (Wilmanns & 
Eisenberg, 1993). Since there is no 
similarity in sequence or 
secondary-structure prediction of
ATP-PRT with these PRTs or other known 
protein structures, we intend to solve the 
structure by multiwavelength anomalous 
dispersion (M A D ).
6. Quaternary structure model of 
ATP-PRT
A quaternary structure model o f ATP-PRT 
based on the crystallographic data can be 
proposed if we assume that the enzyme in 
the crystal is in a hexameric arrangement (in 
the presence of the inhibitor AMP) as shown 
by light scattering (this report), gel separa­
tion (Tebar et al., 1973) and ultra­
centrifugation studies (Klungspyr & Kryvi, 
1971). Taking into account one molecule per 
asymmetric unit, the symmetry in the 
hexamer has to be in accordance to the 
crystallographic symmetry of space group 
R32. Therefore, the twofold and threefold 
symmetry in this space group must be 
reflected by the quaternary structure model. 
The proposed model can be seen in Fig. 3.
Crystal structures of all type I PRTs show  
a dimeric arrangement (Tomchick et al..
(6)
Figure 3
Proposed m odel o f  quaternary structure o f  ATP- 
PRT. (a ) shows a view  o f the hexam eric arrangement 
down the threefold axis. (6 ) is the view  along the 
tw ofold  axis, which is (a) rotated 90° towards the 
viewer. D im ers are indicated by the sam e colour. 
Threefold sym m etry is marked by s  and twofold  
sym m etry by L
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1998) and uracil PRT shows a hexameric 
arrangement in solution (Jensen & Mygind,
1996). Therefore, the proposed model of 
ATP-PRT with dimers arranged within a 
hexamer is in accordance with known 
structures of other PRTs.
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